HOME@>@‹³ŽºÐ‰î@>@Œ€‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)@>@‘“àŠw‰ï

‹³ŽºÐ‰î

‹³ŽºÐ‰î

Œ€‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)

‘“àŠw‰ï

2018”N 2017”N 2016”N
2015”N 2014”N 2013”N
2012”N 2011”N 2010”N
2009”N 2008”N 2007”N
2006”N 2005”N  

2018”N
    ‘æ82‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi3ŒŽ23“ú`25“úA2018”NA‘åãŽsj

    ƒRound Table Discussion„

  1. Shimokawa H. How to Perform Clinical Trials/Studies Successfully: Report from Tohoku University
  2. ƒSymposium„

  3. Sakata Y, Nochioka K, Abe R, Oikawa T, Kasahara S, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Evidence for Sex Differences in Japanese Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  4. Konno R, Tatebe S, Sugimura K, Satoh K, Aoki T, Yamamoto S, Sato H, Kozu K, Shimokawa H. Immunosuppressive Therapy Ameliorates Severe Pulmonary Hypertension and Refractory Vasospastic Angina in a Patient with Eosinophilic Granulomatosis with Polyangiitis
  5. ƒControversy„

  6. Sakata Y, Nochioka K, Miyata S, Shimokawa H. Transition of Left Ventricular Ejection Fraction in Heart Failure: Is HFmrEF Closer to HFpEF than to HFrEF?
  7. ƒSpecial Session„

  8. Takahashi J, Hao K, Satoh K, Shimokawa H. Temporal Trends in Prevalence and Outcomes of Geriatric Patients with Acute Myocardial Infarction Complicated with Heart Failure -Lessons from Miyagi AMI Registry Study-
  9. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  10. Ohyama K, Matsumoto Y, Takanami K, Ota H, Nishimiya K, Sugisawa J, Tsuchiya S, Amamizu H, Uzuka H, Suda A, Shindo T, Kikuchi Y, Hao K, Tsuburaya R, Takahashi J, Miyata S, Sakata Y, Takase K, Shimokawa H. Evidence for Enhanced Inflammation of Coronary Adventitia and Perivascular Adipose Tissue in Patients with Vasospastic Angina -A Multi-modality Imaging Study-iÅ—DGÜŽóÜj
  11. ƒPlenary Sessions„

  12. Uzuka H, Matsumoto Y, Nishimiya K, Ohyama K, Amamizu H, Morosawa S, Hirano M, Shindo T, Kikuchi Y, Hao K, Shiroto T, Takahashi J, Shimokawa H. Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo through the Kidney-Brain-Heart Axis
  13. Sugisawa J, Matsumoto Y, Suda A, Tsuchiya S, Ohyama K, Shindo T, Ikeda S, Hao K, Kikuchi Y, Takahashi J, Ota H, Shimokawa H. Impaired Vasodilator Capacity of Coronary Microvessels in Patients with Vasospatic Angina -Adenosine-Stress Myocardial CT Perfusion Imaging Study-
  14. ƒTopic„

  15. Tatebe S. Diastolic Dysfunction in Adults with Congenital Heart Disease
  16. ƒLate Breaking Cohort Studies 2 (HF)„

  17. Nochioka K, Sakata Y, Shiroto T, Oikawa T, Abe R, Kasahara S, Sato M, Aoyanagi H, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Impaired Glucose Tolerance in Relation with Microalbuminuria in Patients with Chronic Heart Failure: The SUPPORT Trial Subanalysis
  18. ƒOral Presentations (English)„

  19. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Arai H, Furukawa K, Fukumoto Y, Taki Y, Shimokawa H. Brain White Matter Abnormalities Associated with Memory Impairment in Patients with Chronic Heart Failure
  20. Amamizu H, Matsumoto Y, Morosawa S, Ohyama K, Uzuka H, Hirano M, Sugisawa J, Tsuchiya S, Sato K, Suda A, Shindo T, Ikeda S, Nishimiya K, Kikuchi Y, Hao K, Shiroto T, Takahashi J, Shimokawa H. Important Roles of Cardiac Lymphatic Duct System in the Regulation of Coronary Vasomotion in Pigs in Vivo
  21. Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Md Elias Al-Mamun, Shimizu T, Ikeda S, Suzuki K, Satoh T, Omura J, Nogi M, Mohammad Abdul Hai Siddique, Miyata S, Miura M, Shimokawa H. Rho-kinase and Cyclophilin A as Novel Therapeutic Targets for Cardiac Dysfunction and Post-Capillary Pulmonary Hypertension
  22. Nogi M, Satoh K, Sunamura S, Kikuchi N, Sato T, Kurosawa R, Omura J, Md Elias Al-Mamun, Mohammad Abdul Hai Siddique, Kudo S, Akiyama M, Kawamoto S, Saiki Y, Shimokawa H. SmgGDS Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells
  23. Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Matsumoto Y, Sakata Y, Shimokawa H. Sex Differences in Coronary Microvascular Dysfunction in Patients with Vasospastic Angina
  24. Hao K, Takahashi J, Miyata S, Sato K, Shindo T, Ikeda S, Kikuchi Y, Shiroto T, Matsumoto Y, Sakata Y, Shimokawa H. Sex Differences in Clinical Characteristics and Outcome of Patients with Acute Myocardial Infarction with Non-Obstructive Coronary Artery(MINOCA)
  25. Aoki T, Sugimura K, Tatebe S, Yamamoto S, Shimizu T, Yaoita N, Sato H, Kouzu K, Konno R, Terui Y, Nochioka K, Satoh K, Shimokawa H. Normalization of Hemodynamic Responses to Exercise as a Final Goal of Balloon Pulmonary Angioplasty in Patients with CTEPH
  26. Kikuchi Y, Takahashi J, Sato K, Sugisawa J, Tsuchiya S, Suda A, Shindo T, Ikeda S, Hao K, Shiroto T, Matsumoto Y Sakata Y, Shimokawa H. Beneficial Effects of Fasudil, a Selective Rho-kinase Inhibitor, for the Treatment and Prevention of PCI-related Myocardial Ischemia
  27. Kikuchi N, Satoh K, Kurosawa R, Yaoita N, Md. Elias Al-Mamun, Mohammad Abdul Hai Siddique, Omura J, Sato T, Nogi M, Sunamura S, Miyata S, Shimokawa H. Selenoprotein P Promotes Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension -A Possible Novel Therapeutic Target-
  28. Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Shimizu T, Nochioka K, Sato H, Konno R, Satoh K, Miyata S, Shimokawa H. Sex Differences in Hemodynamic Responses and Long-term Survival to Optimal Medical Therapy in Patients with Pulmonary Arterial Hypertension
  29. Mohammad Abdul Hai Siddique, Satoh K, Kurosawa R, Md. Elias Al-Mamun, Kikuchi N, Omura J, Satoh T, Nogi M, Sunamura S, Shimokawa H. Identification of Emetine as a Novel Therapeutic Agent for Pulmonary Hypertension in Rats -High-throughput Screening of 5,562 Compounds-
  30. Sato K, Hao K, Takahashi J, Cui Y, Shindo T, Ikeda S, Kikuchi Y, Matsumoto Y, Shiroto T, Sakata Y, Shimokawa H. Temporal Trends in the Treatment and Outcomes of Heart Failure in Super-Old Patients with Acute Myocardial Infarction
  31. Otsuki T, Satoh K, Shimizu T, Ikeda S, Yaoita N, Sato T, Omura J, Kikuchi N, Kurosawa R, Sunamura S, Nogi M, Sugimura K, Aoki T, Tatebe S, Nochioka K, Yamamoto S, Takahashi J, Miyata S, Shimokawa H. Important Prognostic Impacts of Serum Levels of Adipsin in Patients with Coronary Artery Disease
  32. ƒOral Presentations (Japanese)„

  33. Terui Y, Sugimura K, Ota H, Sato H, Nochioka K, Tatebe S, Aoki T, Yamamoto S, Kozu K, Konno R, Takase K, Shimokawa H. Usefulness of Cardiac MRI in the Management of Cancer Patients Treated with Anthracyclines -Progress in Cardio-oncology-
  34. Kasahara S, Sataka Y, Nochioka K, Abe R, Oikawa T, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Development of a Conversion Formula between B-type Natriuretic Peptide and N-terminal Pro BNP Levels
  35. Aoyanagi H, Sakata Y, Nochioka K, Shiroto T, Oikawa T, Abe R, Kasahara S, Sato M, Takahashi J, Miyata S, Shimokawa H. Impact of Transition of Left Ventricular Ejection Fraction in Patients at Risk for Heart Failure: Report from the CHART-2 Study
  36. ƒFeatured Research Session„

  37. Kurosawa R, Satoh K, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Al-Mamun Md. Elias, Mohammad Abdul Hai Siddique, Shimokawa H. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension -High-throughput Screening of 5,562 Compounds-
  38. ƒPoster Sessions (English)„

  39. Miki K, Nakano M, Hasebe Y, Kimura Y, Chiba T, Fukasawa K, Morosawa S, Shimokawa H. Prevalence and Risk Factors of Silent Cerebral Infarction in Patients with Atrial Fibrillation
  40. Morosawa S, Yamamoto H, Hirano M, Uzuka H, Ohyama K, Hasebe Y, Nakano M, Fukuda K, Takayama K, Shimokawa H. Validation of a New Shock Wave Catheter Ablation System for Ventricular Tachyarrhythmias in Pigs in Vivo
  41. Yamamoto S, Suzuki H, Sugimura K, Tatebe S, Aoki T, Sato H, Kozu K, Konno R, Ota H, Takanami K, Takase K, Nochioka K, Shimokawa H. Assessment of Cardiac Autonomic Nerve Functions by 123I-Meta-Iodobenzylguanidine Imaging in Patients with Anderson-Fabry Disease
  42. Chiba T, Nakano M, Hasebe Y, Kimura Y Fukasawa K, Miki K, Morosawa S, Fukuda K, Shimokawa H. Prognostic Significance of Left Ventricular Ejection Fraction Relevant to Myocardial Damage in Patients with Cardiac Sarcoidosis
  43. Shindo T, Ito K, Eguchi K, Kurosawa R, Kagaya Y, Monma Y, Ichijo S, Shiroto T, Kanai H, Shimokawa H. Low-intensity Pulsed Ultrasound Ameliorates Left Ventricular Dysfunction in ApoE-deficient Mice with Acute Myocardial Infarction in Vivo
  44. ƒPoster Sessions (Japanese)„

  45. Tatebe S, Sugimura K, Saito M, Sakata Y, Satoh K, Aoki T, Yamamoto S, Shimizu T, Sato H, Otsuki T, Kozu K, Konno R, Terui Y, Kawano K, Kimura M, Adachi O, Saiki Y, Shimokawa H. Clinical Profiles of Pregnant Women with Heart Disease
  46. Abe R, Sakata Y, Nochioka K, Oikawa T, Kasahara S, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Sex Differences in Health Consciousness and Prognosis of Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  47. Fukasawa K, Fukuda K, Nakano M, Hasebe Y, Kimura Y, Chiba T, Miki K, Shimokawa H. Impact of Sinus Rhythm Maintenance on Exercise Tolerance after Catheter Ablation in Patients with Non-Paroxysmal Atrial Fibrillation
  48. Eguchi K, Shindo T, Ito K, Kurosawa R, Kagaya Y, Monma Y, Ichijo S, Miyata S, Taki H, Kanai H, Shimokawa H. Crucial Role of Endothelial Nitric Oxide Synthase in the Therapeutic Effects of Low-intensity Pulsed Ultrasound for Dementia in Mice
  49. Tsuchiya S, Matsumoto Y, Sugisawa J, Kikuchi Y, Takahashi J, Kawamoto S, Kumagai K, Saiki Y, Shimokawa H. Evidence for Improved Cognitive Functions after TAVI in Elderly Patients with Severe Aortic Stenosis -Involvement of the Heart-Brain Interaction-
  50. Konno R, Tatebe S, Sugimura K, Satoh K, Aoki T, Yamamoto S, Shimizu T, Sato H, Kozu K, Terui Y, Adachi O, Kimura M, Saiki Y, Shimokawa H. Hepatitis C Virus Positivity Adversely Impacts Cardiac Functions and Long-term Prognosis in Patients with Adult Congenital Heart Disease
  51. Sato M, Sakata Y, Oikawa T, Abe R, Kasahara S, Aoyanagi H, Miura M, Nochioka K, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors in Elderly Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  52. Oikawa T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, Sato M, Aoyanagi H, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Triglycerides Levels in the Secondary Prevention of Patients with Myocardial Infarction -A Report from the CHART-2 Study-
  53. ‘æ47‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2018”N2ŒŽ9“ú`10“úA’·èŽsj

    ƒƒCƒuƒjƒ“ƒOƒZƒ~ƒi[„

  54. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇf—Â̍ŐV‚Ì’mŒ©
  55. ƒYIAƒZƒbƒVƒ‡ƒ“„

  56. »‘ºTˆê˜YA²“¡Œö—YA•àV —ºA‘å’Î’mLA‹e’n‡—TAMd Elias AL-MamunAŽ… ‹œA’r“c®•œA—é–؍N‘ŸA²“¡‘åŽ÷A‘呺~ˆêA–ì–ؐ³“¹AMohammad Abdul Hai SiddiqueA‹{“c •qA‰ºìG–ŸF¶S•s‘S‚É”º‚€”x‚ŒŒˆ³Ç”­Ç‚É‚š‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„•ª’S‚̉𖟁iÅ—DGÜŽóÜj
  57. “c’†C•œA”’ŒË ’A_ŒË–ΗYAꎓ¡‘åŽ÷AˆÉ“¡H‘ãAˆä‹‚—z—SAŠ’JãĎqA²“¡¹—¢A‰ºìG–ŸF”xzŠÂ‚š‚æ‚Ñ”x‚ŒŒˆ³Ç‚É‚š‚¯‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚̏d—v«|’áŽ_‘f—U”­«”x‚ŒŒˆ³Ç‚𒆐S‚Æ‚µ‚œŒŸ“¢|iÅ—DGÜŽóÜj
  58. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j”­•\„

  59. “V…G˜aAŒ–{‘׎¡A”‘ò ‘EA‘åŽR@”nA‰F’Ë—T‹IA•œ–쓹ŠîA™àV A“y‰® ‘A²“¡ŒöˆêA{“c •jAi“¡’q•FA’r“c®•œAŒ‹{Œ’‰îA‹e’n —ƒA‰H”öŽ‹MA”’ŒË ’A‚‹Ž A‰ºìG–ŸFŠ¥“®–¬‰ßŽûk”œ‰ž‚É‚š‚¯‚éS‘ŸƒŠƒ“ƒpŠÇ‚̏d—v«|ƒuƒ^“®•šƒ‚ƒfƒ‹‚ð—p‚¢‚œŒŸ“¢|
  60. –ì–ؐ³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘ºTˆê˜YA•àV —ºA‘å’Î’mLA‰ºìG–ŸF‘å“®–¬•œŠŠ‹Ø×–E‚ÌŒ`Ž¿•ÛŽ‚ð‹@˜‚Æ‚µ‚œ‹¹•”‘å“®–¬áŽ‚ÌŒ`¬‚Æ”j—ô‚ɑ΂·‚éSmgGDS ‚Ì—\–h“IŠÖ—^
  61. “›ˆä³lAŠì–Œ”üAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA²“¡Œö—YA‰ºìG–ŸAVèÍFÉŽ_‰–^ˆŸÉŽ_‰–‚Ì•s‘«‚Í‘ãŽÓÇŒóŒQAŒŒŠÇ•s‘SAS‘Ÿ“Ë‘RŽ€‚ðŽä‹N‚·‚é
  62. “›ˆä³lA¶‰z‹M–ŸAéŒË‹MŽuAâ—œ‚Ü‚äŽqA¬“cŒjŽmA‰€ ŽîǁA–L•œ—R”üŽqA˜aò OlAŽR“c‘s—ºA‰ºìG–ŸA–öŒŽ‰„ÍA–˜a”ŽAŒ} Š°F’áŽ_‘f«”x‚ŒŒˆ³‚É‚š‚¯‚鍜‘NO ‡¬y‘fŒn‚Ì•ÛŒì“I–ðŠ„
  63. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA‰ºìG–ŸA{‰ÁŒŽˆê”ŽAŠ_‰Ô ŠwF”][Ç‚É‚š‚¯‚éNO ‡¬y‘f‚Ì—LŠQ‚ȍì—pF«·‚š‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^
  64. ‘æ11‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2018”N1ŒŽ20“ú`21“úA•Ÿ‰ªŽsj

    ƒ‹€ÃƒVƒ“ƒ|ƒWƒEƒ€„

  65. ‚‹Ž F“Œ“ú–{‘åkÐ‚ªzŠÂŠíŽŸŠ³‚É‹y‚Ú‚µ‚œ‰e‹¿‚Ɛ«·
  66. â“c‘וFF–«S•s‘Sf—Âɂš‚¯‚鐫·F CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  67. ƒ—DG‰‰‘èŒó•âŒû‰‰„

  68. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAÂ–ö ”£A”’ŒË ’A‹{“c •qA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚邪‚ñŽ€–S‹K’èˆöŽq‚Ɛ«·i—DGÜŽóÜj
  69. ŽO–ØŒi‘ŸA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–ŸF”ñ•Ù–ŒÇ«S–[×“®Š³ŽÒ‚É‚š‚¯‚é–³ÇŒó«”][Ç‚̐«·‚ÌŒŸ“¢
  70. ç—t‹M•FA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚É‚š‚¯‚éS‘ŸÄ“¯Šú—Ö@‚Ì—LŒø«‚ÉŠÖ‚·‚鐫·
  71. ²“¡ŒöˆêA‚‹Ž A‰H”öŽ‹MAi“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–ŸF‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚éƒvƒ‰ƒCƒ}ƒŠ[Š¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÃŒø‰Ê‚̐«·‚ÉŠÖ‚·‚錟“¢
  72. ®–ì —ºAŒš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA²“¡Œö—YA”’ŒË ’AˆÀ’B —A–Ø‘º³lA—§–ì Ž A’†“‡O“¹A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF¬læ“V«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚̐«·
  73. Â–ö ”£Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºìG–ŸFS•s‘S”­Ç‚ƒŠƒXƒNŠ³ŽÒ‚É‚š‚¯‚鍶Žº‹ìo—Š‚ÌŒoŽž“I•Ï‰»‚̐«·
  74. ƒƒ|ƒXƒ^[”­•\„

  75. ‰H”öŽ‹MA‚‹Ž A²“¡ŒöˆêAi“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–ŸF”ñ•ÂÇ«Š¥“®–¬‚𔺂€S‹Ø[ÇiMINOCAjŠ³ŽÒ‚̗Տ°‘œ|‹{éŒ§AMI“o˜^Œ€‹†|
  76. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸF‚—îS•s‘SŠ³ŽÒ‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚É‚š‚¯‚鐫·|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  77. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸFBNP‚ÆNT-proBNP‚Ì‘ŠŠÖ‚É‚š‚¯‚鐫·
  78. Œš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œAÖ“¡¹—˜Aì–쌀ŒåAˆÀ’B —A‰ºìG–ŸFzŠÂŠíƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“‚ªs‚í‚ê‚œ”DPÇ—á‚ÌŒŸ“¢

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2017”N
‘æ2‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2017”N12ŒŽ3“úAå‘äŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€„

  1. Œ–{‘׎¡A’|“à‰ëŽjA“y‰® ‘A‹e’r —ƒAì–{r•ãAŒF’J‹Iˆê˜YA‰H”öŽ‹MAi“¡’q•FA’r“c®•œA‚‹Ž AãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸFTAVIp‘O‚Æ–«Šú‚̍‚—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIŒã‚¹‚ñ–Ï‚Ì—\‘ª‚Æ•af˜AŒg‚̏d—v«
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. ²“¡ŒöˆêA‰H”öŽ‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‚‹Ž A‰ºìG–ŸF‰^“®•‰‰×—U”­«Š¥¹k‹·SÇ‚Ì‚P—á
  4. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jA™àV AŠ`‰Ô—²ºA‰ºìG–ŸAãŒŽ³”ŽFCTEPH‚ÆPAH‚ÌŠÓ•Ê‚É‚š‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  5. ™àV AÂ–Ø—³’jAHŒŽŽO“ށA®–ì —ºA_’ÍŽ–çA²“¡ —yAŽR–{¹DAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸF–«ŒŒð•ÂÇ”x‚ˆ³Ç‚É‚š‚¯‚é‰^“®‘Ï—e”\‚Ɖ^“®ŽžŒŒs“®‘Ô‚ÌŒŸ“¢
  6. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA²“¡ —yA_’ÍŽ–çA®–ì —ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF‰^“®•‰‰×‰ESƒJƒe[ƒ‹‚ɑ΂·‚錌s‘ԕω» \ƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ÌŒø‰Ê”»’è‚ւ̉ž—p
  7. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  8. –x —ÇŽqA‰H”öŽ‹MA’·’J•”—Y”òAÂ–Ø—³’jA™‘ºGˆê˜YAŠìƒAƒ†ƒ~A–Ÿ’¿çŒbA—é–ØŽõŽ÷AHŒŽŽO“ށAŠ`‰Ô—²ºA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚Ì“úí¶Šˆ‚É‚š‚¯‚é–â‘è“_‚‚¢‚Ä‚ÌŒŸ“¢
  9. ‘æ165‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N12ŒŽ2“úAå‘äŽsj

    ƒYIAÇ—á”­•\•”–偄

  10. “y‰® ‘AŒ–{‘׎¡A‹e’n —ƒA™àV Ai“¡’q•FA’r“c®•œA‰H”öŽ‹MA‚‹Ž Aì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA–x“à‹v“¿A‰ºìG–ŸFTAVI ‚É‚æ‚èvWF ‚•ªŽq—Ê‘œ—Ê‘ÌŒ‡‘¹‚̉ü‘P‚Ɩэ׌ŒŠÇŠg’£Ç‚̏Á‘Þ‚ð”F‚ß‚œHeyde ÇŒóŒQ‚̈ê—ái—DGÜŽóÜj
  11. ƒYIAŒ€‹†”­•\•”–偄

  12. ç—t‹M•FA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA•Ÿ“c_“ñA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚̐S‹ØáŠQ‚ÉŠÖ˜A‚µ‚œ¶ŽºŽûk”\‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿i—DGÜŽóÜj
  13. ƒˆê”ʉ‰‘聄

  14. Æˆä—m•ãA™‘ºGˆê˜YA²“¡ —yAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA_’ÍŽ–çA®–ì —ºA‘å“c‰pŠöA‚£ Œ\A‰ºìG–ŸFanthracycline ŒnRŠàÜ‚É‚æ‚éS“Ő«‚Ì‘gDŠw“I•]‰¿‚É‚š‚¯‚éS‘ŸMRI ‚Ì—L—p«
  15. ²“¡ —yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãA²“¡Œö—YA‰ºìG–ŸF––œŒ^”x“®–¬‹·ó‚̈ê—á
  16. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DAŽ… ‹œA²“¡ —yA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚̉^“®•‰‰×‰ESƒJƒe[ƒeƒ‹ŒŸž
  17. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œA²“¡ —yA‘å’Î’mLA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãA²“¡Œö—YA‰ª“cŽ“TAˆÀ’B —AHê”ü‹IA‰ºìG–ŸF¶‘Ì”xˆÚA‚ðŽ{s‚µ‚œ¬Ž™Šú”­Ç‚Ì”x“®–¬«”x‚ŒŒˆ³Ç‚Ì‚P—á
  18. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VAÂ–ö ”£A”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸFHFpEF Š³ŽÒ‚É‚š‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA|CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  19. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAÂ–ö ”£AŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚š‚æ‚ѐ«·‚ɂ‚¢‚Ä‚ÌŒŸ“¢|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  20. ²“¡ŒöˆêA‰H”öŽ‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‚‹Ž A‰ºìG–ŸF‰^“®•‰‰×—U”­«Š¥¹k«‹·SÇ‚Ì‚P—á
  21. i“¡’q•FA‚‹Ž AŒ–{‘׎¡A”’ŒË ’A‹e’n —ƒA‰H”öŽ‹MA’r“c®•œA{“c •jA™àV A“y‰® ‘AŠ’JãĎqA²“¡ŒöˆêAÆˆä—m•ãAÂ–ö ”£A‰ºìG–ŸF˜JìŽžŒ“ˆÀÃŽž‹¹’ɂ𔺂€S‹Ø‰Ë‹Ž‚ð‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚̈ê—á
  22. Â–ö ”£Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹Ž A‹{“c •qA‰ºìG–ŸFS•s‘SƒXƒe[ƒW‚ªS–[×“®‚Æ—\Œã‚Æ‚ÌŠÖŒW‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·FCHART-2 Œ€‹†‚©‚ç‚Ì’mŒ©
  23. ’·’J•”—Y”òAŽO–ØŒi‘ŸA”‘ò ‘EA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–ì œA‰ºìG–ŸFS–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ‰i‹vŒ^‰º‘åÃ–¬ƒtƒBƒ‹ƒ^[—¯’uŒã‚̈ê—á
  24. ’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA‰ºìG–ŸFV‹K3D ƒ}ƒbƒsƒ“ƒOƒVƒXƒeƒ€Rhythmia ‚É‚æ‚Á‚ÄŒŸo‚³‚ê‚œ”÷¬“dˆÊ‚Ö‚ÌŽ¡—ª‘tŒ÷‚µ‚œ’ʏíŒ^S–[‘e“®Ç—á
  25. –Ø‘º‹`—²A’†–ì œA’·’J•”—Y”òAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸAŒš•”r‰îA‰ºìG–ŸFƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚ÌATP ŠŽŽó«S–[•p”‚ɑ΂µAƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œˆê—á
  26. ŽO–ØŒi‘ŸA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–ŸFƒpƒbƒ`ƒeƒXƒgŒ‹‰Ê‚ÉŠî‚«AƒSƒAƒeƒbƒNƒX‚ðŽg—p‚¹‚ž‚ÉICD Ažp‚ðŽ{s‚µ‚œ‹à‘®ƒAƒŒƒ‹ƒM[‚Ì‚P—á
  27. âV“¡Œ³ˆêAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DAŽ… ‹œA²“¡ —yA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF”][Ç‚𔭏ǂµt-PA ‚ÆŒŒð‰ñŽû—Ö@‚É‚æ‚èŒãˆâÇ‚È‚­‰ü‘P‚µ‚œDCM ‚̈êÇ—á
  28. ™àV A‹e’n —ƒA“y‰® ‘A²“¡ŒöˆêAÆˆä—m•ãAÂ–ö ”£Ai“¡’q•FA’r“c®•œA‰H”öŽ‹MA”’ŒË ’AŒ–{‘׎¡A‚‹Ž Aâ“c‘וFA‰Í’à ‘Aì–{r•ãAâV–؉ÀŽA‰ºìG–ŸF‹}«S•s‘S”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ‹‘卶Žº“àŒŒð‚Ì‚P—á
  29. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA²“¡ —yA_’ÍŽ–çA®–ì —ºA‰ºìG–ŸF‘å“®–¬Šî•”’uŠ·Œã‚Ì”DPoŽY‚Ì‚P—á
  30. ‘æ58‰ñ“ú–{–¬ŠÇŠw‰ïŠwpW‰ïi2017”N10ŒŽ19“ú`21“úA–ŒŒÃ‰®Žsj

    ƒJCAA‘Il”­•\„

  31. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚̕“I•]‰¿\’·Šú—\Œã‚ƍ‡•¹ÇiÅ—DGÜŽóÜj
  32. ƒƒ|ƒXƒ^[”­•\„

  33. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚Ì–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
  34. ‘æ21‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2017”N10ŒŽ12“ú`14“úAH“cj

    ƒYIA Ržu‰‰ —Տ°„

  35. ²“¡ŒöˆêA‚‹Ž@A›Á@Œ³‹gA‰H”öŽ‹MA‹{“c@•qAâ“c‘וFA‰ºìG–ŸF‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚é—ˆ‰@ŽžS•s‘S‡•¹‚Ì•p“x‚Æ—\Œã‚ÌŒoŽž“I•Ï‰»‚ÉŠÖ‚·‚錟“¢|‹{éAMI“o˜^Œ€‹†|i—DGÜŽóÜj
  36. ‰H”öŽ‹MA‚‹Ž@Aâ“c‘וFA‹{“c@•qA”’ŒË@’AŒã‰ªL‘Ÿ˜YA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚Š‚é‰e‹¿‚ƍ¶Žº‹ìo—Š‚Æ‚ÌŠÖ˜A
  37. ƒYIA Ržu‰‰ Šî‘b„

  38. »‘ºTˆê˜YA²“¡Œö—YAŽ…@‹œA—é–؍N‘ŸA’r“c®•œA‘呺~ˆêA‹e’n‡—TA•àV@—ºA–ì–ؐ³“¹A‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„‚Ìˆá‚¢
  39. ƒˆê”ÊŒû‰‰„

  40. ™‘ºGˆê˜YAŽR–{¹DAÂ–Ø—³’jAŒš•”r‰îA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–ŸFƒAƒ“ƒ_[ƒ\ƒ“Eƒtƒ@ƒuƒŠ[•a‚̐f’f‚É‚š‚¯‚錌Ÿ÷’†ƒOƒƒ{ƒgƒŠƒAƒIƒVƒ‹ƒXƒtƒBƒ“ƒSƒVƒ“‘ª’è‚Ì—L—p«
  41. ’†–ì@œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFƒGƒ“ƒpƒOƒŠƒtƒƒWƒ““Š—^‚ªS•s‘S‰ü‘P‚É‘tŒ÷‚µ‚œ“œ”A•a‡•¹‹•ŒŒ«S‹ØÇ‚̈ê—á
  42. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YAÂ–Ø—³’jAŽR–{¹DAˆÀ’B@—A–Ø‘º³lAâV–؉ÀŽF¬læ“V«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éHCV—z«‚̐S‹@”\‚â—\Œã‚É—^‚Š‚é‰e‹¿
  43. Œã‰ªL‘Ÿ˜YAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFŒoŒûƒuƒhƒE“œ•‰‰×ŽŽŒ±‚Æ”÷—ʃAƒ‹ƒuƒ~ƒ“”A‚É‚æ‚閝«S•s‘SŠ³ŽÒ‚̃ŠƒXƒN•]‰¿|SUPPORTŽŽŒ±ƒTƒu‰ðÍ|
  44. ’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‚‹Ž@A‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚ª’†’ö“x‚É•Û‚œ‚ê‚œS•s‘S‚̗Տ°“I“Á’¥FCHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  45. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚Ì•Û‚œ‚ê‚œ–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  46. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãA“y‰®@‘A‚‹Ž@A‹{“c@•qAãŒŽ³”ŽArˆäŒ[sAâV–؉ÀŽA‰ºìG–ŸFTAVIp‘O‚Æ–«Šú‚É‚š‚¯‚鍂—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIpŒã‚¹‚ñ–Ï‚Ì—\‘ª‚ƃtƒŒƒCƒ‹ƒKƒCƒh•af˜AŒg‚̏d—v«
  47. ‘å’Î’mLA²“¡Œö—YA–î”ö”M—TA‘呺~ˆêA‹e’n‡—TA•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹A‹{“c@•qA‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SŠ³ŽÒ‚Ì’·Šú—\Œã—\‘ª
  48. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚邪‚ñŽ€–SƒŠƒXƒN‚Ì‘‰Á |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  49. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  50. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DAâV“¡¹—˜Aì–쌀ŒåA–Ø‘º³lAˆÀ’B@—A²“¡Œö—YA‰ºìG–ŸFSŽŸŠ³‡•¹”DP‚ÌŒŸ“¢ |“Œ–k‘åŠw•a‰@‚ÌŒoŒ±|
  51. ƒƒ|ƒXƒ^[„

  52. ˆ¢•”—Ú—žAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAŽO‰Y³’šA”’ŒË’A‹{“c@•qA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚ÌŒ’NŠÇ—ˆÓŽ¯‚Æ—\Œã‚É‚š‚¯‚鐫·‚ÉŠÖ‚·‚錀‹† |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  53. ²“¡@—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DAŽ…@‹œA²“¡Œö—YA•ŸŒŽ‹KŽqA‘å“c‰pŠöA‰ºìG–ŸFS‘ŸMRI‚ªf’f‚É—L—p‚Ÿ‚Á‚œSƒAƒ~ƒƒCƒh[ƒVƒX‚̈ê—á
  54. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸF‚—«S•s‘SŠ³ŽÒ‚Ì—\Œã‚š‚æ‚Ñ—\Œã‹K’èˆöŽq‚ɂ‚¢‚ā|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  55. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFHFpEFABorderline HFpEFAHFrEF‚É‚š‚¯‚éBNP‚Ì—\Œã—\‘ª”\‚Ì”äŠr|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  56. –Ø‘º‹`—²A•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA‡‰®‰ë•FA‰ºìG–ŸFŠŽõƒŠ[ƒh”²‹Ž‚É‚æ‚èS•s‘S‚©‚ç‚̉ü‘P‚ª‰Â”\‚Æ‚È‚Á‚œ•s®–¬ŒŽ«‰EŽºS‹ØÇ‚̈ê—á
  57. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  58. ‰ºì@G–ŸFR‹ÃŒÅ—Ö@‚É‚š‚¯‚éÅV‚Ì’mŒ©
  59. ™‘º@Gˆê˜YFfabry•a ‘Šúf’f‚Ì‚œ‚ß‚ÌŽŽ‚Ý
  60. ‘æ212‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi9ŒŽ9“úA2017”NA·‰ªŽsj
  61. ²“¡ŒöˆêA‰H”öŽ‹MA™àV@A“y‰®@‘Ai“¡’q•FA’r“c®•œA‹e’n@—ƒAŒ–{‘׎¡A‚‹Ž@A‰ºìG–ŸF‰^“®•‰‰×‚Æ–òÜ•‰‰×‚Ì—ŒŽÒ‚ª—z«‚ðŽŠ‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  62. •y‰iŒc‘ŸA²“¡@ꡁA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DAŽ…@‹œA_’ÍŽ–çA®–ì@—ºA‰ºìG–ŸF––œŒ^”x“®–¬‹·ó‚Ì1—á.
  63. ‘æ23‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi7ŒŽ15“ú`16“úA2017”NAŠò•ŒŽsj
  64. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAÂ–ö@”£AŒã‰ªL‘Ÿ˜YA”’ŒË@’A‚‹Ž@A‹{“c@•qA‰ºìG–ŸF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰^“®KŠµ‚Æ—\Œã‚ÉŠÖ‚·‚錀‹† -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
  65. ‘æ70‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2017”N6ŒŽ28“ú`29“úA‚‚­‚ÎŽsj

    ƒŒû‰‰”­•\„

  66. ‹e’n‡—TA²“¡Œö—YAMd. Elias-Al-Mamun, Mohammad Abdul Hai Siddique, ‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A»‘ºTˆê˜YA‹{“c@•qA‰ºìG–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\D
  67. ‘æ164‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N6ŒŽ10“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–偄i*—DGÜŽóÜj

  68. *™àVA‰H”öŽ‹MA“y‰®‘Ai“¡’q•FA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚»‚̉Á—Âɂæ‚è‰^“®‘Ï—e”\‚ª’˜–Ÿ‚ɉü‘P‚µ‚œ”ì‘åŒ^S‹ØÇ‚Ì1—á
  69. ƒYIAŒ€‹†”­•\•”–偄i*Å—DGÜŽóÜj

  70. *_’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA®–ì—ºA@Œã‰ªL‘Ÿ˜YA²“¡Œö—YA‹{“c•qA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Ɛ«·‚ÌŠÖ˜A
  71. ƒˆê”ʉ‰‘聄

  72. ’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFpŒãˆê‰ß«–[ŽºƒuƒƒbƒN‚ð’悵‚œ’†Šu•›“`“±˜H‚ð—L‚·‚éWPWÇŒóŒQ‚̈ê—á
  73. ’·’J•”—Y”òAŽO–ØŒi‘ŸA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–쐜A‰ºìG–ŸF‘m–X•Ù—Ö3 Žž•ûŒü‚ɐS–[Å‘Šú‹»•±•”ˆÊ‚ð”F‚ß‚œfast/slow Œ^AVNRT ‚̈ê—á
  74. ’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFReverse common AFL ‚É—ÞŽ—‚µ‚œpropagation ‚ð’悵‚œLLRA‹NŒ¹AT ‚̈ê—á
  75. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA@²“¡Œö—YA‰ºìG–ŸF“¯ˆê‰ÆŒn“àFabry •aŠ³ŽÒ‚É‚š‚¯‚é—Տ°‘œ
  76. ²“¡—yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì—ºA@²“¡Œö—YA•ŸŒŽ‹KŽqA‰ºì@G–ŸFSƒAƒ~ƒƒCƒh[ƒVƒX‚̊ӕʂɐS‘ŸMRI T1 ƒ}ƒbƒsƒ“ƒO‚ª—L—p‚Å‚ ‚Á‚œ‘œ”­«œ‘Žî‚̈ê—á
  77. “y‰®‘AŒ–{‘׎¡A‹e’n—ƒA™àVA‰H”öŽ‹MA‚‹ŽAì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA‰ºìG–ŸFValsalva “ŽŒa‚©‚猟“¢‚µ‚œŒoƒJƒe[ƒeƒ‹“I‘å“®–¬•Ù’uŠ·piTAVIj device ‚Ì‘I‘ð@- “–‰@‚É‚š‚¯‚éŒoŒ±-
  78. ™àVAŒ–{‘׎¡A“y‰®‘A{“c•jAi“¡’q•FA‰H”öŽ‹MA‹e’n—ƒA‚‹ŽAâ“c‘וFA‰ºìG–ŸF‰^“®—U”­«Š¥¹k‚É”º‚€–³ÇŒó«S‹Ø‹•ŒŒ‚Ì1 —á
  79. ‹e’n—ƒA“y‰®‘A™àVA{“c•jAi“¡’q•FA‰H”öŽ‹MA”’ŒË’AŒ–{‘׎¡A‚‹ŽA‰ºìG–ŸFŠ¥¹k•”ˆÊ‚̊펿“I‹·ó‚̐is‚ðOFDI ‚ÅŠÏŽ@‚Å‚«‚œ1 —á
  80. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã
  81. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚Ì5 Ç—á
  82. ®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡Œö—YAˆÀ’B—A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸFBridge to candidacy ‚Æ‚µ‚Ä‘ÌŠOŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚œC³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  83. HŽR³”NA‰Í’яA‹g‰ªˆê˜NAˆÀ’B—AŒF’J‹Iˆê˜YA‚‹ŽA™‘ºGˆê˜YAÂ–Ø—³’jAì–{r•ãA‰ºìG–ŸAâV–؉ÀŽF“–‰@‚É‚š‚¯‚éAž‚ÝŒ^¶S•â•lHS‘Ÿ50 —á‚̐¬Ñ
  84. ˆ¢•”—Ú—žAâ“c‘וFA‹{“c•qAŽO‰Y³’šAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çA²“¡‰ë”VAÂ–ö”£AŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚錒NŠÇ—ˆÓŽ¯‚Ɛ«·‚ÉŠÖ‚·‚錀‹†-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
  85. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAÂ–ö”£AŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
  86. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VAÂ–ö”£A”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸFHFpEFAHFmrEFAHFrEF ‚É‚š‚¯‚éBNP ‚Ì—\Œã—\‘ª”\-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
  87. ‘æ2‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2017”N6ŒŽ2`3“úAŽD–yŽsj

    ƒ”ªŠªÜŽóÜu‰‰„

  88. ²“¡Œö—YF’vŽ€«ŽŸŠ³”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚œŽ¡—ÖòŠJ”­
  89. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  90. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸF“œ”A•aŽ¡—Öòƒƒgƒzƒ‹ƒ~ƒ“‚É‚æ‚é”x‚ŒŒˆ³ÇŽ¡—Â̊ù‘¶–òÄŠJ”­
  91. ™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA²“¡@—yA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFCTEPH ‚É‚š‚¯‚é“à•žŽ¡—Ã
  92. ™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çAé“c—SŽqAÎˆä’q“¿A‰ºìG–ŸFäPŒŽ•aŠÖ˜A”x‚ŒŒˆ³Ç‚É‚š‚¯‚é”xŒŒŠÇŠg’£–òŽg—p‚ÌŽÀÛ
  93. Œš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA®–ì@—ºAˆÀ’B@—A–Ø‘º³lA—§–ì@Ž A’†“‡O“¹A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF¬læ“V«SŽŸŠ³Š³ŽÒ‚Ì”x‚ŒŒˆ³Ç ] ‘œŽ{Ý“o˜^Œ€‹†‚©‚ç]
  94. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸFŒŒŽ’†ƒTƒCƒgƒJƒCƒ“‚É‚æ‚錌ŠÇ“à”çAMPK —}§‚Æ”x‚ŒŒˆ³‘£i‹@\
  95. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  96. Œš•”r‰îA™‘ºGˆê˜YA_’ÍŽ–çAÂ–Ø—³’jA‰ºìG–ŸF”x‚ŒŒˆ³ÇŠ³ŽÒ‚ÉŠÖ‚·‚é‘OŒü‚«‘å‹K–ÍŽÀ‘Ô’²ž
  97. ƒ‰ï’·“Á•ÊŠé‰æ„

  98. Satoh K, Shimokawa H. Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension.
  99. ƒYIA ƒZƒbƒVƒ‡ƒ“iŠî‘bE—DG‰‰‘èj„

  100. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö”M—TAAl-Mamun Md EliasASiddique Mohammad Abdul HaiA‹e’n‡—TA‘呺~ˆêA•àV@—ºA‹{“c@•qA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’TAFI ‚Ì‹@”\‰ðÍiYIA—DGÜŽóÜj
  101. •àV@—ºA²“¡Œö—YA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷AAbdul Hai Siddique MohammadAElias Al-Mamun Md.A»‘ºTˆê˜YA–ì–ؐ³“¹A‰ºìG–ŸF–ò•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³Ž¡—ÖòCelastamycin‚Ì”­Œ©iYIA—DGÜŽóÜj
  102. ‹e’n‡—TA²“¡Œö—YA•àV@—ºAElias-Al-Mamun Md.AAbdul Hai Siddique MohammadA‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A‹{“c@•qA‰ºìG–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\iYIAÅ—DGÜŽóÜj
  103. ƒˆê”ʉ‰‘聄

  104. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’ADAMTS8 ‚Ì‹@”\‰ðÍ
  105. Mohammad Abdul Hai SiddiqueA²“¡Œö—YA•àV@—ºAMd. Elias Al-MamunA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A»‘ºTˆê˜YA‘å’Î’mLA‰ºìG–ŸFDiscovery of Emetine as a Novel Therapeutic Agent for PAH
  106. –î”ö”M—TA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF’SŠàŠ³ŽÒ‚É‚š‚¯‚é”xÇðÇ‚̋ÌŐü—nŒn‚Ì“Á’¥
  107. Md. Elias Al-MamunA²“¡Œö—YA²“¡‘åŽ÷A–î”ö”M—TAMohammad Abdul Hai SiddiqueA‹e’n‡—TA‘呺~ˆêA•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹A‰ºìG–ŸFRivaroxaban prevents the development of CTEPH in mice
  108. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜NA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚ÌCTEPH ‚É‚š‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
  109. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFInoperable CTEPH ‚ɑ΂·‚é BPA Ž¡—Â̒·Šú—\Œã
  110. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA®–ì@—ºA²“¡Œö—YAˆÀ’B@—A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF‘ÌŠOŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚œC³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  111. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA”’ˆä„ŽuA²“¡Œö—YA‰ºìG–ŸF“«Š¥¹k«‹·SÇ‚Æ’˜–Ÿ‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚œEGPA ‚Ì1 —á
  112. …àVˆ»”TA”~“à‚Ђ낊A¯Žq@Œ\A‚–ì^ˆËŽqA–Ÿ’¿çŒbAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA™‘ºGˆê˜YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒ`ƒjƒ‹Ž‘±”牺“Š—^Š³ŽÒ‚Ìáu’ɂɑ΂·‚éŠÅŒìƒPƒA
  113. –î”ö”M—TA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇŠg’£–ò’†Ž~‚̉e‹¿
  114. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŠ`‰Ô—²ºAãŒŽ³”ŽA‰ºìG–ŸFCTEPH ‚ÆPAH ‚ÌŠÓ•Ê‚É‚š‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  115. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚œ5 Ç—á
  116. ²“¡@—yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‘å“c‰pŠöA‰ºìG–ŸF‰EŽºŒ`‘ԕω»‚ð’·ŠúŠÏŽ@‚Å‚«‚œ“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì2 Ç—á
  117. _’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yAŒã‰ªL‘Ÿ˜NA²“¡Œö—YA‹{“c@•qA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Ɛ«·‚ÌŠÖ˜A
  118. ‘æ17‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2017”N5ŒŽ19“ú`20“úA“¿“‡Žsj
  119. ˆä‹‚—z—SAŠ’JãĎqAˆÉ“¡H‘ãA“c’†C•œAÖ“¡‘åŽ÷A_ŒË–ΗYA”’ŒË@’A‰ºìG–ŸFŠ¥zŠÂ‚̍Pí«ˆÛŽ‚É‚š‚¯‚éPKG1a‚ÌŽ_‰»“IŠˆ«‰»‚̈Ӌ`‚ÌŒŸ“¢D
  120. “›ˆä³lAâ—œ‚Ü‚äŽqA•œ—Ç—YŽiA“à“c‘Ÿ˜YAŒèr”ŽA–ìŒûŽ•FA’‡@ª~ŽqA‰ºìG–ŸF2/3t“ENO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚Ì“Ë‘RŽ€‚É‚š‚¯‚鐫·D
  121. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA‰ºìG–ŸA{‰ÁŒŽˆê”ŽAŠ_‰Ô@ŠwF”][Ç‚É‚š‚¯‚éNO‡¬y‘f‚Ì—LŠQ‚ȍì—pF«·‚š‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^D
  122. ‘æ3‰ñ“ú–{S‹ØÇŒ€‹†‰ïi2017”N4ŒŽ22“úAŠò•ŒŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[„

  123. ™‘ºGˆê˜YAŽR–{¹DAŒš•”r‰îAÂ–Ø—³’jA–î”ö”M—TA_’ÍŽ–çA²“¡—yA®–ì—ºA‰ºìG–ŸFS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[SFabry•a‚É‚š‚¯‚鑁Šúf’f‚Ì‚œ‚߂̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[.
  124. ƒƒ|ƒXƒ^[”­•\„

  125. Œã‰ªL‘Ÿ˜YAâ“c‘וFA‹ž—ºˆêA”’ŒË’A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹ŽA‹{“c•qA‰ºìG–ŸF‰ä‚ª‘‚É‚š‚¯‚éŠg’£Œ^S‹ØÇ‚Ì—\Œã‚̉ü‘PFCHART-1/2Œ€‹†‚æ‚è.
  126. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸAꎓ¡—ÁŽqA‹g’·P–ŸA–îè³‰pFƒgƒ‰ƒ“ƒXƒTƒCƒŒƒ`ƒ“Œ^ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì2—á.
  127. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºA‰ºìG–ŸAHŽR³”NAì–{r•ãAâV–؉ÀŽFŒ€ÇŒ^S‹Ø‰Š‚ð‡•¹‚µ‚œ–òÜ«‰ß•qÇÇŒóŒQ‚Ì1—á.
  128. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi3ŒŽ17“ú`19“úA2017”NA‹à‘òŽsj

    ƒPlenary Session„

  129. (PL03-3:Late Complications after Repair in Adult Congenital Heart Disease)Tatebe S, Sugimura K, Aoki T, Yamamoto S, Yaoita N, Kouzu K, Sato H, Satoh K, Shimokawa H. Clinical Importance of Pulmonary Hypertension in Adults with Congenital Heart Disease after Cardiac Surgery.
  130. (PL08-5:“ú–{”­‚̃rƒbƒOƒf[ƒ^‚ð—p‚¢‚œ—Տ°Œ€‹†)Shiroto T, Sakata Y, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Nochioka K, Takahashi J, Miyata S, Shimokawa H. How can We Utilize Clinical Big Data in an Observational Study? \Lessons from the CHART-2 Study\
  131. ƒSymposium„

  132. (SY01-1:’Ž‚—ŽÐ‰ï‚É‚š‚¯‚éS•s‘S‚ÌŠÇ—EŽ¡—Ã)Takahashi J, Cui Y, Hao K, Ito K, Shimokawa H. Temporal Trends in the Prevalence and Outcomes of Heart Failure in Geriatric Patients with Acute Myocardial Infarction.
  133. (SY02-1:Vascular Biology as Interactive Science of Cardiovascular Disease)Satoh K, Sunamura S, Nogi M, Kurosawa R, Kudo S, Omura J, Kikuchi N, Sato T, Otsuki T, Suzuki K, Miura M, Aoki T, Tatebe S, Sugimura K, Sakata Y, Shimokawa H. Novel Therapeutic Targets for Cardiovascular Diseases \Rho-kinase, Cyclophilin A and Its Receptor, Basigin\
  134. (SY10-3:Molecular Basis of Cardiovascular Dysfunction in Metabolic Diseases) Godo S, Enkhjargal B, Noda K, Saito H, Shimokawa H. Importance of Endothelial Dysfunction in the Pathogenesis of Cardiovascular Insufficiency in Metabolic Disorders.
  135. (SY12-3: Understanding the Mechanism of Pulmonary Hypertension)Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Otsuki T, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Thrombin-Activatable Fibrinolysis Inhibitor Plays a Crucial Role in The Development of Chronic Throm-boembolic Pulmonary Hypertension\A Possible Novel Therapeutic Target\
  136. (SY19-2: S‘ŸˆÚA¬ÑŒüã‚Ì‚œ‚ß‚ÌŽæ‚è‘g‚Ý)Aoki T, Sugimura K,Tatebe S, Yamamoto S, Yaoita N, Sato H, Kozu K, Satoh K, Akiyama M, Kawamoto S, Saiki Y, Shimokawa H. Pulmonary Hypertension in Potential Heart Transplant Recipients with Implantable Ventricular Assist Device.
  137. ƒSpecial Session„

  138. (SS12-5:‘å‹K–͍ЊQ‚ƏzŠÂŠí•aFŽñ“s’Œ‰ºŒ^\“ìŠCƒgƒ‰ƒt‚Ö‚Ì”õ‚Š)Takahashi J, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on Cardiovascular Diseases.
  139. ƒLate Breaking Cohort Studies„

  140. (LBCS1-2:Heart Failure: Multi-organ Interaction and Treatment)Tatebe S, Sakata Y, Sugimura K, Satoh K, Shiroto T, Konno R, Adachi O, Kimura M, Tateno S, Nakajima H, Oyama K, Saiki Y, Shimokawa H. Clinical Characteristics of Adult Congenital Heart Disease in a Prospective Multicenter Cohort Study \An Initial Report from the CHART-2 Study\
  141. (LBCS2-1:Bio- and Genetic Markers for Cardiovascular Events)Odaka Y, Takahashi J, Tsuburaya R, Nishimiya K, Hao K, Matsumoto Y, Ito K, Sakata Y, Miyata S, Manita D, Hirowatari Y, Shimokawa H. Plasma Levels of Serotonin as a Novel Biomarker for Co-presence of Coronary Microvascular Dysfunction in Patient with Vasospastic Angina.
  142. (LBCS4-1:Environmental Factors of Atrial Fibrillation and Treatment)Sakata Y, Yamauchi T, Nochioka K, Shiroto T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Ninomiya T, Shimokawa H. Establishment of Predictive Models of New-onset Atrial Fibrillation Based on Clinical Background: Insights from the CHART-2 and the Hisayama Studies.
  143. (LBCS6-6:Advanced Vascular Interventions: Techniques and Outcomes)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Kozu K, Sato H, Konno R, Nochioka K, Satoh K, Shimokawa H. Long-term Beneficial Effects of Balloon Pulmonary Angioplasty on Hemodynamics and Prognosis in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  144. ƒLate Breaking Cohort Studies-poster„

  145. (LBCSP2-2:Systemic Thrombosis and Treatment)Shiroto T, Sakata Y, Nochioka K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Shimokawa H. Temporal Trend in Antithrombotic Therapies in Patients with Cardiovascular Diseases \Report from the CHART-2 Study\
  146. (LBCSP1-3:Risk Factor Analysis for Cardiovascular Events)Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Sato H, Nochioka K, Satoh K, Miyata S, Shimokawa H. Long-term Prognosis of Patients with Pulmonary Hypertension for All Subtypes \A Single Center Experience\
  147. ƒJapan Heart Foundation Satoh Memorial Award Lecture„

  148. Satoh K. Development of Novel Therapies for Cardiovascular Diseases by Clinical Application of Basic Research.
  149. ƒCirculation Journal Award Session„

  150. (Clinical Investigation:Second Place)Suzuki H. Hippocampal Blood Flow Abnormality Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure.
  151. ƒYoung Investigator's Award Finalists Lectures (Basic Research)„

  152. Kikuchi N, Satoh K, Omura J, Satoh T, Kurosawa R, Nogi M, Sunamura S, Otsuki T, Numano K, Yaoita N, Yamamoto S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Pulmonary Arterial Smooth Muscle Cell Proliferation and Pulmonary Arterial Hypertension. iÅ—DGÜŽóÜj
  153. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  154. Odaka Y, Takahashi J, Suda A, Komatsu M, Kikuchi Y, Hao K, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Plasma Concentration of Serotonin is a Novel Biomarker for Coronary Microvascular Dysfunction in Patients with Suspected Angina and Unobstructive Coronary Arteries.
  155. ƒYoung Investigatorfs Award for International Students Finalists Lectures„

  156. Mohammad Abdul Hai Siddique, Satoh K, Kurosawa R, Md. Elias-Al Mamun, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Shimokawa H. Identification of Emetine as a Novel Therapeutic Agent for Pulmonary Hypertension in Rats\Highthroughput Screening of 5,562 Compounds\
  157. ƒLuncheon Seminar„

  158. (LS67-2:zŠÂŠí“à‰Èˆã‚Ì“úíf—Âɐö‚Þˆâ“`«ŽŸŠ³)Sugimura K.ƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚鑁Šúf’fE‘ŠúŽ¡—Â̏d—v«`“–‰@@zŠÂŠí“à‰È‚É‚š‚¯‚éf’fEŽ¡—Â̎æ‚è‘g‚Ý.
  159. ƒOral Presentation (English)„

  160. (OE-063:Fontan/ACHD)Kimura Y, Fukuda K, Nakano M, Hasebe Y, Chiba T, Miki K, Tatebe S, Kimura M, Adachi O, Saiki Y, Shimokawa H. Clinical Impact of Atrioventricular Conduction Disturbance on Lethal Ventricular Arrhythmias in Patients with Total Correction of Tetralogy of Fallot.
  161. (OE-079:Angina Pectoris (Clinical) 1)Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Komatsu M, Odaka Y, Matsumoto Y, Sakata Y, Shimokawa H. Rho-kinase Inhibition with Intracoronary Fasudil Restores Coronary Microvascular Dysfunction in Patients with Vasospastic Angina.
  162. (OE-141:Heart Failure (Laboratory/Biomarkers)1)Otsuki T, Satoh K, Omura J, Kikuchi N, Sato T, Kurosawa R, Sunamura S, Nogi M, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Plasma Levels of Cyclophilin A are Associated with Increased Mortality in Patients with Heart Failure.
  163. (OE-205:Heart Failure (Basic))Sunamura S, Satoh K, Suzuki K, Kudo S, Ikeda S, Omura J, Kikuchi N, Sato T, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H. Crucial Role of ROCK1 to Maintain Cardiac Contractile Function in Response to Chronic Pressure-Overload in Mice.
  164. (OE-248:Heart Failure (Laboratory/Biomarkers) 2)Nochioka K, Sakata Y, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Shirato T, Miyata S, Takahashi J, Shimokawa H. Incidence and Determinant Factors of Hospitalization for Worsening Heart Failure in Patients Treated with Diuretics in the CHART-2 Study.
  165. (OE-259:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Ohtsuki T, Kozu K, Suzuki K, Yaoita N, Aoki T, Tatebe S, Sugimura K, Shimokawa H. A Disintegrin and Metalloproteinase with Throm- bospondin Motifs 8 (ADAMTS8) Promotes Hypoxia-induced Pulmonary Hypertension in Mice.
  166. (OE-330:Arrhythmia, Others (Clinical/Diagnosis/Treatment)1)Nakano M, Fukuda K, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Feasibility of Subcutaneous Implantable Cardioverter Defibrillator on the Detection Mechanisms.
  167. (OE-295:Vascular Biology)Nogi M, Satoh K, Kudo S, Omura J, Kikuchi N, Sato T, Sunamura S, Kurosawa R, Otsuki T, Suzuki K, Shimokawa H. Protective Roles of Small GTP-binding Protein GDP Dissociation Stimulator (SmgGDS) against Angiotensin II-induced Thoracic Aortic Dissection and Rupture in Mice.
  168. (OE-366:ACS/AMI (Basic))Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shiroto T, Miyata S, Taki H, Kanai H, Shimokawa H. Molecular Mechanisms for Low-intensity Pulsed Ultrasound-induced Angiogenesis: Contribution of Mechano-transduction.
  169. ƒOral Presentation (Japanese) „

  170. (OJ-014:Heart Failure (Laboratory/Biomarkers))Kasahara S, Sakata Y, Nochioka K,Tsuji K, Onose T, Abe R, Oikawa T, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Prognostic Risk Stratification with B-type Natriuretic Peptide for HFpEF, Borderline HFpEF and HFrEF Patients \A Report from the CHART-2 Study\
  171. (OJ-053:Cardiomyopathy/Hypertrophy (Clinical))Yamamoto S, Sugimura K, Suzuki H, Tatebe S, Aoki T, Yaoita N, Sato H, Kozu K, Ota H, Takanami K, Takase K, Satoh K, Shimokawa H. Novel Diagnostic Strategy for Cardiac Involvement in Patients with Anderson-Fabry Disease.
  172. (OJ-079:Heart Failure (Pharmacology))Oikawa T, Sakata Y, Nochioka K, Tsuji K, Onose T, Abe R, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Intensity of Statin Therapy and Prognosis in Patients with Ischemic Heart Failure\A Report from the CHART-2 Study\
  173. (OJ-091:Angina Pectoris (Clinical))Odaka Y, Takahashi J, Hao K, Kikuchi Y, Suda A, Komatsu M, Matsumoto Y, Ito K, Miyata S, Sakata Y, Shimokawa H. Sustained Myocardial Ischemia in Patients with Microvascular Angina Even after Nitrate Administration.
  174. ƒFeatured Research Session„

  175. (FRS-099:Coronary Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Morosawa S, Hirano M, Watabe H, Funaki Y, Takahashi J, Ito K, Shimokawa H. Inflammatory Changes of Perivascular Adipose Tissue in the Pathogenesis of DES-induced Hyperconstricting Responses in Pigs \Usefulness of 18F-FDG PET Imaging\
  176. (FRS-106:Pulmonary Circulation)Kurosawa R, Satoh K, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Suzuki K, Hai Siddique Mohammad Abdul, Shimokawa H. Celastramycin Inhibits Pulmonary Arterial Smooth Muscle Cell Proliferation and Ameliorates Hypoxia-induced Pulmonary Hypertension.

    ƒExcellent Case Presentation by Young Careers in English„

  177. (ECP2-1)Sugisawa J, Matsumoto Y, Tsuchiya S, Suda A, Shindo T, Kikuchi Y, Hao K, Takahashi J, Shimokawa H. Silent Myocardial Ischemia Associated with Exercise-Induced Coronary Artery Spasm.
  178. ƒPoster Session (English)„

  179. (PE-264:Heart Failure (Non-pharmacology) 1)Hao K, Takahashi J, Sakata Y, Miyata S, Shiroto T, Nochioka K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Sato M, Kasahara S, Shimokawa H. Prognostic Impact of Residual Coronary Artery Stenosis in Patients with Ischemic Heart Failure after Percutaneous Coronary Intervention.
  180. (PE-395:Arrhythmia, Others (Basic))Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Morosawa S, Amamizu H, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System\A Validation Study in Pigs in Vivo\
  181. (PE-442:Heart Failure (Basic) 2)Ogata T, Ito K, Shindo T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Contractile Cardiac Func-tion of Pressure-Overloaded Hearts in Mice.
  182. (PE-458:Heart Failure (Laboratory/Biomarkers) 2)Sato M, Sakata Y, Nochioka K, Sato K, Onose T, Tsuji K, Oikawa T, Abe R, Kasahara S, Yamauchi T, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure: A Report from the CHART-2 Study.
  183. (PE-685:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical) 2)Uzuka H, Matsumoto Y, Nishimiya K, Ohyama K, Amamizu H, Morosawa S, Hirano M, Shindo T, Kikuchi Y, Hao K, Shiroto T, Ito K, Takahashi J, Fukuda K, Funaki Y, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo \Evidence for the Kidney-Brain-Heart Axis\
  184. (PE-393:Arrhythmia, Others (Basic))Morosawa S, Yamamoto H, Hirano M, Uzuka H, Oyama K, Hasebe Y, Nakano M, Fukuda K, Shimokawa H. Impact of a New Shock Wave Catheter Ablation System on the Depth of Myocardial Lesions in Pigs in Vivo.
  185. (PE-786:Pulmonary Circulation 2)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Sato H, Kouzu K, Nochioka K, Satoh K, Shimokawa H. Effectiveness and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  186. ƒPoster Session (Japanese)„

  187. (PJ-219:Heart Failure, Atrial Fibrillation, and Obesity)Abe R, Sakata Y, Nochioka K, Onose T, Tsuji K, Oikawa T, Kasahara S, Sato M, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Association between Health Consciousness and Mortality in Patients with Heart Failure \A Report from the CHART-2 Study\
  188. (PJ-278:Heart Failure (Non-pharmacology))Tsuji K, Sakata Y, Nochioka K, Miura M, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics of Heart Failure Patients with Mid-range Ejection Fraction \A Report from the CHART-2 Study\
  189. (PJ-284:Pulmonary Circulation)Sato H, Ota H, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Kozu K, Satoh K, Shimokawa H. Balloon Pulmonary Angioplasty Improves Biventricular Functions in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  190. (PJ-285:Pulmonary Circulation)Tanaka S, Sato S, Kajitani S, Ikumi Y, Ito A, Saito H, Godo S, Shiroto T, Shimokawa H. Roles of Endothelium-Dependent Hyperpolarization in Pulmonary Microcirculation in Mice \Implications for Pulmonary Hypertension\
  191. (PJ-242: Ventricular Arrhythmia (Clinical/Diagnosis/Treatment)2)Hasebe Y, Fukuda K, Nakano M, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Enlarged Left Ventricular Dimension on Ventricular Fibrillation Event in Patients with Ischemic Cardiomyopathy and Implantable Cardioverter Defibrillator.
  192. (PJ-290:ACS/AMI (Clinical/Treatment) 1)Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Kikuchi Y, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in Emergency Care and Outcomes of Geriatric Patients with Acute Myocardial Infarction in Japan.
  193. (PJ-311:Gender Differences)Onose T, Sakata Y, Nochioka K, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Miyata S, Takahashi J, Shimokawa H. Sex Differences in Post-traumatic Stress Disorder in Cardiovascular Patients after the Great East Japan Earthquake \The CHART-2 Study\
  194. (PJ-346:Arrhythmia, Others (Clinical/Diagnosis/Treatment)3)Miki K, Fukuda K, Nakano M, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Morosawa S, Shimokawa H. Impact of Types of Atrial Fibrillation on Characteristics of Silent Brain Infarcts in Patients with Non-valvular Atrial Fibrillation.
  195. (PJ-673:Cardiac Arrest/Resuscitation)Komatsu M, Takahashi J, Hao K, Kikuchi Y, Odaka Y, Suda A, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Long-term Prognosis of Out-of-hospital Cardiac Arrest Survivors with Vasospastic Angina \An Update\
  196. (CP-236:ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Eg‘ÌŠˆ“®6)Takeuchi M, Matsumoto Y, Kawamoto S, Takahashi J, Aoki T, Sugimura K, Miyata S, Kozuki M, Arai H, Saiki Y, Shimokawa H. ŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚ɑ΂·‚éŒp‘±“I‚ȃtƒŒƒCƒ‹ƒKƒCƒh‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚́ApŒã‰ñ•œƒŒƒxƒ‹‚ð—\‘ª‚µAÝ‘îŠú‚ÌQOL ‚ƃtƒŒƒCƒ‹‚ð‰ü‘P‚·‚é.
  197. ‘æ46‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2ŒŽ10“ú`11“úA2017”NA“ß”eŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS–¬ŠÇì“®•šŽ¿‚Ì‹Ž“n‚µŒ€‹†„

  198. ²“¡Œö—YA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’‚É’…–Ú‚µ‚œ‘Šúf’f–@‚ƐV‹KŽ¡—ÖòŠJ”­‚̉”\«
  199. ƒYIAƒZƒbƒVƒ‡ƒ“„

  200. •àV —ºFV‹K”x‚ŒŒˆ³ÇŽ¡—ÖòƒZƒ‰ƒXƒgƒ‰ƒ}ƒCƒVƒ“‚Ì”­Œ©
  201. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  202. –ì–ؐ³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘º Tˆê˜YA•àV —ºA‘å’Î’mLAÀ–ì˜a•FA—é–؍N‘ŸA‰ºìG–ŸFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“2ŽhŒƒ‚ł̃}ƒEƒX‚Ì‹¹•”‘å“®–¬‰ð—£‚š‚æ‚Ñ‹¹•”‘å“®–¬áŽƒ‚ƒfƒ‹‚É‚š‚¯‚éSmall GTP-binding Protein GDP Dissociation Stimulator‚Ì•ÛŒì“I‚È–ðŠ„
  203. »‘º Tˆê˜YA²“¡Œö—YA—é–؍N‘ŸAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºA–ì–ؐ³“¹A‘å’Î’mLAÀ–ì˜a•FA‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  204. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö” M—TA‹e’n‡—TA‘呺~ˆêA•àV —ºAMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’TAFI‚Ì‹@”\‰ðÍ
  205. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºAÀ–ì˜a•FA_’ÍŽ–çAÂ–Ø—³’jAŒš•”r‰îA™‘º Gˆê˜YA‰ºìG–ŸFADAMTS8‚Í”x‚ŒŒˆ³‚É‚š‚¯‚é”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚ƉES•s‘S‚𑝈«‚³‚¹‚é
  206. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  207. ‰ºì G–ŸFŽ‰Ž¿ˆÙíÇŽ¡—Â̍ŋ߂̐i•à
  208. ‘æ10‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2017”N1ŒŽ28`29“úA–ŒŒÃ‰®j

    ƒÅ—DG‰‰‘èÜ„

  209. {“c@•jA‚‹Ž@A‰H”öŽ‹MAi“¡’q•FA¬Œ^‹±A¬‘é—I“ñAŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚銥”÷¬ŒŒŠÇ‹@”\ˆÙí‚̐«·‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
  210. ƒ—DG‰‰‘èŒó•â„

  211. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YA¬–쐣„¶A’ҁ@ŒOØŽqAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‹{“c@•qA‰ºìG–ŸFS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚éƒXƒ^ƒ`ƒ“Ž¡—Ẩe‹¿‚Ì’j—·.
  212. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚ª–«S•s‘SŠ³ŽÒ‚ÌBNP’l‚Æ—\Œã‚Æ‚Ì‘ŠŠÖ‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·FCHART-2Œ€‹†‚©‚ç‚Ì•ñ.
  213. _’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡@ꡁAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‹{“c@•qF’PˆêŽ{Ý‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‘S—Տ°•ª—Þ‚Ì’·Šú—\Œã‚ÌŒŸ“¢.
  214. ƒƒVƒ“ƒ|ƒWƒEƒ€FzŠÂŠíŽŸŠ³‚É‚š‚¯‚鐫·‚Æ‚»‚̑Ήž„

  215. ‚‹Ž@A‰ºìG–ŸFŠ¥zŠÂ‹@”\ˆÙí‚É‚š‚¯‚鐫·.
  216. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  217. ’ҁ@ŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA¬–쐣„¶A‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA”’ŒË@’A‹{“c@•qA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚̍¶Žº‹ìo—Š‚ÌŒoŽž•Ï‰»‚Ɛ«·@\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  218. ›Á@Œ³‹gA‰H”öŽ‹MA‚‹Ž@A‹{“c@•qAi“¡’q•FA‹e’n@—ƒAŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸF‚—îS‹Ø[ÇŠ³ŽÒ‚ÌŠ³ŽÒ”wŒi‚Ɖ@“àŽ€–S—Š‚É‚š‚¯‚鐫·‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
  219. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–ŸFS–[×“®Š³ŽÒ‚Ì•aŠú‚É‚æ‚鍶SŽšŒŒ—¬‘¬“x’ቺ—\‘ªˆöŽq‚̐«·‚ÉŠÖ‚·‚錟“¢.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2016”N(*µ‘ҍu‰‰j
‘æ1‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2016”N12ŒŽ4“úAå‘äj

    ƒˆê”ʉ‰‘èiŒûqj„

  1. ˆÉ“¡CA‰ºìG–ŸAãŒŽ³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ãŽt‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. [àV‹±”V˜NA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘ŸA‰ºìG–ŸFS–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‰^“®‘Ï—e”\‚É—^‚Š‚é—L—p«‚ɂ‚¢‚Ä
  4. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  5. ™àVAŠ`‰Ô—²ºA{“c•jAi“¡’q•FA‰H”öŽ‹MA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽAâ“c‘וFA‰ºìG–ŸF•ÂÇ«“®–¬d‰»Ç‚ɑ΂·‚é‰^“®—Ö@ŒãA•às‹——£‚̉„’·‚É‚æ‚è‹·S’É‚ªŒ°Ý‰»‚µAŒŒsÄŒš‚ðŽ{s‚µ‚œ‚P—á
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA’|“à‰ëŽjAŠ`‰Ô—²ºA‰ºìG–ŸAãŒŽ³”ŽF”x“®–¬‹·ó‚É‚æ‚é”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—ÂƕÀs‚µAˆÀ‘S‚ɉ^“®—Ö@‚ðŽ{s‚µ‚œ1—á
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  9. ’|“à‰ëŽjAŒ–{‘׎¡A‰ºìG–ŸFzŠÂŠíf—Âɂš‚¢‚ătƒŒƒCƒ‹‚ð‚Ç‚Ì‚æ‚€‚ɍŽ•ž‚·‚é‚©|S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì–ðŠ„|
‘æ163‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N12ŒŽ3“úAå‘äj

    ƒYIAÇ—á”­•\•”–偄i*Å—DGÜŽóÜj

  1. *®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA‰H”öŽ‹MA‚‹ŽA’†–쐜A•Ÿ“c_“ñA‰ºìG–ŸA”’ˆä„ŽuAÎˆä’q“¿A™‰Y‹v•qA’†“ˆ@‘s‘ŸFSŽº×“®‚Å”­Ç‚µŠ¥¹k«‹·SÇ‚Æ”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œDŽ_‹…«‘œ”­ŒŒŠÇ‰Š«“÷‰èŽîÇiEGPAj‚Ì‚P—á
  2. ƒYIAŒ€‹†”­•\•”–偄i*Å—DGÜŽóÜj

  3. *’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË’A‚‹ŽA‹{“c•qA‰ºì@G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¢‚趎º‹ìo—Š‚̕ω»‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿ |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  4. ƒˆê”ʉ‰‘聄

  5. ²“¡ŒöˆêA˜Q‘Ő¬lA™]³A‘ëˆä’šA‹ž—ºˆêA‰Á“¡“ցA‰ºìG–ŸFÁ‰»ŠÇoŒŒŠ³ŽÒ‚ªŽó‚¯‚Ä‚¢‚œRŒŒð—Ö@‚Æ‚»‚Ì——R
  6. ²“¡—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–ŸF‘å“®–¬•Ù“ñë•Ù‚É‚æ‚é‘å“®–¬•Ù•Âœ•s‘SÇ‚ƍ¶Žºãk–§‰»áŠQ‚ª‡•¹‚µ‚œˆê—á
  7. ‚–Ø—S‰îAH“¡rA”·Œ’ˆê˜YA£ì«lA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸFdÇ‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚é‹Ù‹}ƒoƒ‹[ƒ“Šg’£p‚̗Տ°¬Ñ
  8. “y‰®‘AŒ–{‘׎¡A‚‹ŽA™‘ºGˆê˜YA‹e’n—ƒA‰H”öŽ‹MAi“¡’q•FA{“c•jA™àVA‰ºìG–ŸAŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽF’áS‹@”\‚𔺂Á‚œdÇ‘å“®–¬•Ù‹·óÇ‚ɐlHS”xƒTƒ|[ƒg‰º‚Å TAVI ‚ðŽ{s‚µ‚œ 2 —á
  9. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF—¯’u‚©‚ç 1 ”N‚ðŒo‚Ä IVC filter ‚𔲋Ž‚µ‚œ 1 —á
  10. ”·Œ’ˆê˜YA£ì«lAH“¡rA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸF”DP 37 T‚Å‚­‚à–Œ‰ºoŒŒ‚𔭏ǂµAS•s‘S‚ð‡•¹AS‹@”\’ቺ‚ª‘J‰„‚µ‚œ 1 —á
  11. {“c•jA‚‹ŽA‰H”öŽ‹MA‹e’n—ƒAi“¡’q•FA™àVAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k‚É‚æ‚é”ñ•ÂÇ«Š¥“®–¬S‹Ø[Ç (MINOCA) ‚ª‹^‚í‚ê‚œˆê—á
  12. ™àVA‰H”öŽ‹MA{“c•jA›ÁŒ³‹gAi“¡’q•FA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽAˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºì@G–ŸF¶‰ñùŽ}‘€Ž}‚ðÓ”C•a•Ï‚Æ‚·‚é‹}«S‹Ø[Ç‚É“û“ª‹Ø’f—ô‚ð‡•¹‚µ‚œ‚P—á
  13. Š’JãĎqA‹e’n—ƒA“y‰®‘A™àVA{“c•jA›ÁŒ³‹gAi“¡’q•FA‰H”öŽ‹MAŒ–{‘׎¡A‚‹ŽAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFbó‘B‹@”\˜ŽiŽž‚ÉŠ¥¹k‚É‚æ‚éSŽº×“®‚𔭏ǂµ‚œˆê—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFƒfƒoƒCƒXŠŽõ‚𗈂µƒŒ[ƒU[ƒŠ[ƒh”²‹Ž‚š‚æ‚є牺Až‚ÝŒ^œ×“®ŠíAž‚ݏp‚ðŽ{s‚µ‚œ“Á”­«SŽº×“®Ç—á
  15. ’†–쐜A•Ÿ“c_“ñA’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF‰EŽº“û“ª‹Ø‹NŒ¹SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œ•s®–¬ŒŽ«‰EŽºS‹ØÇÇ—á
  16. £ì«lAH“¡rA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸFSŒ¹«Çð‚ð 2 “x‹N‚±‚µ‚œS–[×“®‚̈ê—á
  17. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò‘EA‰ºìG–ŸF‘OŽž_‚ÌŒŽˆö‚Æ‚µ‚ĐSŽº•p”‚ƐS–[•p”‚ÌŠÓ•Ê‚ªd—v‚Å‚ ‚Á‚œƒtƒ@ƒ[Žl’¥ÇpŒã‚Ì‚P—á
  18. [àV‹±”V˜NA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘ŸA‰ºìG–ŸF”­ì«S–[×“®Š³ŽÒ‚̉^“®‘Ï—p”\‚ƃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é“Ž’²—¥ˆÛŽ‚ÌŠÖ˜A
  19. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸAHŽR³”NAì–{r•ãAâV–؉ÀŽFA‚Šž‚ÝŒ^•â•lHS‘Ÿ‘•’…Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  20. ”—“c‚Ý‚­AÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA²“¡—yAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFÄ”­«ŠŽõ«S“à–Œ‰Š‚̈ê—á
  21. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YA™³•¶A‰ºìG–Ÿ FSFA ‚ÌŒŒð«•ÂÇ‚É‚š‚¯‚錌ð—n‰ð—Ö@‚𕹗p‚µ‚œ 2-step EVT –@‚ÌŒŸ“¢
  22. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YA™³•¶A‰ºìG–ŸFOPTIMO Sheathless ƒJƒe[ƒeƒ‹‚Ì•¹—p‚É‚Ä SFA ‚̃Xƒeƒ“ƒg“àŒŒð«•ÂÇ‚ÌŠ®‘SŒŒsÄŒš‚ɐ¬Œ÷‚µ‚œˆê—á
  23. ²“¡‰ë”VAâ“c‘וFAŒã‰ªL‘Ÿ˜YA²“¡Œª“ñ˜YA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŽR“à‹BA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢ |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  24. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ðˆÀ‘S‚ÉŽ{s‚Å‚«‚œƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
  25. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šA¬–쐣„¶A’ÒŒOØŽqAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çA²“¡‰ë”VAŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚錒NˆÓŽ¯‚ƐS•s‘S“ü‰@‚ÉŠÖ‚·‚錀‹† |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  26. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË’A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹ŽA‰ºìG–ŸA‹{“c•qFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì—\Œã‚ւ̉e‹¿ |CHART-2Œ€‹†‚æ‚è|
  27. Œã‰ªL‘Ÿ˜YAâ“c‘וFA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF–«S•s‘S‚̐S•s‘S“ü‰@D”­ŽžŠúEŠëŒ¯ˆöŽqFCHART-2 Œ€‹†
‘æ13‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ïi2016”N10ŒŽ22“úAå‘äj

    ƒ“Á•Êu‰‰„

  1. *‰ºìG–ŸFzŠÂŠíŠÅŒì‚É‚š‚¯‚éƒn[ƒgƒ`[ƒ€‚̏d—v«
‘æ57‰ñ “ú–{–¬ŠÇŠw‰ï‘‰ïi2016”N10ŒŽ13`15“úA“ޗǁj

    ƒˆê”ʉ‰‘è@Œûq„

  1. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éBPA‚̍‡•¹Ç‚Æ—\Œã‚ÌŒŸ“¢
  2. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[„

  3. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ªˆÀ‘S‚ÉŽ{s‚Å‚«‚œƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
‘æ20‰ñ“ú–{S•s‘SŠw‰ïi2016”N10ŒŽ7`9“úAŽD–yj

    ƒ“Á•ÊŠé‰æ2 “Á”­«S‹ØÇ’²žŒ€‹†”ǁEŠg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ€‹†”Ǎ‡“¯¬‰Ê•ñ `S‹ØÇŒ€‹†‚̍őOü`i“Á”­«S‹ØÇ’²žŒ€‹†”Ç / Šg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ€‹†”Ç / ‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïj„

  1. ‰ºìG–ŸFTrends in Clinical Characteristics, Treatments and Prognosis in Patients with Dilated Cardiomyopathy in Japan -Epidemiologic Insights from the CHART Studies-
  2. ƒYIA Ržu‰‰ —Տ°2„

  3. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šA‹{“c•qAŒã‰ªL‘Ÿ˜YAŽR“à‹BA¬–쐣„A”’ŒË’A‚‹ŽA‰ºìG–ŸF¶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚̗Տ°Šw“I“Á’¥‚ɂ‚¢‚ā@-CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©-
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€4 ‹•ŒŒ«S•s‘S‚ÌŽ¡—Ð헪„

  5. ‰H”öŽ‹MA‚‹ŽA‹{“c•qAâ“c‘וFA‰ºìG–ŸF‹•ŒŒ«S•s‘SŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚Š‚é‰e‹¿
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€6 •â•lHS‘Ÿ‚Ì–â‘è“_‚ðl‚Š‚遄

  7. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡Œö—YAHŽR³”NAì–{r•ãAÖ–؉ÀŽA‰ºìG–ŸFSŽº•â•ƒfƒoƒCƒXŽg—pŠ³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÌŒŸ“¢
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€14 S•s‘S‚̃oƒCƒIƒ}[ƒJ[„

  9. ²“¡Œö—YA—é–؍N‘ŸA‘å’Î’mLA»‘ºTˆê˜YAH“¡rA’r“c®•œAŽ…‹œA‰ºìG–ŸFS•s‘S‚̐V‚µ‚¢ƒoƒCƒIƒ}[ƒJ[: Cyclophilin A‚ÆBasigin -Šî‘bŒ€‹†‚̗Տ°‰ž—p-
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€16 S–[×“®‡•¹S•s‘SŠ³ŽÒ‚Ì–â‘è“_‚ÆŽ¡—Ð헪„

  11. ŽR“à‹BAâ“c‘וFA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‹{“c•qA‰ºìG–ŸF–«S•s‘S‚É‚š‚¯‚éS–[×“®”­ÇŒã‚ÌŒo‰ßŽžŠÔ‚Æ—\Œã‚ւ̉e‹¿‚Æ‚ÌŠÖ˜A‚ÌŒŸ“¢FCHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  12. ƒƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€5 “ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï@‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  13. â“c‘וFA‰ºìG–ŸFHeart Failure Pandemic : Lessons from Japan's Experience
  14. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3 V‚œ‚ȐS•s‘SŽ¡—ÊJ”­Œ€‹†iŠî‘bA—Տ°A‰uŠwŒ€‹†‚Ì—§ê‚©‚çj„

  15. â“c‘וFA‰ºìG–ŸFV‚œ‚ȐS•s‘SŽ¡—ÊJ”­Œ€‹†:‰uŠwŒ€‹†‚Ì—§ê‚©‚ç -‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^Œ€‹†‚©‚ç‚Ì’mŒ©-
  16. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[13 ƒtƒ@ƒuƒŠ[•af—Â̎ÀÛ`‚»‚ÌŽæ‚è‘g‚݂ɂ‚¢‚ā`„

  17. ™‘ºGˆê˜YFƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚鑁ŠúŒŸžEf’fEŽ¡—Â̏d—v«@`ƒtƒ@ƒuƒŠ[•a‘΍ô‚̏d“_ƒ|ƒCƒ“ƒg`
  18. ƒˆê”ÊŒû‰‰6 ‹•ŒŒ«ŽŸŠ³1„

  19. ‹yì‘ì–çAâ“c‘וFAŽR“à‹BA’ÒŒOØŽqA¬–쐣„¶AŠ}ŒŽM‘Ÿ˜YA”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸFƒXƒ^ƒ`ƒ“‚ª‹•ŒŒ«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢@-CHART-2 Œ€‹†‚É‚š‚¯‚é–òÜ‹­“x•Ê‚ÌŒŸ“¢-
  20. ƒˆê”ÊŒû‰‰11 ‰æ‘œf’f„

  21. ŽR–{¹DA—é–؏G–ŸA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šA–î”ö”M—TA‚˜QŒ’‘Ÿ˜YA‚£Œ\A‰ºìG–ŸFFabry•aŠ³ŽÒ‚É‚š‚¯‚éS‹ØMIBGƒVƒ“ƒ`ƒOƒ‰ƒtƒB[‚Ì—L—p«
  22. ƒˆê”ÊŒû‰‰12 ƒoƒCƒIƒ}[ƒJ[3„

  23. ‘å’Î’mLA²“¡Œö—YA‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A»‘ºTˆê˜YA™‘ºGˆê˜YAŒš•”r‰îA‹{“c•qA‰ºìG–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SŠ³ŽÒ‚Ì’·Šú—\Œã—\‘ª
  24. ƒˆê”ÊŒû‰‰13 •Ù–ŒÇ1„

  25. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãAŒF’J‹Iˆê˜YAŽO‰Y³’šA™‘ºGˆê˜YA‚‹ŽAÖ–؉ÀŽAãŒŽ³”ŽA‰ºìG–ŸFSƒŠƒn‚Í‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚é‘Sg–ƒŒ‰ºTAVIŒã‚ɒቺ‚·‚ég‘Ì‹@”\‚ð‰ü‘P‚·‚éFƒtƒŒƒCƒ‹•]‰¿‚̏d—v
  26. ƒˆê”ÊŒû‰‰26 CRT„

  27. ç—t‹M•FA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF–{–M‚É‚š‚¯‚éCRTƒy[ƒVƒ“ƒO•”ˆÊ‚É‚æ‚é—Տ°Œø‰Ê‚ÉŠÖ‚·‚錟“¢
  28. ƒƒ|ƒXƒ^[6 S‹Ø‰Ši1j-Ç—á•ñ„

  29. ®–ì—ºAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çAHŽR³”NAÖ–؉ÀŽA‰ºìG–ŸFƒƒLƒVƒŒƒ`ƒ“‚É‚æ‚é–òÜ«‰ß•qÇÇŒóŒQiDIHSj‚ÉŒ€ÇŒ^S‹Ø‰Š‚𕹔­‚µ‚œˆê—á
  30. ƒE ƒ|ƒXƒ^[9 Šî‘bŒ€‹†4„

  31. »‘ºTˆê˜YA²“¡Œö—YA—é–؍N‘ŸA’r“c®•œA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A–ì–ؐ³“¹AŽ…‹œA‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  32. ƒE ƒ|ƒXƒ^[13 International3„

  33. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŽR“à‹BA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË’A‹{“c•qA‰ºìG–ŸFHFpEF‚ÆHFrEF‚É‚š‚¯‚éBNP‚Ì“¯“™‚È—\Œã—\‘ªŒø‰Ê -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
‘æ1‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2016”N10ŒŽ1`2“úA“Œ‹žj

    ƒYIA ƒZƒbƒVƒ‡ƒ“„

  1. ‘呺 ~ˆêA²“¡ Œö—YA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–ŸFAMPK ‚Ì”x‚ŒŒˆ³Ç”­Ç‚ɑ΂·‚é—}§‹@\‚̉𖟁i—DGÜŽóÜj
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€3 ‹­”çÇ‚É‚æ‚é”x‚ŒŒˆ³Ç‚Ì–â‘è“_if’fAŽ¡—ÁA“W–]j„

  3. é“c —SŽqAÎˆä —IãāA¯ —z‰îA“¡“c —mŽqA”’ˆä „ŽuA“¡ˆä ”ŽŽiA™‘º Gˆê˜YA‰ºì G–ŸAÎˆä ’q“¿A’£‘Ö G˜YF‹­”çÇ‚ƃVƒF[ƒOƒŒƒ“ÇŒóŒQ‡•¹”x“®–¬«”x‚ŒŒˆ³Ç‚ÌŽ¡—Ã
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€6 PH ‚ɑ΂·‚éÅVŠî‘bŒ€‹†‚̐¬‰Ê„

  5. ²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’”­Œ©‚ƐV‹KŽ¡—Öò’Tõ
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€7 ”x“®–¬Œ`¬‚Ì‚·‚ׂā„

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA_’à Ž–çA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFOCT guided BPA
  8. ƒˆê”ʉ‰‘è2 Ç—á•ñ1„

  9. ‹e’n —ƒAŽR–{ ¹DA™‘º Gˆê˜YAÈÀ ‚肱A‘å–{ ‰pŽŸ˜YA“n•” Œ«A‚‹Ž Ž–ŸAŒˆä Š²”VAŒã“¡ •q˜aA‰ºì G–ŸF––œŒŒŠ²×–EˆÚA‚É‚æ‚è”x‚ŒŒˆ³‚ª‰ü‘P‚µ‚œPOEMS ÇŒóŒQ‚Ì‚P—á
  10. ƒˆê”ʉ‰‘è3 —Տ°Œ€‹†1„

  11. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA_’à Ž–çA²“¡ Œö—YAHŽR ³”NAì–{ r•ãAâV–Ø ‰ÀŽA‰ºì G–ŸFA‚Šž‚ÝŒ^•â•lHS‘Ÿ‘•’…Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  12. ƒˆê”ʉ‰‘è5 ”x‚ŒŒˆ³E”xzŠÂ‚ÌŠî‘b„

  13. •àV —ºA²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷AMohammad Abdul Hai SiddiqueA Md. Elias Al-MamunAŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–ŸF‰»‡•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­
  14. ‹e’n ‡—TA²“¡ Œö—YA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹AŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. ²“¡ ‘åŽ÷A²“¡ Œö—YA–î”ö” M—TA‹e’n ‡—TA‘呺 ~ˆêA•àV —ºAMd. Elias Al-MamunA Mohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºì G–ŸFV‹K•aˆö’`”’TAFI ‚É‚æ‚閝«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”­Ç‹@\
  16. ƒˆê”ʉ‰‘è6 ŠO‰ÈŽ¡—ÁiPEAA”xˆÚAjE‚»‚Ì‘Œ„

  17. HŒŽ ŽO“ށA™‘º Gˆê˜YAÂ–Ø —³’jAŠ`‰Ô —²ºAˆÉ“¡ CAãŒŽ ³”ŽA‰ºì G–ŸFCTEPH ‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚œ”ñNP“I‚ȏdÇ“x•]‰¿–@
  18. —é–Ø G–ŸA™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇiCTEPHj‚Æ“‡Žž’²Ç‚ÌŠÖ˜A
  19. ƒˆê”ʉ‰‘è9 ”x‚ŒŒˆ³Ç‚Æ–òÜ„

  20. ®–ì —ºAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF“–‰@‚É‚š‚¯‚éƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ÌŽg—pŒoŒ±
  21. ƒˆê”ʉ‰‘è10 Ç—á•ñ2„

  22. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŒš•” r‰îAŽR–{ ¹DA²“¡ Œö—YA‰ºì G–ŸF‘O–э׌ŒŠÇ«”x‚ŒŒˆ³Ç‚©‚çŒã–э׌ŒŠÇ«”x‚ŒŒˆ³Ç‚Æ‚È‚Á‚œ‚P—á
  23. ƒˆê”ʉ‰‘è11 –«”xŒŒðÇðÇ ”x‚ŒŒˆ³Ç„

  24. _’à Ž–çA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA‹{“c •qA‰ºì G–ŸFCTEPH ‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌŒŒŸ÷Cyclophilin A ”Z“x‚Ì—L—p«
  25. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŒã‰ª L‘Ÿ˜NAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF”ñŽèp“K‰ž‚ÌCTEPH Ç—á‚ɑ΂·‚éBPA ‚Ì’·Šú—\Œã‚ÆŽüpŠú‡•¹Ç
‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2016”N9ŒŽ23`25“úA“Œ‹žj

    ƒ“Á•ÊŠé‰æ1 Žc‘¶ƒŠƒXƒNŒž­‚Ì‚œ‚߂̐V‚œ‚ȃoƒCƒIƒ}[ƒJ[’T‚µ„

  1. ²“¡Œö—YFLDL-C‚Ɉˑ¶‚µ‚È‚¢‘S‚­V‚µ‚¢V‹K•aˆö’`”’‚ƃoƒCƒIƒ}[ƒJ[‚̗Տ°‰ž—p
  2. ƒ“Á•ÊŠé‰æ5 S‘Ÿ•a—Տ°Œ€‹†‚̐V‚µ‚¢•ûŒü«‚ðl‚Š‚遄

  3. â“cN•FF‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^iCHART-2jŒ€‹†‚ÌŒ»ó‚Æ“W–]
  4. ƒ“Á•ÊŠé‰æ9 kÐ‚ƐSŒŒŠÇŽŸŠ³F‚»‚̑΍ô‚ÆŽÀ‘H„

  5. Â–Ø —³’jF“Œ“ú–{‘åkÐ‚©‚çŠw‚ñ‚Ÿ‚±‚Æ
  6. ƒ“Á•ÊŠé‰æ10 “ú–{‚ÌACS“o˜^Œ€‹†‚ÌŒ»ó‚©‚玟‚ÌŽž‘ã‚ց„

  7. ‚‹Ž A‰H”ö Ž‹MA›Á Œ³‹gAˆÉ“¡ Œ’‘ŸAâ“c ‘וFA‰ºì G–Ÿ F ‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚Ì‹ß”N‚É‚š‚¯‚éŒo”N•Ï‰»\Miyagi AMI Registry Studyi1985-2014j‚©‚ç‚Ì•ñ\
  8. ƒ“Á•ÊŠé‰æ14 ICT‚ðŠˆ—p‚µ‚œƒrƒbƒOƒf[ƒ^‚©‚ç‚Ì’mŽ¯‚̐¶¬F‰ä‘‚ÌŒ»ó‚Ɖۑ聄

  9. ’†ŽR ‰ë°A‰ºìG–ŸFf—Ïî•ñƒXƒgƒŒ[ƒW•W€‹K–ñSS-MIX2‚ð—p‚¢‚œƒrƒbƒOƒf[ƒ^ŽûW‚É‚š‚¯‚錻ó‚Æ–â‘è“_
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€3 S–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃Xƒgƒ‰ƒeƒW[‚Æ’·Šú—\Œã„

  11. [àV ‹±”V˜NA•Ÿ“c _“ñA’†–ì œA‹ß“¡ ³‹PA£ì «lAç—t ‹M•FAŽO–Ø Œi‘ŸA‰ºì G–Ÿ FS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚Ì“Ž’²—¥ˆÛŽ‚ª‰^“®‘Ï—p”\‚É—^‚Š‚é—L—p«
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€8 S‹Ø‹•ŒŒ‚ð‚Ç‚€•]‰¿‚µAŽ¡—Âɔœ‰f‚³‚¹‚é‚©„

  13. ¬‘é —I“ñA‚‹Ž Aš¢’J —²Ž¡A ‰H”ö Ž‹MAŒ‹{ Œ’‰îA{“c •jA¬Œ ^‹±AŒ–{ ‘׎¡A ˆÉ“¡ Œ’‘ŸA‰ºì G–ŸFŠ¥”÷¬ŒŒŠÇáŠQ‚ÆŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€13 “ñŽŸ«S‹ØÇ‚̐f’f‚̐i•à`ƒCƒ[ƒWƒ“ƒO‚ƃoƒCƒIƒ}[ƒJ[`„

  15. ŽR–{ ¹DA™‘º Gˆê˜YA—é–Ø G–ŸAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‚˜Q Œ’‘Ÿ˜YA‰ºì G–ŸFFabry•aŠ³ŽÒ‚É‚š‚¯‚é‰æ‘œf’f‚ƃoƒCƒIƒ}[ƒJ[
  16. ƒƒVƒ“ƒ|ƒWƒEƒ€15 “ú–{‚©‚ç”­M‚·‚é”x‚ŒŒˆ³f—Á„

  17. ²“¡ Œö—YA™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹A»‘º Tˆê˜YA_’à Ž–çA‰ºì G–ŸF”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚œ‘Šúf’f‚ÆŽ¡—ÖòŠJ”­‚̉”\«
  18. ƒŽRŒû“O‚ÆŠw‚ԏzŠÂŠí•a‚̍ŋ߂̎¡—ÃPart III ”x‚ŒŒˆ³„

  19. ²“¡ Œö—YA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAŽR–{ ¹DAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA‰ºì G–ŸF”x‚ŒŒˆ³Ç‚̍ŐV‚Ì–ò•šŽ¡—Âƍ¡Œã‚ÌŽ¡—ÖòŠJ”­
  20. ƒJCC-ACCƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ Current and Future in TAVI and BRS in US and Japan„

  21. ‚‹Ž FAn Excellent Experience of the ACC Leadership Training Program yReport-ACC Leadership training programz
  22. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ŃtƒŒƒCƒ‹‚ðŽ•ž‚µ‚æ‚€„

  23. ’|“à ‰ëŽjAŒ–{ ‘׎¡AX M–FA‚‹Ž A™‘º Gˆê˜YAŽO‰Y ³’šAì–{ r•ãAŒF’J ‹Iˆê˜YAãŒŽ ³”ŽAâV–Ø ‰ÀŽA‰ºì G–ŸFŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“\—Šw—Ö@Žm‚Ì—§ê‚©‚çuƒtƒŒƒCƒ‹v‚ð”FŽ¯‚µ‘Ήž‚·‚éd—v«\
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6 Š¥¹k‚̍ŐV’mŒ©„

  25. ‘åŽR @”nFŠ¥“®–¬‰ßŽûk”œ‰ž‚É‚š‚¯‚銥“®–¬ŽüˆÍŽ‰–b‘gD‚Ì–ðŠ„\Š¥“®–¬ŠO–Œ‘€‚É’–Ú‚µ‚ā\
  26. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘S@”ñ–ò•š“I—Ö@A•a‘ԁ„

  27. ”öŒ` „AˆÉ“¡ Œ’‘ŸAi“¡ ’q•FA”©’† ˜a–ŸA]Œû ‹v”üŽqA‘ë G•¶A‹àˆä _A‰ºì G–ŸF’áo—̓pƒ‹ƒX”g‚ð—p‚¢‚œ’Ž‰¹”gŒŒŠÇV¶—Ö@‚́Aˆ³•‰‰×S•s‘Sƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚š‚¢‚āAS‹@”\’ቺ‚ð—}§‚·‚é
  28. ƒˆê”ʉ‰‘è@Œû‰‰ •Ù–ŒÇ2„

  29. ‚–Ø —S‰îA™ ³•¶AH“¡ rA”· Œ’ˆê˜YA“ñ•r ‘Ÿ˜YA£ì «lA‘ŠàV Œ’‘Ÿ˜YAŽR–{ ‹`lA‰ºì G–ŸFdÇ‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚̗Տ°¬Ñ
  30. ƒˆê”ʉ‰‘è@Œû‰‰ ‹~‹}E“Ë‘RŽ€EŽ©—¥_ŒoEƒXƒgƒŒƒXESg„

  31. ¬–쐣 „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•Ï‰»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  32. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  33. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†Cyclophilin A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  34. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  35. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†Adipsin”Z“x‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  36. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  37. Š}ŒŽ M‘Ÿ˜YAâ“c ‘וFAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA²“¡ ‰ë”VA‚‹Ž A‹{“c •qA‰ºì G–ŸFHFpEFŠ³ŽÒ‚É‚š‚¯‚éBNP’l‚Æ—\Œã‚Æ‚ÌŠÖ˜A‚ÍHFrEFŠ³ŽÒ‚Æ“¯“™‚Å‚ ‚é
  38. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  39. ¬–쐣 „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA ‰ºì G–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  40. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  41. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YAŒã‰ª L‘Ÿ˜YA ‚‹Ž A‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‚š‚¯‚鍶Žº‹ìo—Š‚Æ•nŒŒ‚̘AŠÖ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  42. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  43. Š}ŒŽ M‘Ÿ˜YAâ“c ‘וFA’A–Ø šáˆê˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA‚‹Ž A‹{“c •qA‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éV‚µ‚¢—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA
  44. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  45. ŽR“à ‹BAâ“c ‘וFA”’ŒË ’A¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA²“¡ ‰ë”VAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFS•s‘SƒnƒCƒŠƒXƒNÇ—á‚É‚š‚¯‚éS–[×“®‚Ì—\Œã‚ւ̉e‹¿‚Æ”­Ç—\‘ªƒŠƒXƒNƒXƒRƒA‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  46. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  47. ‹yì ‘ì–çAâ“c ‘וFAŽO‰Y ³’šA’A–Ø šáˆê˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFƒXƒ^ƒ`ƒ“‚Ì–òÜ‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢ \ CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  48. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  49. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA—é–Ø G–ŸA²“¡ Œö—YA ‰ºì G–ŸFBartonella quintanaŠŽõ‚É”º‚€ŠŽõ«S“à–Œ‰Š‚̈ê—á
  50. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  51. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA—é–Ø G–ŸA²“¡ Œö—YA‰ºì G–ŸFBartonella quintanaŠŽõ‚É”º‚€ŠŽõ«S“à–Œ‰Š‚̈ê—á
  52. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ •s®–¬Eƒy[ƒXƒ[ƒJ[‚ƐSƒGƒR[„

  53. ŽO–Ø Œi‘ŸA•Ÿ“c _“ñA’†–ì œA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîA[àV ‹±”V˜NA”‘ò ‘EA‰ºì G–ŸFS–[×“®Š³ŽÒ‚É‚š‚¯‚鍶SŽšŒŒ—¬‘¬“x’ቺ‚ÌŠñ—^ˆöŽq‚ÌŒŸ“¢
  54. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S@—\‘ªˆöŽq2„

  55. ç—t ‹M•FA’†–ì œA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîA[àV ‹±”V˜NAŽO–Ø Œi‘ŸA”‘ò ‘EA•Ÿ“c _“ñA‰ºì G–ŸFS‘ŸÄ“¯Šú—Ö@iCRTj‚̍¶Žº4‹ÉƒŠ[ƒh‚É‚š‚¯‚é—LŒø«‚š‚æ‚ѐSŒŒŠÇƒCƒxƒ“ƒg‚ÉŠÖ‚·‚錟“¢
  56. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ CTPEHE”xŒŒð„

  57. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã‰ü‘PŒø‰Ê
‘æ22‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2016”N7ŒŽ16“ú`17“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€9FŠî‘bŒ€‹†‚ð—\–hS‘Ÿ•aŠw‚Ì–¢—ˆ‚ÉŠˆ‚©‚·„

  1. Œ–{‘׎¡A‹ààV³”́A‰F’Ë—T‹IA‰ºìG–ŸFS‹Ø[ÇŒã‚̍œ‚̕ω»‚Ɖ^“®—Ö@‚É‚æ‚é‰î“üŒø‰ÊF“®•šƒ‚ƒfƒ‹‚ð—p‚¢‚œSEœŠÖ˜Ai‘æ13‰ñ–Ø‘º“oÜiŠw‰ïÜjŽóÜj
  2. ƒYIAƒZƒbƒVƒ‡ƒ“„

  3. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãAXM–FAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘ŸAâ“c‘וFAãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽE‰ð—£‚ɑ΂·‚ép‘O‚©‚ç‚̌ċzƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍŽüpŠúŒÄ‹zŠí‡•¹Ç‚ðŒž­‚·‚éiÅ—DGÜŽóÜj
  4. ’A–Øšáˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–啶r–ŸA‘ã“c_”VAˆÀ“c‘A‰ºìG–ŸFS•s‘SŠ³ŽÒ‚š‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚š‚¯‚é‰^“®‘jŠQˆöŽq‚ÌŒŸ“¢|‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚èi—DGÜŽóÜj
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€4F”x‚ŒŒˆ³Ç‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“„

  6. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŠ`‰Ô—²ºAXM–FAˆÉ“¡CA‰ºìG–ŸAãŒŽ³”ŽF–«ŒŒðÇð«”x‚ŒŒˆ³‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚œ”ñNP“I‚ȏdÇ“x•]‰¿–@
‘æ162‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N6ŒŽ4“úA·‰ªj

    ƒYIAÇ—á”­•\•”–偄

  1. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–ŸF•s®–¬ŒŽ«‰EŽºS‹ØÇ‚̗Տ°‘œ‚ɍ“Ž—‚µ‚œSƒTƒ‹ƒRƒCƒh[ ƒVƒX‚Ì‚P—á
  2. ƒYIAŒ€‹†”­•\•”–偄i–Å—DGÜŽóÜj

  3. ¬‘é—I“ñA‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA{“c@•jA¬Œ^‹±AŒ–{‘׎¡A ˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x‚ÍŠ¥”÷¬ŒŒŠÇáŠQ‚𔜉f‚·‚é
  4. ƒˆê”ʉ‰‘聄

  5. ‚ŒŽ^ŒáA‰Í’Á@‘AHŽR³”NAì–{r•ãAâV–؉ÀŽAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–ŸFR‘ÌŠÖ˜AŒ^‹‘â”œ‰žiAMRj‚ð‡•¹‚µ‚œS‘ŸˆÚA‚̈ê—á
  6. {“c@•jAŒ‹{Œ’‰îAš¢’J—²Ž¡A‰H”öŽ‹MAŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA²“¡‰pºAXìF‘¥AŠC–ì—Ï–ŸFHybridŽèpŽº‚É‚š‚¢‚ďW–ñ“I‰Á—Âð—v‚µ‚œu‚œ‚±‚‚ڌ^S‹ØÇv‚̈ê—á
  7. ›Á@Œ³‹gA‰H”öŽ‹MAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFSƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÉŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚œ2Ç—á
  8. Š}ŒŽM‘Ÿ˜YAâ“c‘וFA’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF–«S•s‘SŠ³ŽÒ‚ÌŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒX ƒRƒA‚ÌŠJ”­
  9. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šAŽR“à@‹BA¬–쐣„¶A’ÒŒOØŽqA ‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éÝ‘NŠÇ—‚Æ—\Œã‚ÉŠÖ‚·‚錀‹†|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  10. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA ’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF¶Žº‹ìo—Š‚ª’ቺ‚µ‚œS•s‘S‚ƍ¶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘S‚̗Տ°Šw“I“Á’¥‚É‚š‚¯‚鍷|CHART-2Œ€‹†‚Ì’mŒ©|
  11. ’†–ì@œA•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•œ–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFƒtƒ@ƒ[Žl’¥ÇpŒã‚ÌPVC‚ɑ΂µA‘å“®–¬Š¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚œˆê—á
  12. [àV‹±”V˜NA’†–ì@œA‹ß“¡³‹PA£ì«lAç—t‹M•FAŽO–ØŒi‘ŸA•Ÿ“c_“ñA‰ºìG–ŸFJ wave‚ÌŠÖ˜A‚ªŽŠŽ‚³‚ê‚éSŽº×“®”­ì‚ð‹N‚±‚µ‚œŽá”NBrugadaÇŒóŒQ‚̈ê—á
  13. ’†–ì@œA•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•œ–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFì“®Šm”FƒeƒXƒg‚É‚æ‚è“K³‚ÈICDÝ’肪‰Â”\‚Å‚ ‚Á‚œ•ÂÇ«”ì‘åŒ^S‹ØÇ‚Ì1—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA•œ–쓹ŠîA[àV‹±”V˜NA–Ø‘º‹`—²AŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ÌŠÖ—^‚ª‹^‚í‚ê‚éSŽº×“®‚ɑ΂µ‚ÄS-ICDAž‚Ý‚ðŽ{s‚µ‚œ1—á
  15. ™àV@AŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF”œ•œ‚·‚é”sŒŒÇ«”xÇð‚ÅŽèpŽ¡—ÂƂȂÁ‚œVSD‡•¹ŠŽõ«S“à–Œ‰Š‚Ì1—á
  16. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸA¬ŽRk‘Ÿ˜YA’†Œé•¶AXè—TŽqA‰ª“cŽ“WAˆÀ’B@—AâV–؉ÀŽFBMPR2ˆâ“`Žq•ÏˆÙ‚ªf’f‚³‚ê‚œASD‡•¹”x“®–¬«‚ŒŒˆ³Ç‚Ì1—á
  17. –î”ö”M—TA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA—é–؏G–ŸA²“¡Œö—YA‰ºìG–ŸF‹}‘¬‚ɐis‚µ‚œ‹­”çÇ‚É”º‚€”x‚ŒŒˆ³Ç‚Ì1—á
  18. Â–Ø—³’jA™‘ºGˆê˜YA—é–؏G–ŸAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Æ“‡Žž’²Ç‚ɂ‚¢‚Ä‚ÌŒŸ“¢
  19. ‚‹ŽA‰ºìG–ŸF‰ä‚ª‘‚Ì–x«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ĐS–[×“®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ€‹†‚©‚ç‚Ì•ñˆê
  20. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‹{“c@•qA‚‹ŽA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•Ê‚É‚š‚¯‚éŒoŽž•Ï‰»‚ÌŒŸ“¢
  21. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘ԁ[OFDI‚É‚æ‚錟“¢[
‘æ2‰ñ“ú–{S‹ØÇŒ€‹†‰ïi2016”N5ŒŽ14“úAŒ–{Žsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f„

  1. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA•œ–쓹ŠîAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFRecent progress in the management of cardiac sarcoidosis.
  2. ƒˆê”ÊŒû‰‰„

  3. Œ“‡«ŽmAŒŠì^‘Ÿ˜YA–k•—­ŽjA•Ÿ“cŒbˆêA’|Î‹±’mA‰ºìG–ŸAÖ“¡”\•FA“›ˆä—T”VF‚킪‘‚ÌŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ð‘ΏۂƂµ‚œ‘œŽ{Ý“o˜^ŠÏŽ@Œ€‹†.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. ™àV@A‰H”öŽ‹MAŒ‹{Œ’‰îAŽR–{¹DAš¢’J—²Ž¡AŒ–{‘׎¡A™‘ºGˆê˜YA‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFFabry•a‚ÉŠ¥¹k«‚ð‡•¹‚µ‚œˆê—á.
  6. ŽO–ØŒ[‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‚•FA[àV‹±”V˜NA‰ºìG–ŸF•s®–¬ŒŽ«‰EŽºS‹ØÇ‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á.
  7. _’ÍŽ–çA—é–؏G–ŸAŒŽRC•œA²“¡@ꡁA–î”ö”M—TAŽR–{¹DA‰H”öŽ‹MAŽO‰Y³’šAÂ–Ø—³’jAŒ–{‘׎¡A™‘ºGˆê˜YAÂ–ؐ³ŽuA‰ºìG–ŸF‘œ”­«d‰»Ç‚Ì”]Š²•a•Ï‚É‚æ‚é‚œ‚±‚‚ڐS‹ØÇ‚̈ê—á.
  8. Œ‹{Œ’‰îAŒ–{‘׎¡A‰H”öŽ‹MAš¢’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA“n粗ŽHA¯ì@NA‰ª“cŽ“TA‰ºìG–ŸF•ÂÇ«”ì‘åŒ^S‹ØÇ‚É‚œ‚±‚‚ڐS‹ØÇ‚𕹔­‚µ‚œ”xˆÚAÇ—á.
“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ€‹†‰È•‘®‘n¶‰ž—pˆãŠwŒ€‹†ƒZƒ“ƒ^[ 2016ƒVƒ“ƒ|ƒWƒEƒ€i2016”N3ŒŽ22“úAå‘äŽsj
  1. ‰ºìG–ŸFƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`•”–åÐ‰î.
  2. ‰ºìG–ŸFæiˆã—ÊJ”­ƒRƒAƒZƒ“ƒ^[.
‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2016”N3ŒŽ18“ú`20“úAå‘äj

    ƒCongress Chairperson's Lecture„

  1. Shimokawa H. The Past, Present and Future of Cardiovascular Medicine in Japan\Lessons from the Great East Japan Earthquake\Circ J. 2016, 80(Suppl. I):I-3
  2. ƒPlenary Session„

  3. (PL01:Creating New Trends for Diagnosis and Treatment of Heart Failure\Integration of Basic Science, Clinical Research and Medical Practice\) Suzuki H, Matsumoto Y, Sumiyoshi A, Kaneta T, Ota H, Yoshikawa T, Sugimura K, Aoki T, Tatebe S, Miura M, Takahashi J, Satoh K, Miyata S, Ito K, Furukawa K, Fukumoto Y, Arai H, Yanai K, Kawashima R, Taki Y, Shimokawa H. Emerging Role of the Heart-Brain Axis via the Hippocampus in the Pathogenesis of Heart Failure. Circ J. 2016, 80(Suppl. I):I-29
  4. (PL03:The Great East Japan Earthquake: What We Learned in the past 5 Years and Future Perspectives) Aoki T, Sugimura K, Nakano M, Hao K, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H. Lessons from the Great East Japan Earthquake Disaster. Circ J. 2016, 80(Suppl. I):I-40
  5. Yasuda S, Tahara Y, Miyamoto Y, Nishimura K , Takegami M, Ogawa H, Hirata K, Morino Y, Nakamura M, Takeishi Y, Shimokawa H, Naito H. Survey of Emergencies Adapting Business Continuity Plan for (non) Disaster-Base Hospitals; Report from Ministry of Health, Labour and Welfare Grant-in-Aid Investigators. Circ J. 2016, 80(Suppl. I):I-45
  6. (PL05:Treatment Paradigm of Coronary Artery Disease: 20 Years From Now!!) Hao K, Takahashi J, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in the Incidence and Mortality of AMI for 30 Years \A Report from the Miyagi AMI Registry Study\ Circ J. 2016, 80(Suppl. I):I-53
  7. (PL07:Let's Discuss the Near Future of Cardiovascular Medicine)Ito K, Shindo T, Hatanaka K, Ogata T, Kurosawa R, Eguchi K, Kagaya Y, Nishimiya K, Tsuburaya R, Hao K, Taki H, Matsumoto Y, Takahashi J, Kanai H, Shimokawa H. Non-invasive Angiogenic Therapies with Acoustic Waves for Cardiovascular Diseases \Promising Approaches for the Future\ Circ J. 2016, 80(Suppl. I):I-68
  8. (PL08:Progress and Future in Pulmonary Hypertension Clinic) Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Suzuki K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Yaoita N, Fukumoto Y, Miyata S, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Cyclophilin A and Its Receptor Basigin Promote Vascular Smooth Muscle Proliferation and Pulmonary Hypertension \Possible Novel Therapeutic Target Pathway\ Circ J. 2016, 80(Suppl. I):I-76
  9. (PL09:Gender-Specific Medicine in Cardiovascular Disease\Up to Date\)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H. Sex Differences in the Clinical Characteristics and Prognosis of Heart Failure with Preserved Ejection Fraction \Insights from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-85
  10. ƒSymposium„

  11. (SY02:Diagnosis and Treatment Using Recently Developed and Emerging Devices) Chiba T, Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impacts of Quadripolar Left Ventricular Lead and Left Ventricular Reverse Remodeling in Patients with Cardiac Resynchronization Therapy. Circ J. 2016, 80(Suppl. I):I-110
  12. (SY05:Frontline of CTEPH Practice in Japan in 2016) Yaoita N, Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Numano K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Horiuchi H, Shimokawa H. Crucial Role of Thrombin-Activated Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-131
  13. (SY07:Unsolved Issues in Heart Failure with Preserved Ejection Fraction (HFpEF) Based on Cohort Studies and Clinical Trials) Miura M, Sakata Y, Ushigome R, Tsuji K, Sato K, Tadaki S, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Perspectives of Medical Therapies for Heart Failure with Preserved Ejection Fraction \Lessons from the CHART Studies and the SUPPORT Trial\ Circ J. 2016, 80(Suppl. I):I-145
  14. (SY10:New Strategy for the Secondary Prevention after Acute Coronary Syndrome Based on Cohort Studies) Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Statins after Myocardial Infarction in the CHART-2 Study\A Validation Analysis of the gFire and Forgeth Theory\ Circ J. 2016, 80(Suppl. I):I-165
  15. (SY15:Bioresorbable Scaffolds (BRS) in Current and Future) Nishimiya K, Matsumoto Y, Uzuka H, Amamizu H, Oyama K, Hirano M, Shindo T, Tsuburaya R, Takahashi J, Ito K, Shimokawa H. Beneficial Effects of Novel Bioresorbable Polymer Coating on Enhanced Coronary Vasoconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-195
  16. (SY19:How Do We Establish Usefulness of Left Ventricular Assist Device in Japan?) Akiyam Ma, Fujiwara H, Katahira S, Kumagai K, Aoki T, Sugimura K, Fukuda K, Takahashi J, Kawamoto S, Shimokawa H, Saiki Y. Patient Selection for Mechanical Circulatory Support: A Single Center Review of 39 Patients. Circ J. 2016, 80(Suppl. I):I-224
  17. (SY20:Functional Impairment of Coronary Arteries; Clinical Implications and Further Evaluation)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-230
  18. (SY22:The Role of Heart Team Approach for Patients with CVD; Prevention to Rehabilitation)Kajikawa A, Miura M, Tanaka H, Saito Y, Suzuki H, Kakihana T, Takeuchi M, Syojima K, Myochin C, Kondoh M, Hao K, Sugimura K, Shimokawa H. Importance of Evidence-Based Approach for Heart Team in Heart Failure Practice. Circ J. 2016, 80(Suppl. I):I-244
  19. (SY24:How Should We Design and Conduct Sensible Clinical Research in Japan?) Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The CHART-2 (Chronic Heart Failure Analysis and Registry in the Tohoku District-2) Study \Working Model of Observational Study in Japan\ Circ J. 2016, 80(Suppl. I):I-256
  20. (SY27:Mechanisms of Atherosclerosis in Metabolic Syndrome: From Bench to Bedside) Noda K, Fukumoto Y, Saito H, Godo S, Tsutsui M, Shimokawa H. Crucial Role of Rho-kinase in the Pathogenesis of Metabolic Syndrome \Suppression of Endothelial Nitric Oxide Synthase and AMP-activated Protein Kinase. Circ J. 2016, 80(Suppl. I):I-277
  21. ƒSpecial Session„

  22. (SS01:Let's Learn Medical Statistics in 3 Days! ‡@) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡@ Circ J. 2016, 80(Suppl. I):I-288
  23. (SS04:Editors-in-Chief of the Top Medical Journals) Shimokawa H. Circulation Journal. Circ J. 2016, 80(Suppl. I):I-301
  24. (SS05:Let's Learn Medical Statistics in 3 Days! ‡A) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡A Circ J. 2016, 80(Suppl. I):I-308
  25. (SS06:Novel Therapeutic Targets in Cardiovascular Disease)Satoh K, Suzuki K, Sunamura S , Otsuki T, Shimizu T, Ikeda I, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial Roles of Rho-kinase, Cyclophilin A and Its Receptor, Basigin, for Cardiac Hypertrophy, Fibrosis and Failure\Novel Therapeutic Targets of Heart Failure\ Circ J. 2016, 80(Suppl. I):I-310
  26. (SS07:Heart Failure Pandemic: An Emerging Agenda in the Super-aged Society) Miura M, Sakata Y, Miyata S, Ushigome R, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Current Status and Future Perspectives of Chronic Heart Failure in Japan \Lessons from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-318
  27. (SS08:30th Anniversary of NO Research: What Have We Learned and Where to Go) Tsutsui M, Shimokawa H, Yanagihara N, Mukae H, Otsuji Y. Circ J. Diverse Roles of NO Synthases \ Lessons from Genetically Modified Mice \ Circ J. 2016, 80(Suppl. I):I-324
  28. (SS09:Development of Non-invasive Therapy for Cardiovascular Diseases)Matsubara T, Ito K, Shimokawa H. Cardiac Shock Wave Therapy. Circ J. 2016, 80(Suppl. I):I-329
  29. Ito K, Shindo T, Kanai H, Shimokawa H. A New Angiogenic Therapy Using Low-intensity Pulsed Ultrasound for Angina Pectoris. Circ J. 2016, 80(Suppl. I):I-330
  30. (SS14:Let's Learn Medical Statistics in 3 Days! ‡B)Miyata S. Let's Learn Medical Statistics in 3 Days! ‡B Circ J. 2016, 80(Suppl. I):I-354
  31. (SS15:Large-scale Disasters and Cardiovascular Disease)Aoki T, Sugimura K, Nakano M, Hao K, Nihei T, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H . Cardiovascular Diseases after the Great East Japan Earthquake Disaster \ Risk Factor for Cardiovascular Diseases. Circ J. 2016, 80(Suppl. I):I-357
  32. (SS17:Information and Communication Technology Will Launch a New Era in Cardiovascular Medicine)Ito K, Takahashi J, Hao K, Inoue K, Hiramoto T, Shimokawa H. A Prehospital 12-lead Electrocardiogram Transmission System in Emergency Cardiovascular Care in Miyagi. Circ J. 2016, 80(Suppl. I):I-371
  33. (SS18:Importance of Cardio-Oncology)Sugimura K, Yaoita N, Shimokawa H. Pulmonary Vascular Diseases in Patients with Malignancy. Circ J. 2016, 80(Suppl. I):I-377
  34. ƒESC-JCS Joint Symposium„

  35. (ESC-JCS JS:Coronary Microvascular Dysfunction Revisited)Takahashi J, Odaka Y, Shimokawa H. Plasma Serotonin Level is a Novel Biomarker for Presence of Coronary Microvascular Dysfunction in Patients with Unobstructive Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-384
  36. ƒRound Table Discussion„

  37. (RT04:Management of Heart Failure Patients in the Highly Aged Society in Japan) Sakata Y, Miura M, Sato K, Tadaki S, Ushigome R, Yamauchi T, Miyata S, Takahashi J, Shimokawa H. Clinical Characteristics Treatments and Prognosis of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-424
  38. (RT08:The Present Situation of Sudden Cardiac Death and the Role of ICDs in Japan)Fukuda K. Satake H, Sakata Y, Miyata S, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Current Status of Sudden Cardiac Death with Implantable Cardioverter-Defibrillator in Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-444
  39. ƒTopic„

  40. (TP02:Clinical Practice of Right Heart Failure)Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H. Pathophysiology and Treatment of Right Heart Failure in Patients with Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-479
  41. (TP07:The Vascular Adventitia: An Active Participant in Vessel Pathogenesis from the gOutside inh)Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-516
  42. (TP08:Implication of Frailty and Sarcopenia in Cardiology Practice)Matsumoto Y, Takeuchi M, Mori N , Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Important Roles of Frailty Assessment and Rehabilitation for the Elderly Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Circ J. 2016, 80(Suppl. I):I-521
  43. ƒMeet the Expert„

  44. (ME01:Therapeutic Strategy for Brugada Syndrome)Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Overview of Brugada Syndrome \Epidemiology and Diagnosis\ Circ J. 2016, 80(Suppl. I):I-542
  45. Matsumoto Y, Takeuchi M, Mori N, Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Roles of Transcatheter Aortic Valve Replacement and Cardiac Rehabilitation for the Elderly Patients with Aortic Stenosis. Circ J. 2016, 80(Suppl. I):I-550
  46. (ME04:Balloon Pulmonary Angioplasty: Recent Advances of Management for Patients with Chronic Thromboembolic Pulmonary Hypertension)Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H . Efficacy and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-559
  47. (ME05:Use of Bio-makers in the Cardiovascular Medicine)Satoh K, Otsuki T, Shimokawa H. Cyclophilin A: A Novel Biomarker for Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-562
  48. (ME10:Diagnosis of Vasospastic Angina)Tsuburaya R, Takahashi J, Nishimiya K, Hao K, Matsumoto Y, Shimokawa H. Coronary Hyperconstricting Response Induced by a Drug-eluting Stent as a Remaining Important Issue Even in the Second Generation Era \ Beneficial Effects of Long-acting Nifedipine. Circ J. 2016, 80(Suppl. I):I-593
  49. ƒMorning Lecture„

  50. (ML22:Management of Chronic Tromboembolic Pulmonary Hypertension)Sugimura K, Shimokawa H. Management of Chronic Tromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-618
  51. ƒLate Breaking Clinical Trials/Cohort Studies„

  52. (LBCT/LBCS I:Coronary Artery Disease)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Statin Intensity in Patients with Ischemic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-627
  53. (LBCT/LBCS II:Arrhythmia, Hypertension)Ikeda T, Ogawa H, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kaikita K, Kamouchi M, Fukuda K, Matsui K, Shimokawa H. Effectiveness and Safety of Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation \The Second Report from the EXPAND Study\ 11 Circ J. 2016, 80(Suppl. I):I-632
  54. (LBCT/LBCS III:Intervention)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-639
  55. (LBCT/LBCS IV:Heart Failure)Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Beneficial Effect of Additive Use of Olmesartan to Beta-Blockers in Hypertensive Patients with Heart Failure with Preserved Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-643
  56. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Suzuki H, Yaoita N, Kouzu K, Miyata S, Sakata Y, Shimokawa H. Prognostic Impact of Furosemide in Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-645
  57. Kotooka N, Sato Y, Mizuno A, Eguchi K, Inomata T, Yamamoto K, Tsutsui H, Masuyama T, Kitakaze M, Inoue T, Shimokawa H, Shin-Ichi Momomura, Yoshihiko Seino, Koichi Node. Home Telemonitoring Study for Japanese Patients with Heart Failure (HOMES-HF). Circ J. 2016, 80(Suppl. I):I-647
  58. ƒFeatured Research Session„

  59. (FRS05:Heart Failure, Treatment)Suda A, Takahashi J, Hao K, Sakata Y, Miyata S, Miura M, Shimokawa H. Prognostic Impacts of Revascularization Strategy and Residual Coronary Stenosis in Patients with Ischemic Heart Failure. Circ J. 2016, 80(Suppl. I):I-688
  60. (FRS06:Heart Failure, Basic and Cardiac Function)Suzuki K, Satoh K, Ikeda S, Sunamura S, Otsuki T, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Numano K, Sugimura K, Aoki T, Tatebe S, Miyata S, Mukherjee R, Francis G Spinale, Kadomatsu K, Shimokawa H. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-695
  61. (FRS13:Coronary Artery Disease, Treatment)Uzuka H, Matsumoto Y, Nishimiya K, Amamizu H, Ohyama K, Hirano M, Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-733
  62. Hatanaka K, Ito K, Shindo T, Ogata T, Kurosawa R, Kagaya Y, Eguchi K, Shimokawa H. Molecular Mechanisms of Angiogenic Effects of Low-energy Shock Wave Therapy: Potential Involvement of Mechanotransduction Pathways. Circ J. 2016, 80(Suppl. I):I-734
  63. (FRS14:Cardiovascular Disease, Preventive Medicine)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. The Risk Score to Predict Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-739
  64. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Backgrounds and Prognostic Impacts of New Onset Atrial Fibrillation \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-742
  65. (FRS19:Heart Failure, Pulmonary Hypertension)Kikuchi N, Satoh K, Omura J, Sato T, Kurosawa R, Nogi M, Otsuki T, Numano K, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension \A Possible Novel Therapeutic Target\ Circ J. 2016, 80(Suppl. I):I-769
  66. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Suzuki K, Shimokawa H. nvolvement of Thrombin Activatable Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-771
  67. Tsutsui M, Ishida M, Noguchi K, Shimokawa H. Protective Role of Myelocytic Nitric Oxide Synthases in Hypoxic Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-773
  68. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  69. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Furukawa K, Arai H, Fukumoto Y, Taki Y, Shimokawa H. Hippocampus Abnormalities are Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure. Circ J. 2016, 80(Suppl. I):I-841
  70. Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-844
  71. ƒYoung Investigator's Award Finalists Lectures (Basic Research) )„

  72. Godo S, Sawada A, Saito H, Ikeda S, Enkhjargal B, Suzuki K, Tanaka S, Shimokawa H. Disruption of Physiological Balance between Nitric Oxide and Endothelium-dependent Hyperpolarization Impairs Cardiovascular Homeostasis in Mice. Circ J. 2016, 80(Suppl. I):I-846
  73. ƒOral Presentation (English)„

  74. (OE07:ACS/AMI, Basic)Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Hanawa K, Aizawa K, Shirato T, Miyata S, Taki H, Hasegawa H, Kanai H, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Mouse Model of Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-894
  75. (OE12:ACS/AMI, Clinical/Pathophysiology 1)Nihei T, Yamamoto Y, Kudo S, Hanawa K, Hasebe Y, Takagi Y, Minatoya Y, Sugi M, Shimokawa H. Impact of the Fukushima Daiichi Nuclear Power Plant Disaster on Acute Myocardial Infarction in Iwaki City. Circ J. 2016, 80(Suppl. I):I-923
  76. (OE17:Heart Failure, Basic 1)Mukaiyama Y, Matsuhashi T, Kikuchi K, Shima H, Takeuchi Y, Mishima E, Akiyama Y, Suzuki C, Suzuki T, Aoki T, Ito S, Nakada K, Hayashi K, Osaka H, Abe T. Mitochonic Acid MA-5 Binds to Mitochondria and Ameliorates Mitochondrial Disease Cardiac Myocyte Damage. Circ J. 2016, 80(Suppl. I):I-950
  77. (OE32:Atherosclerosis, Clinical 1) Otsuki T, Satoh K, Sugimura K Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1043
  78. (OE38:Preventive Medicine/Epidemiology/Education 2)Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Temporal Changes in Post-Traumatic Stress Disorder after the Great East Japan Earthquake \A Report from the CHART-2 Study\Circ J. 2016, 80(Suppl. I):I-1076
  79. (OE39:Ventricular Arrhythmia 4)Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S , Shimokawa H. Effectiveness of Radiofrequency Catheter Ablation on Premature Ventricular Contraction-Triggered Ventricular Fibrillation in Patients with Idiopathic Ventricular Fibrillation. Circ J. 2016, 80(Suppl. I):I-1082
  80. (OE44:Heart Failure, Basic 2) Sunamura S, Satoh K, Suzuki K, Ikeda S, Omura J, Kikuchi N, Sato Th, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H . Crucial Role of ROCK1 to Maintain Contractile Function in Response to Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-1114
  81. (OE48:Atherosclerosis, Clinical 2) Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H . Prognostic Impacts of Plasma Levels of Adipsin in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1139
  82. (OE59:CTEPH BPA)Kozu K, Satoh K, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Otsuki T, Sato H, Miyata S, Shimokawa H. Plasma Cyclophilin A as a Useful Biomarker for the Effects of Percutaneous Transluminal Pulmonary Angioplasty in Patients with CTEPH. Circ J. 2016, 80(Suppl. I):I-1202
  83. Aoki T, Sugimura K, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Satoh K, Shimokawa H. Effects of Percutaneous Transluminal Pulmonary Angioplasty on Oxygenation Capacity in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-1203
  84. ƒOral Presentation (Japanese) „

  85. (OJ01:ACS/AMI, Clinical/Treatment)Kagaya Y, Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Shindo T, Ogata T, Kurosawa R, Eguchi K, Hatanaka K, Miyata S, Shimokawa H. Low-energy Cardiac Shock Wave Therapy Ameliorates Left Ventricular Remodeling in Patients with Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-1225
  86. (OJ04:Ventricular Arrhythmia, Conduction Block)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Prognostic Impacts of Corticosteroid Therapy in Cardiac Sarcoidosis Patients with Advanced Heart Block. Circ J. 2016, 80(Suppl. I):I-1243
  87. (OJ07:Preventive Medicine/Epidemiology/Education)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. LDL-independent Beneficial Prognostic Impacts of Statins in Patients with Old Myocardial Infarction \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-1256
  88. (OJ12:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Sato T, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H . Disruption of Endothelial AMP-activated Protein Kinase Worsens Hypoxia-induced Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-1291
  89. (OJ18:Intravascular Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Hao K, Tsuburaya R, Takahashi J, Shimokawa H . Increased Coronary Perivascular Adipose Tissue Volume in Patients with Vasospastic Angina\Correlations with Adventitial Vasa Vasorum Formation and Rho-kinase Activity\ Circ J. 2016, 80(Suppl. I):I-1326
  90. (OJ30:Coronary Artery Disease, Clinical)Nishimiya K, Wang H, Matsumoto Y, Takahashi J, Uzuka H, Hao K, Tsuburaya R, Amamizu H, Ohyama K, Masayasu Komatsu, Odaka Y, Ito K, Shimokawa H. Association of Enhanced Adventitial Vasa Vasorum Formation with Atherosclerotic Changes Adjacent to Myocardial Bridge \An Optical Frequency Domain Imaging Study\ Circ J. 2016, 80(Suppl. I):I-1395
  91. Yada T, Shimokawa H, Gotoh M, Ogasawara Y, Kajiya F. Important Role of Endogenous H2O2 during Reactive Hyperemia in Dogs in Vivo \An Infrared Fluorescence Microscope Study\ Circ J. 2016, 80(Suppl. I):I-1397
  92. (OJ40:Cost-health Care System) Nakayama M, Takehana K, Kohro T, Shimokawa H, IHE-J Cardiology Technical Committee. Japanese Circulation Society Releases the Standard Export Data Format for Standardized Structured Medical Information Exchange Extended Storage. Circ J. 2016, 80(Suppl. I):I-1457
  93. (OJ43:Heart Failure, Treatment 3)Miura M, Sakata Y, Miyata S, Sato K, Ushigome R, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Abe R, Nochioka K, Takahashi J, Shimokawa H. Prognostic Impacts of Supplemental Use of Angiotensin Receptor Blocker Olmesartan with a Special Reference to Left Ventricular Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-1473
  94. ƒPoster Session (English)„

  95. (PE043:Metabolic Disorder 1)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Miura T, Yano M, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic Impacts of Metabolic Syndrome in Patients with Chronic Heart Failure\A Report from the Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-1759
  96. (PE044:Stroke)Tsutsui M, Kubota H, Noguchi K, Ishida M, Shimokawa H, Ohya Y. Complete Disruption of All Nitric Oxide Synthases Markedly Reduces Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Mice. Circ J. 2016, 80(Suppl. I):I-1767
  97. (PE085:Preventive Medicine/Epidemiology/Education 1)Abe R, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Assessment of Self-care Behavior in Patients with Chronic Heart Failure \A Report from the CHART Study\ Circ J. 2016, 80(Suppl. I):I-2039
  98. (PE089:Atrial/Supraventricular Arrhythmia, Clinical/Treatment 10)Fukasawa K, Fukuda K, Nakano M, Kondoh M, Segawa M, Hirano M, Chiba T, Miki K, Morosawa S, Shimokawa H. Impact of Sinus Rhythm Maintenance with Atrial Fibrillation Ablation on Exercise Tolerance. Circ J. 2016, 80(Suppl. I):I-2063
  99. (PE098:Cardiomyopathy 2)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H . Improved Long-term Prognosis of Patients with Cardiac Sarcoidosis in the Present Era. Circ J. 2016, 80(Suppl. I):I-2115
  100. (PE099:Heart Failure, Prognosis)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. B-Type Natriuretic Peptide Predicts Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2122
  101. (PE107:Preventive Medicine/Epidemiology/Education 2)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Yano M, Kadokami T, Yasuda S, Daida H, Shimokawa H. Prognostic Impacts of Factors Interfering Daily Exercise in Patients with Chronic Heart Failure \A Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-2180
  102. (PE117:Pulmonary Circulation 1)Hidenobu Takagi, Ota H, Sugimura K, Shimokawa H, Takase K. Clinical Severity of Chronic Thromboembolic Pulmonary Hypertension: Assessment on Lung Perfused Blood Volume Images Acquired by Dual-energy CT. Circ J. 2016, 80(Suppl. I):I-2241
  103. ƒPoster Session (Japanese)„

  104. (PJ019:Arrhythmia, Clinical/Diagnosis/Treatment 3)Hasebe Y, Kudo S, Nihei T, Hanawa K, Takagi Y, Minatoya Y, Yamamoto Y, Sugi M, Shimokawa H. Current Status of Triplet Therapy in Patients with Atrial Fibrillation Undergoing Coronary Angioplasty with Drug-eluting Stent in the NOAC Era. Circ J. 2016, 80(Suppl. I):I-2425
  105. (PJ029:Heart Failure, Prognosis)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Abe R, Kasahara S, Takahashi J, Shimokawa H. Different Clinical Characteristics between HFpEF and HFrEF \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2492
  106. (PJ042:CTEPH BPA)Yaoita N, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Influence of Discontinuation of Medications after Successful Percutaneous Transluminal Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2574
  107. Sato H, Ota H, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Kouzu K, Satoh K, Takase K, Shimokawa H. Percutaneous Transluminal Pulmonary Angioplasty Improves Biventricular Functions and Pulmonary Flow in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2576
  108. (PJ044:Heart Failure, Treatment 1)Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Miyata S, Sakata Y, Shimokawa H. Prognostic Effect of Diuretics for Japanese Patients with Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2588
  109. (PJ066:Heart Failure, Pathophysiology)Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2729
  110. (PJ070:Arrhythmia, Clinical/Diagnosis/Treatment 8)Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Amamizu H, Morosawa S, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System \A Preclinical Validation Study\ Circ J. 2016, 80(Suppl. I):I-2762
  111. (PJ079:Vascular Biology 1)Saito H, Sato S, Itoh A, Ikumi Y, Tanaka S, Godo S, Ida T, Fujii S, Akaike T, Shimokawa H. Important Roles of Endothelial Caveolin-1 in Maintaining Microvascular Homeostasis \Possible Protective System against Nitrative Stress\ Circ J. 2016, 80(Suppl. I):I-2820
  112. (PJ094:Thromboembolism/Antithrombotic Therapy/Thrombolysis 4)Miki K, Fukuda K, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Morosawa S, Fukasawa K, Shimokawa H. Effectiveness and Safety of NOACs in Atrial Fibrillation Patients Undergoing Ablation Therapy with a Special Reference to Left Atrial Function. Circ J. 2016, 80(Suppl. I):I-2920
  113. (PJ107:Preventive Medicine/Epidemiology/Education 3)Ushigome R, Sakata Y, Miyata S, Miura M, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Nochioka K, Shimokawa H. Temporal Changes in Sex Differences in Clinical Profiles of Patients with Symptomatic Heart Failure \A Report from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-3005
  114. (PJ108:Congenital Heart Disease/Kawasaki's Disease)Kondo M, Fukuda K, Nakano M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Prolonged QRS Duration for Tachyarrhythmic Events in Adult Patients with Postoperative Tetralogy of Fallot. Circ J. 2016, 80(Suppl. I):I-3011
‘æ207‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ29“úAå‘äŽsj
  1. ™àVAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒž­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚œ1—á.
‘æ39‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ13“úAå‘äŽsj
  1. ™àVAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒž­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚œ1—á.
  2. {“c•jA‚‹Ž@A_ŒË–ΗYA‹{ì”T—ŽqAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‹vŽu–{–ÎŽ÷A‰ºìG–ŸFŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚œˆê—á.
‘æ45‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2016”N2ŒŽ5`6“úA“¿“‡Žsj
  1. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA_’ÍŽ–çAÂ–Ø—³’jAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸF”x“®–¬ŒŒŠÇ“à”çAMPK‚Í”x‚ŒŒˆ³Ç‚̐is‚ð—}§‚·‚é.
  2. ‘å’Î’mGA²“¡Œö—YA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA“ñ•r‘Ÿ˜YA‚‹Ž@A‹{“c@•qA‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª.
‘æ9‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2016”N1ŒŽ30“ú`31“úAŽD–yŽsj

    ƒÅ—DG‰‰‘èÜ„

  1. ’ҁ@ŒOØŽqAâ“c‘וFAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶Aˆ¢•”—Ú—žAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‹{“c@•qA‰ºìG–ŸF‚킪‘‚É‚š‚¯‚鍶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚̗Տ°“I“Á’¥‚É‚š‚¯‚鐫·@\CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©\
  2. ƒÅ—DG‰‰‘èÜ„

  3. ›Á@Œ³‹gA‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚ÌŒo”N•Ï‰»‚̐«·‚ÉŠÖ‚·‚錟“¢@\Miyagi AMI Registry‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘聄

  5. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šA—é–؏G–ŸA‰ºìG–ŸFƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚éƒwƒeƒÚ‡‘̏—«Š³ŽÒ‚̃XƒNƒŠ[ƒjƒ“ƒO.
  6. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîA[àV‹±Žj˜NAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸF—ŒSŽº‚؁[ƒVƒ“ƒO‚É‚æ‚鍶Žºk¬Œø‰Ê‚ƐSŒŒŠÇƒCƒxƒ“ƒg‚ÌŠÖ˜A‚É‚š‚¯‚鐫·‚ÌŒŸ“¢.
  7. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA[àV‹±Žj˜NA”‘ò@‘EA‰ºìG–ŸFS–[×“®‚Ì”xÃ–¬Šu—£p‘Ώۊ³ŽÒ‚É‚š‚¯‚鍶–[‚̍\‘¢“I‚š‚æ‚Ñ‹@”\“I•Ï‰»‚̐«·.
  8. ¬–쐣„¶Aâ“c‘וFA‹{“c@•qAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à@‹BA’ҁ@ŒOØŽqAˆ¢•”—Ú—žAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒo”N•Ï‰»‚Ɛ«·@\CHART-2Œ€‹†‚©‚ç\
  9. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–ŸA‘ã“c_”VAˆÀ“c@‘A‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚š‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNŒQ‚É‚š‚¯‚é‰^“®‘jŠQˆöŽq‚̐«·‚ÌŒŸ“¢@\‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚è\
  10. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇŠ³ŽÒ‚̐«·‚É‚æ‚é—\Œã‚ÌŒŸ“¢.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2015”N
‘æ161‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N12ŒŽ5“úAå‘äj

    ƒYIAŒ€‹†”­•\•”–偄i–—DGÜŽóÜj

  1. _’ÍŽ–çA—é–؏G–ŸA²“¡—yA–î”ö”M—TAŽR–{¹DA‰H”öŽ‹MAŽO‰Y³’šAŒš•”r‰îAÂ–Ø—³’jAŒ–{‘׎¡A™‘ºGˆê˜YA‰ºìG–ŸF‘œ”­«d‰»Ç‚Ì”]Š²•a•Ï‚É‚æ‚é‚œ‚±‚‚ڐS‹ØÇ‚̈ê—á
  2. ƒYIAÇ—á”­•\•”–偄i–—DGÜŽóÜj

  3. £ì«lA•Ÿ“c_“ñA’†–쐜A‹ß“¡³‹PA•œ–쓹•æAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX‚É‚š‚¯‚éƒXƒeƒƒCƒhŽ¡—ÊJŽnŒã‚̐SŽº«•s®–¬‚ÌŒoŽž“I“Á’¥‚Ɖe‹¿ˆöŽq‚ÉŠÖ‚·‚錟“¢
  4. ƒˆê”ʉ‰‘聄

  5. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šA—é–؏G–ŸA–î”ö”M—TA²“¡—yA²“¡Œö—YA‰ºìG–ŸF“–‰È‚É‚š‚¯‚éFabry•a‚̐f—Âɂ‚¢‚Ä
  6. ’†–쐜A•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•œ–쓹•æAç—t‹M•FA[•Y‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFƒsƒ‹ƒWƒJƒCƒjƒh“Š—^‚ŏoŒ»‚µ‚œ’x‰„“dˆÊ‚Ö‚ÌRFCA‚ª—LŒø‚Å‚ ‚Á‚œ‚ƍl‚Š‚ç‚ê‚éBrugadaÇŒóŒQÇ—á
  7. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–쐜A£ì«lA•œ–쓹ŠîAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF¶”xÃ–¬‹€’ÊŠ²‚ð—L‚µCryoballoonablationŽ{sŒã‚ɍĔ­‚ð”F‚ß‚œ”­ì«S–[×“®‚̈ê—á
  8. ‹yì‘ì–çAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YAŽR“à‹BA’ÒŒOØŽqA¬–쐣„¶Aˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA‚‹ŽAŽO‰Y³’šA‹{“c•qA‰ºìG–ŸF6ƒXƒ^ƒ`ƒ“‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢| CHART-2Œ€‹†‚æ‚è[
  9. {“c•jA_ŒË–ΗYA‚‹ŽAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‰ºìG–ŸFŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚œˆê—á
  10. ‰Á‰ê’J—T‘ŸAˆÉ“¡Œ’‘ŸA‚‹ŽAŒ–{‘׎¡A‰€’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îAi“¡’q•FA”öŒ`„A•àV—ºA]Œû‹v”üŽqA”©’†˜a–ŸA‹{“c•qA‰ºìG–ŸF‹}«S‹Ø[ÇŒã‚̍¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̌ø‰Ê
  11. ‰H”öŽ‹MAŒ‹{Œ’‰îAŽR–{¹DA‰€’J—²Ž¡AŒ–{‘׎¡A™‘ºGˆê˜YA‚‹ŽAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFFabry•a‚ÉŠ¥Šlk«‹·SÇ‚ð‡•¹‚µ‚œˆê—á
  12. [àV‹±”V˜NAŒ—’J—²Ž¡A‚‹ŽA{“c•jAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF”ñS‘ŸŽèp’†‚É”­Ç‚µ‚œ–òÜ—noƒXƒeƒ“ƒg—¯’uŒãˆŸ‹}«ƒXƒeƒ“ƒgŒŒðÇ‚̈ê—á
  13. “n•”Œ«A‹e’n—ƒAŽuŠ™@‘ñA‘哹Ž›”ò—Y”nA‰Á“¡d•FA‚‹ŽŽ–ŸA‹Ê“c–F–ŸA•Ÿˆäº’jA–îì@—F•ÛAŒˆäŠ²”VAŒã“¡•q˜aAŽR–{¹DA™‘ºGˆê˜YA‰ºìG–ŸF‰Â‹t«‚̍¶ŽºáŠQ‚ð‚«‚œ‚µ”x‚ŒŒˆ³‚ð‡•¹‚µ‚œPOEMSÇŒóŒQ‚Ì1—á
  14. ‘å]’@Â–Ø—³’jA_’ÍŽ–çA—é–؏G–ŸAŽR–{¹DAŽO‰Y³’šAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸFŠO‰È“IŒŒð“Eœp‚ŗǍD‚ÈŒo‰ß‚ª“Ÿ‚ç‚ê‚œ”xÇðÇ‚̈ê—á
  15. —é–؏G–ŸA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA‰ºìG–ŸF“‡Žž’²Ç‚ð”wŒi‚ɍRƒŠƒ“Ž‰Ž¿R‘̏njóŒQ‚Å”­Ç‚µ‚œ”xÇðÇ‚̈ê—á
  16. ŽR“à‹BAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çAŒã‰ªL‘Ÿ˜YA‹{“c•qAŽO‰Y³’šA‚‹ŽA‰ºìG–ŸF‰ä‚ª‘‚Ì–x«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ĐS–[×“®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ€‹†‚©‚ç‚Ì•ñˆê
  17. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’š@’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‹{“c@•qA‚‹ŽA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•Ê‚É‚š‚¯‚éŒoŽž•Ï‰»‚ÌŒŸ“¢
  18. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘ԁ[OFDI‚É‚æ‚錟“¢[
‘æ56‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2015”N10ŒŽ29“ú`31“úA“Œ‹žj
  1. ¬‘é—I“ñA‚‹Ž@A{“c@•jA¬Œ^‹±AŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥”÷¬zŠÂáŠQ‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  2. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a‘ÔŒ`¬@\OFDI‚É‚æ‚錟“¢\
  3. Â–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇŠ³ŽÒ‚É‚š‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚ÌŽ_‘f‰»”\‚Ö‚ÌŒø‰Ê.
‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2015”N10ŒŽ22`24“úA‘åãj

    ƒYIARžu‰‰FŠî‘bŒn„iYIAŽóÜj

  1. Suzuki K, Satoh K, Omura J, Sato T, Kudo S, Otsuki T, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice
  2. ƒYIARžu‰‰F—Տ°Œn„iFinalistj

  3. Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Prognostic impacts of plasma levels of cyclophilin A in patients with heart failure
  4. ƒ“Á•ÊŠé‰æ3F“ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  5. Sakata Y, Shimokawa H. Temporal trends in clinical profiles of symptomatic heart failure in Japan@- A report from the CHART Studies -
  6. ƒ“Á•ÊŠé‰æ4F“ú–{EŠØ‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  7. Sakata Y, Shimokawa H. Differences in clinical characteristics and prognosis between HFpEF and HFrEF@-A report from the CHART-2 Study-
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€4FS•s‘S‚É‚š‚¯‚é‹@”\•]‰¿|Žûk‹@”\EŠg’£‹@”\E‰ES‹@”\|„

  9. ²“¡@—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡Œö—YA‘å“c‰p‹PA‰ºìG–ŸFS‘ŸMRI‚ð—p‚¢‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  10. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FƒTƒ‹ƒRƒCƒh[ƒVƒXS‹ØÇ‚É”º‚€––ŠúS•s‘S‚ɑ΂·‚鎡—Á„

  11. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA•œ–쓹ŠîAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA[àV‹±”V˜NA‰ºìG–ŸASƒTƒ‹ƒRƒCƒh[ƒVƒX––ŠúS•s‘S‚É‚š‚¯‚鍡Œã‚̉ۑè
  12. ƒƒ[ƒNƒVƒ‡ƒbƒv1FHFpEF‚̐f’f‚ÆŽ¡—Á„

  13. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‹{“c@•qA‰ºìG–ŸF‰ä‚ª‘‚É‚š‚¯‚鍶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚Ì—\Œã‚ÆŽ¡—à -CAHRT-2Œ€‹†‚©‚ç‚Ì•ñ-
  14. ƒƒ[ƒNƒVƒ‡ƒbƒv6FS•s‘SŠî‘bŒ€‹†‚̍őOü„

  15. Sato K, Suzuki K, Sunamura S, Otsuki T, Shimizu T,Ikeda S, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial roles of Rho-kinase, cyclophilin A and its receptor, basigin, for cardiac hypertrophy, fibrosis and failure -novel therapeutic targets-
  16. ƒƒ[ƒNƒVƒ‡ƒbƒv7F¬læ“V«SŽŸŠ³––ŠúŠ³ŽÒ‚ÌŠÇ—„

  17. Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Sato K, Shimokawa H. Current status of the management for adult congenital heart disease associated with end-stage pulmonary arterial hypertension
  18. ƒƒ[ƒNƒVƒ‡ƒbƒv9F‘å‹K–ÍŒ€‹†@|ƒŒƒWƒXƒgƒŠŒ€‹†‚Æ‘OŒü‚«Š„‚è•t‚¯ŽŽŒ±|„

  19. Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Yamauchi T, Sato K, Nochioka K, Takahashi J, Shimokawa H. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartaniSUPPORTjtrial
  20. Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2iCHART-2jStudy as a model of Japanese observational study
  21. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€2FS•s‘S•a‘ÔƒXƒe[ƒW•Ê‚̉h—{ŠÇ—„

  22. “c’†—T”üAŽO‰Y³’šAâ“c‘וFA™‘ºGˆê˜YA‹ß“¡³‹PA‰H”öŽ‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚éCONUTƒXƒRƒA‚É‚æ‚é‰h—{•]‰¿‚Ì—L—p«
  23. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€3FS•s‘SƒPƒA‚É‚š‚¯‚闝‘z“I‚Ȉã—Ðê–åEƒ`[ƒ€iIPWj‚ð\’z‚·‚é‚ɂ́H„

  24. ŠìƒAƒ†ƒ~AŽO‰Y³’šA™‘ºGˆê˜YA‹ß“¡³‹PA‰H”öŽ‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA“c’†—T”üA‰ºìG–ŸF“–‰@‚É‚š‚¯‚éƒn[ƒgƒ`[ƒ€‚Ì—§‚¿ã‚°‚ÌŒ»ó‚Ɖۑè
  25. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€6F‚—îŽÒS•s‘SŠ³ŽÒ‚ɑ΂·‚éƒAƒvƒ[ƒ`@|ƒtƒŒƒCƒ‹A”F’mÇA‘ŸŠíáŠQ|„

  26. ²“¡Œª“ñ˜YAâ“c‘וFA‹{“c@•qAŽO‰Y³’šA‹ž—ºˆêA’A–Ø‘sˆê˜YA¬–쐣„¶A’ҁ@ŒOØŽqAŽR“à@‹BA‰ºìG–ŸF ‚—îŽÒS•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰îŒì•K—v“x‚š‚æ‚щh—{ó‘Ô‚Ì•]‰¿‚Ƒ΍ô‚̏d—v«: CHART-2Œ€‹†‚©‚ç‚Ì•ñ
  27. ƒˆê”ÊŒû‰‰2F“ñŽŸ«S‹ØÇi1j`SƒTƒ‹ƒRƒCƒh[ƒVƒX`„

  28. Segawa M, Fukuda K, Nakano M, Kondo M, Hirano M, Chiba T, Miki K, Morosawa S, Fukazawa K, Shimokawa H. The significance of advanced heart block in patients with cardiac sarcoidosis
  29. ƒˆê”ÊŒû‰‰10F‚œ‚±‚‚ڐS‹ØÇ„

  30. Suzuki H, Matsumoto Y, Sugimura K, Takahashi J, Fukumoto Y, Shimokawa H. Evidence for brain activation in patients with Takotsubo cardiomyopathy -A new finding of cardio-cerebral connection-
  31. Kochi R, Aoki T, Sugimura K, Tatebe S, Miura M, Yaoita N, Takahashi J, Matsumoto Y, Satou K, Shimokawa H. Takotsubo cardiomyopathy in a case of recurrent pheochromocytoma
  32. ƒˆê”ÊŒû‰‰15F–«S•s‘Si‚Pj„

  33. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Miyata S, Shimokawa H. Prognostic impact of de-novo atrial fibrillation in patients with chronic heart failure - A report from the CHART-2 Study-
  34. ƒˆê”ÊŒû‰‰18FS•s‘SES”ì‘å‚Ì•ªŽq‹@\i‚Pj„

  35. Sunamura S, Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. ROCK1 plays a crucial role to maintain cardiac function in response to pressure-overload in mice
  36. ƒˆê”ÊŒû‰‰35F“ñŽŸ«S‹ØÇi3j`”ì‘åŒ^`„

  37. Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukazawa K, Miki K, Morosawa S, Shimokawa H. Implantable cardioverter defibrillator for primary prevention properly perminated ventricular tachycardia in patient with cardiac fabry disease
  38. ƒˆê”ÊŒû‰‰37F–«S•s‘Si3j„

  39. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Shimokawa H. Temporal trends in drug therapies and clinical outcomes in patients with symptomatic heart failure: Lessons from the CHART Studies
  40. ƒƒ|ƒXƒ^[6F‰æ‘œf’f„

  41. Obe H, Suzuki H, Ota H, Aoki T, Sugimura K, Matsumoto Y, Kushimoto S, Shimokawa H. Cardiac magnetic resonance as an alternative diagnostic method for Takotsubo cardiomyopathy in a patient with allergy to iodine contrast media
  42. ƒƒ|ƒXƒ^[9F—˜”AÜŽ¡—Á„

  43. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Satoh K, Miyata S, Sakata Y, Shimokawa H. Prognostic impacts of diuretics in Japanese patients with chronic heart failure
‘æ4‰ñ “ú–{”xzŠÂŠw‰ïE‘æ3‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïŠwpW‰ïi10ŒŽ3“ú`4“úA2015”NA“Œ‹žj

    ƒYIAƒZƒbƒVƒ‡ƒ“„

  1. ²“¡@‘åŽ÷A²“¡@Œö—YA–î”ö”@M—TA‹e’n@‡—TA‘呺@~ˆêA•àV@—ºA™‘º@Gˆê˜YA’†‘º@ˆê•¶AˆÉ“¡@_A‰ºì@G–ŸFTEPH ‚É‚š‚¯‚éV‹K•aˆö’`”’ TAFI ‚ÌŠî‘b“I E —Տ°“I‹@”\‰ðÍ.
  2. “n糁@—ŽHA¯ì@NAˆÀ’B@—AVˆäì@O“¹AŒ“c@ˆÀŽjA–ì“c@‰ëŽjAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸAÄ–؁@‰ÀŽA‰ª“c@Ž“TF“V«SŽŸŠ³‚ÉŠÖ˜A‚µ‚œ”x‚ŒŒˆ³Ç‚ɑ΂·‚é”xˆÚA.
  3. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ES•s‘S‚̃Cƒ[ƒWƒ“ƒO„

  4. Œš•”@r‰îA™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA —é–؁@G–ŸA²“¡@—yA_’Á@Ž–çA²“¡@Œö—YA‰ºìG–ŸFOCT‚É‚æ‚éPH‚̐f’f.
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€6FTEPH ––œŒ^‚ɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚̐¬Ñ‚Æ–â‘è“_ /CTEPH ‚ɑ΂·‚é PEA‚š‚æ‚Ñ EPA ‚Ì’†ŠúE‰“Šu¬Ñ„

  6. ™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA —é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸF“–‰@‚É‚š‚¯‚é PTPA ‚̐¬Ñ‚Æ–â‘è
  7. ƒƒVƒ“ƒ|ƒWƒEƒ€8F”x‚ŒŒˆ³Ž¡—Öò‚Ì”xŒŒŠÇˆÈŠO‚ւ̍ì—p‚ð‰î‚µ‚œ”x‚ŒŒˆ³•a‘Ô‰ü‘P‚̉”\«„

  8. ²“¡@Œö—YA‰ºì@G–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\‚Æ‚»‚̗Տ°‰ž—p.
  9. ƒˆê”ʉ‰‘聄

  10. ‘呺@~ˆêA²“¡@Œö—YA‹e’n@‡—TA²“¡@‘åŽ÷A•àV@—ºA_’Á@Ž–çAÀ–ì@˜a•FAÂ–؁@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸF”x“®–¬ŒŒŠÇ“à”ç AMPK ‚Í”x‚ŒŒˆ³Ç‚̐is‚ð—}§‚·‚é.
  11. À–ì@˜a•FA²“¡@Œö—YA‘å’΁@’mLA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºAÂ–؁@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸFPH Š³ŽÒ‚ÌŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚ƉŠÇ«ƒTƒCƒgƒJƒCƒ“‚Ì‘ŠŠÖ.
  12. •àV@—ºA²“¡@Œö—YA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A–ì–؁@³“¹AÀ–ì@˜a•FAMohammad SiddiqueAElias Al-MamunA™‘º@Gˆê˜YA‰ºì@G–ŸF‰»‡•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­.
  13. Œš•”@r‰îA™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFDiastolic pulmonary gradient ‚É‚æ‚é Group2 PH Š³ŽÒ‚Ì—\Œã—\‘ª.
  14. ‹e’n@‡—TA²“¡@Œö—YA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºA–ì–؁@³“¹A‘å’΁@’mLAŒš•”@r‰îAÂ–؁@—³’jA™‘º@Gˆê˜YA‰ºì@G–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“ P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. Â–؁@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’šAŒš•”@r‰îA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA_’Á@Ž–çA²“¡@Œö—YA‰ºì@G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚é OFDI ‚ð—p‚¢‚œ•a•ÏŒ`‘Ô‚ÌŠÏŽ@.
  16. –î”ö”@M—TA²“¡@Œö—YA²“¡@‘åŽ÷A™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŒš•”@r‰îA•Ÿ–{@‹`OA‰ºì@G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚š‚¯‚é TAFI ‚ÌŠÖ—^.
  17. Â–؁@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’šAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFCTEPH‚É‚š‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚̌ċz‹@”\‚Ö‚ÌŒø‰Ê.
  18. ²“¡@Œö—YA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šA–î”ö”@M—TA—é–؁@G–ŸAŽR–{@¹DA_’Á@Ž–çA‘å’΁@’mLA‰ºì@G–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚Í PTPA Ž¡—Â̗LŒø«‚𔜉f‚·‚é.
  19. ²“¡@—yA‘å“c@‰pŠöA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@Œö—YA‰ºì@G–ŸFS‘Ÿ MRI ‚ð—p‚¢‚œŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢.
  20. ŽO‰Y@³’šA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA
  21. —é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“Ÿ‚ç‚ê‚œ”xÃ–¬•ÂÇ«ŽŸŠ³‚̈ê—á.
  22. —é–؁@G–ŸA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA²“¡@Œö—YA‹vŽu–{@¬Ž÷A‰ºì@G–ŸF“‡Žž’²Ç‚É”º‚€RƒŠƒ“Ž‰Ž¿R‘̏njóŒQ‚Å”­Ç‚µ‚œ”xÇðÇ‚̈ê—á.
  23. ¯Žq@Œ\A™‘º@Gˆê˜YAŽO‰Y@³’šA‹g“c@KŽ}AŽ›Œ@Œb”üA¯“‡@˜a¢A–Ÿ’¿@çŒbA—é–؁@ŽõŽ÷AŠ`‰Ô@—²ºA‰ºì@G–ŸF”x“®–¬«”x‚ŒŒˆ³ÇŠ³ŽÒ‚ɑ΂·‚éƒ`[ƒ€ˆã—Ã.
‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2015”N9ŒŽ18`20“úA‰¡•lj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŒŒŠÇ‹@”\•]‰¿‚ÌŒ»ó‚Ɖۑ聄

  1. Œ‹{ Œ’‰îAŒ–{ ‘׎¡A‰F’Ë —T‹IA‘åŽR @”nAi“¡ ’q•FA•œ–ì “¹ŠîA¬‘é —I“ñA‰H”ö Ž‹MAš¢’J —²Ž¡A‚‹Ž AˆÉ“¡ Œ’‘ŸA‰ºì G–ŸFŠ¥“®–¬¹k‚É‚š‚¯‚銥“®–¬ƒCƒ[ƒWƒ“ƒO‚̏d—v«
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‹}«Š¥ÇŒóŒQ‚̐f—Â̐i•à|‚³‚ç‚È‚é—\Œã‚̉ü‘P‚ÉŒü‚¯‚ā|„

  3. ‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA‹{“c •qA›Á Œ³‹gAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç‚Ì”­Ç—Š‚Ɖ@“àŽ€–S—Š‚Ì‹ß”N‚É‚š‚¯‚éŒo”N•Ï‰»\MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ\
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€3FS‘Ÿ“Ë‘RŽ€‚Ì—\’m‚Æ—\–h‚̍őOü„

  5. ²’| —m”VA•Ÿ“c _“ñAâ“c ‘וFA‹{“c •qA’†–ì œA‹ß“¡ ³‹PA•œ–ì “¹ŠîA£ì «lA‰ºì G–ŸF–{–M–«S•s‘SŠ³ŽÒ‚̐S‘Ÿ“Ë‘RŽ€‚ɑ΂·‚éˆêŽŸ—\–h–Ú“I‚̐A‚Šž‚ÝŒ^œ×“®Ší‚ÌŒ»ó\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€4FŠó­SŒŒŠÇŽŸŠ³‚ðŒ©’Œ‚·„

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸF“–‰@‚É‚š‚¯‚éFabry•af—Â̌»ó
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€5FV‚œ‚ȃGƒrƒfƒ“ƒX‚ÉŠî‚­kÐŽžzŠÂŠíŽŸŠ³‚Ì—\–h‚ÆŠÇ—F‹}«Šú‚©‚疝«Šú‚ց„

  9. ‚‹Ž A‰ºì G–ŸF‘åkÐ‚ƐS•s‘S ¬–쐣 „¶Aâ“c ‘וFAŒã‰ª L‘Ÿ˜YA‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA’Ò ŒOØŽqAˆ¢•” —Ú—žA‚‹Ž A‰ºì G–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Æ‚»‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€8FS•s‘S‘ˆ«‚ð‚à‚œ‚ç‚·”ñS‘ŸˆöŽqi”]A”xj„

  11. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€9F‰uŠwŒ€‹†‚ðzŠÂŠíŽŸŠ³—\–h‚ÉŠˆ‚©‚·„

  13. â“c ‘וFAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸF‰ä‚ª‘‚É‚š‚¯‚閝«S•s‘S‘å‹K–ÍŠÏŽ@Œ€‹†FCHART-2Œ€‹†
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€14FSŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“œ”A•a‚ÌŠÇ—„

  15. ŽO‰Y ³’šAâ“c ‘וFA‹{“c •qA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚š‚¯‚é“œ”A•a‚Ì—\Œã‚ւ̉e‹¿\tÇ‚ÌŠÏ“_‚©‚ç‚̍lŽ@\
  16. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚©‚çƒtƒŒƒCƒ‹‚ðl‚Š‚遄

  17. Œ–{ ‘׎¡A’|“à ‰ëŽjA‚‹Ž A™‘º Gˆê˜YAŽO‰Y ³’šAãŒŽ ³”ŽA‰ºì G–ŸFŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠ‚Ì–ðŠ„`ƒtƒŒƒCƒ‹iFrailtyj‚Ì”FŽ¯‚ƌċzE‰^“®‹@”\ŠÇ—‚̏d—v«`
  18. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“iˆãŽtj„

  19. š¢’J —²Ž¡A‚‹Ž A’†‘º –Ÿ_A–ìè ‰p“ñA™ ³•¶AŽR–{ ‹`lA•œ–{ “N–çA–xŒû ‘Aˆäã Š°ˆêAŒã“¡ •q˜aA‰Á“¡ “ցAŽÂè ‹BA‰ºì G–ŸF’·ŽžŠÔì—pŒ^ƒjƒtƒFƒWƒsƒ“‚É‚æ‚é–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŒŒŠÇ•ÛŒìŒø‰ÊFNOVELŽŽŒ±
  20. ƒŽáŽèÇ—áPresenterÜF”ñNP“I‰æ‘œf’f„

  21. ‘åç³ Š°KA—é–Ø G–ŸA‘å“c ‰pŠöAÂ–Ø —³’jA™‘º Gˆê˜YAŒ–{ ‘׎¡A‹vŽu–{ ¬Ž÷A‰ºì G–ŸF“®–¬ƒKƒX”]ÇðÇ‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڐS‹ØÇ‚Ì1—áFƒˆ[ƒh‘¢‰eÜƒAƒŒƒ‹ƒM[Ç—á‚É‚š‚¯‚éS‘ŸMRI‚Ì—L—p«
  22. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[3F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª„

  23. ‚‹Ž F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6FŠ¥¹k‚̍ŐV’mŒ©„

  25. Œ‹{ Œ’‰îFŠ¥¹k«‹·SÇ‚É‚š‚¯‚éŠO–ŒVasa vasorum‚ÌŠÖ—^`Optical frequency domain imagingiOFDIj‚ð—p‚¢‚œŒŸ“¢`
  26. ƒˆê”ʉ‰‘èFŒû‰‰„

  27. –î”ö” M—TA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŒš•” r‰îA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚š‚¯‚éTAFI‚Ì–ðŠ„‚Æ‚»‚Ì‹@”\“IˆÓ‹`
  28. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  29. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  30. ²“¡ Œª“ñ˜YAâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA‹ž —ºˆêA’A–Ø šáˆê˜YA¬–쐣 „¶A’Ò ŒOØŽqAŽR“à ‹BAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‰ä‚ª‘‚É‚š‚¯‚鍂—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq: ‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^(CHART-2)Œ€‹†‚©‚ç‚Ì•ñ
  31. ‹ž —ºˆêAâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‰ä‚ª‘‚̏nj󐫖«S•s‘Sf—Â̕ϑJ‚Ɛ«·FCHARTŒ€‹†‚©‚ç‚Ì•ñ
  32. ›Á Œ³‹gA‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA‹{“c •qAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚Ì”N‘ã•ÊŒo”N•Ï‰»‚ÌŒŸ“¢\Miyagi AMI Registry Study‚©‚ç‚Ì•ñ
  33. Â–Ø —³’jA™‘º Gˆê˜YAŽO‰Y ³’šAŒš•” r‰îA–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFŒo”ç“I”x“®–¬Šg’£p‚Í–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¢‚ÄŒŒs“®‘ԂɉÁ‚Š‚ÄŽ_‘f‰»‚à‰ü‘P‚·‚é
  34. ²“¡ —yA‘å“c ‰pŠöA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA²“¡ Œö—YA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  35. ’†–ì œA•Ÿ“c _“ñA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîAç—t ‹M•FA‰ºì G–ŸFICDƒŠ[ƒh‚̕ύX‚ª—LŒø‚Å‚ ‚Á‚œ‚œ×“®è‡’l‚ð’悵‚œBrugadaÇŒóŒQ‚̈ê—á
  36. “c’† îc˜NAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA‰ºì G–ŸF‘œŠj‹×–E‚ð”F‚ß‚œŒ€ÇŒ^S‹Ø‰Š‚̈ê—á
  37. £ì «lA•Ÿ“c _“ñAÂ–Ø —³’jA’†–ì œA‹ß“¡ ³‹PA•œ–ì “¹ŠîA™‘º Gˆê˜YA‰ºì G–ŸFPETAMRIŽž‘ã‚É‚š‚¢‚ăKƒŠƒEƒ€ƒVƒ“ƒ`‚ªSƒTƒ‹ƒRƒCƒh[ƒVƒXf—Âɉʂœ‚·–ðŠ„
  38. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFDiastolic pulmonary gradient‚ð—p‚¢‚œpost-capillary PHŠ³ŽÒ‚Ì—\Œã—\‘ª
‘æ21‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2015”N7ŒŽ18`19“úA•Ÿ‰ªŽsj

    ƒYIA session„

  1. ‹ààV³”́AŒ–{‘׎¡AŠÝ–{ŒõŽiAAxel LinkeA‰ºìG–ŸFƒgƒŒƒbƒhƒ~ƒ‹‰^“®—Ö@‚͐S‹Ø[ÇŒã‚̍œ–§“x’ቺ‚ð—\–h‚·‚é@\S‹Ø[Çƒ}ƒEƒXƒ‚ƒfƒ‹‚Å‚ÌŒŸ“¢\iÅ—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. ‰H”öŽ‹MAŒ–{‘׎¡AX@M–FAŒ‹{Œ’‰îA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFAãŒŽ³”ŽA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚ɑ΂·‚éƒJƒ‹ƒVƒEƒ€hR–ò‚̉^“®‘Ï—e”\‰ü‘PŒø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢
  4. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–ŸA‘ã“c_”VAˆÀ“c@‘A‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚š‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚š‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@\‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚è[
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. ŽO‰Y³’šA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jA–î”ö”M—TA²“¡@ꡁA“c’†—T”üAŠìƒAƒ†ƒ~A²X–Ø•S‡‰ÔAŠ`‰Ô—²ºA—é–ØŽõŽ÷A²“¡Œö—YA‰ºìG–ŸFS•s‘SŽè’ ‚ðŽg—p‚µŠO—ˆ‚ÅŒo‰ßŠÏŽ@‚µ‚œŠg’£Œ^S‹ØÇ‚É‚æ‚édÇS•s‘S‚̈ê—á.
‘æ15‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2015”N6ŒŽ26`27“úA–L’†Žsj

    ƒYIA session„

  1. Ö“¡‘åŽ÷A²“¡¹—¢A“c’†C•œA_ŒË–ΗYA‰ºìG–ŸFŒŒŠÇ“à”ç‚É‚š‚¯‚éCaveolin-1/“à”çŒ^ˆêŽ_‰»’‚‘f‡¬y‘f•¡‡‘Ì‚ÌŒ`¬‚ªEDH‚ð‰î‚µ‚œ”÷¬zŠÂ‚̍Pí«‚̈ێ‚ɏd—v‚Å‚ ‚é.i—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. “›ˆä³lA“à“c‘Ÿ˜YA’J–{º‰pA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LA“c‘º‰ëmFƒCƒ‹ƒxƒTƒ‹ƒ^ƒ“‚ƃAƒ€ƒƒWƒsƒ“‚Ì•¹—p“Š—^‚Í2/3t“ENOSsŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é‹}«S‹Ø[Ç‚Ì”­Ç‚ð’˜–Ÿ‚É—}§‚·‚é.
  4. ¶‰z‹M–ŸAéŒË‹MŽuA“›ˆä³lA–˜a”ŽAÎ–{—TŽmAŽR“c‘‘—ºA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽ‰„ÍAŒ}@Š°FNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é’áŽ_‘f«”x‚ŒŒˆ³Ç.
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. _ŒË–ΗYAÖ“¡‘åŽ÷A“c’†C•œA²“¡¹—¢A‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO‚ÆEDHF‚̐¶—“Iƒoƒ‰ƒ“ƒX‚̏d—v«.
  7. ²’|—m•œA²“¡Œö—YAŠC–@N—TArˆä—zˆêA‰ºìG–ŸFäNã÷Žûk’oŠÉ‹@\‚É‚š‚¯‚éŠeŽíNOŽY¶‡¬y‘f‚Ì‹@”\“I–ðŠ„•ª’S.
  8. –î“c–L—²A‰ºìG–ŸA—§‰Ô”Ž”VA¬Š}ŒŽN•vFƒCƒk¶‘Ì“à“œ”A•a«Š¥”÷¬‘€•›ŒŒŠÇ‚É‚š‚¢‚ĉߎ_‰»…‘f‚É‚æ‚銥”÷¬‘€•›ŒŒŠÇŠg’£‚́AŠ¥“®–¬•ÂÇŽž‚ÌNO‚É‚æ‚錌ŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  9. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  10. ‰ºìG–ŸFd—v«‚𑝂·S•s‘S‚̐f—Ã.
‘æ205‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ20“úAå‘äŽsj
  1. ŽR–{—ŽˆêA‹vŽu–{¬Ž÷A—é–؏G–ŸA‰ºìG–ŸFSepsis-induced encephalopathy‚É‚æ‚é‘J‰„«ˆÓŽ¯áŠQ‚ð’悵‚œŠŽõ«S“à–Œ‰Š‚Ì1—á.
  2. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–؏G–ŸA’†–ì@œA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–ŸF“ª•”ŠO‚É‚æ‚éR‹ÃŒÅ—Ö@’†’fŒã‚É”­Ç‚µ‚œ‘œ”­ÇðÇ‚Ì1—á.
  3. ˆÉ“¡‚ä‚«‚́A‘å粊°KA‹vŽu–{¬Ž÷A—é–؏G–ŸAŒš•”r‰îAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–ŸF‘–Œ‰Š‚É‚Í”­Ç‚µ‚œ”x‰Š‹…‹Û‚É‚æ‚銎õ«S“à–Œ‰Š‚Ì1—á.
‘æ160‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ6“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–偄

  1. ²“¡@—yAŽO‰Y³’šA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸFƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“Ÿ‚ç‚ê‚œ”xÃ–¬•ÂÇ«ŽŸŠ³‚̈ê—á.
  2. ƒYIAÇ—á”­•\•”–偄i–Å—DGÜŽóÜj

  3. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‹ž@—ºˆêAŽR“à@‹BA²“¡Œª“ñ˜YA’ҁ@ŒOØŽqAˆ¢•”—Ú—žA‚‹Ž@A‹{“c@•qA‰ºìG–ŸFS‘Ÿ•aŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•Ï‰»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢.
  4. ƒˆê”ʉ‰‘聄

  5. Â–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îA–î”ö”M—TA²“¡@—yA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¢‚ÄŒo”ç“I”x“®–¬Šg’£p‚ÍŒŒs“®‘ԂɉÁ‚Š‚ÄŽ_‘f‰»‚à‰ü‘P‚³‚¹‚é.
  6. ŒÃ’m—ŽŽO˜YAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šA–î”ö”M—TA²“¡@—yA‚‹Ž@AŒ–{‘׎¡A‰H”öŽ‹MA²“¡Œö—YA‰ºìG–Ÿ: ‚œ‚±‚‚ڌ^S‹ØÇ—l‚ÌŽûkáŠQ‚𗈂œ‚µ‚œŠŒF×–EŽî‚̈ê
  7. Œ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA“n粗ŽHA¯ì@NA‰ª“c@Ž“TF•ÂÇ«”ì‘åŒ^S‚É‚œ‚±‚‚ڌ^S‹ØÇ‚𕹔­‚µ‚œ”xˆÚAÇ—á.
  8. š¢’J@—²Ž¡A‚‹Ž@AŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–Ÿ:“ûŽ_ƒAƒVƒh[ƒVƒX‚ð‡•¹‚µ‚œ”ñST ãžŒ^S‹Ø[Ç‚̈ê—á.
  9. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–؏G–ŸA’†–ì@œA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–Ÿ: “ª•”ŠOŒã‚̍R‹ÃŒÅ—Ö@’†’f‚É‚æ‚è‘Sg«ÇðÇ‚𔭏ǂµ‚œS–[×“®‚̈ê—á.
  10. ŽRè—ŽˆêA‹vŽu–{¬Ž÷A—é–؏G–ŸA‰ºìG–ŸFSepsis-induced encepharopathy ‚É‚æ‚è‘J‰„«ˆÓŽ¯áŠQ‚ð’悵‚œŠŽõ«S“à–Œ‰Š‚̈ê—á.
  11. ˆÉ“¡‚ä‚«‚́A‘å糊°KA‹vŽu–{¬Ž÷A—é–؏G–ŸAŒš•”r‰îAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–Ÿ: ×‹Û«‘–Œ‰Š‚É‚Ä”­Ç‚µ‚œ”x‰Š‹…‹Û‚É‚æ‚銎õ«S“à–Œ‰Š‚Ì1—á.
  12. ’A–Øšáˆê˜YAâ“c‘וFAŽO‰Y³’šA‹ž—ºˆêA²“¡Œª“ñ˜YA¬–쐣„¶AŽR“à@‹BA’ҁ@ŒOØŽqAˆ¢•”@—Ú—žA‹{“c@•qA‰ºìG–ŸF–«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  13. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA£ì«lA•œ–쓹ŠîAç—t‹M•FA‰ºìG–ŸF‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒOƒVƒXƒeƒ€‚É‚æ‚èICDƒVƒ‡ƒbƒNì“®•s‘S‚𑁊ú‚ɐf’f‚Å‚«‚œŠg’£Œ^S‹ØÇ‚̈ê—á.
  14. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA‰ºìG–Ÿ: High DFT‚ð’悵AICDƒŠ[ƒh‚̕ύX‚ª—LŒø‚Å‚ ‚Á‚œBrugada ÇŒóŒQ‚̈ê—á.
  15. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîA‰ºìG–ŸF‘å“®–¬‰EŠ¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚œ‰EŽº—¬o˜H‚ÌExit ‚ð‚à‚—¬o˜H‹NŒ¹PVC ‚̈ê—á.
  16. •Ð•œW‘Ÿ˜YAHŽR³”NA‰Í’Á@‘A‚ŒŽ^ŒáA“n粍W—CA“¡ŒŽ‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽA™‘ºGˆê˜YA‰ºìG–ŸF‘ÌŠOŽ®VAD ‚©‚çAžŒ^VAD ‚Öconversion ‚µ‚œÇ—á‚ÌŒŸ“¢.
  17. HŽR³”NA•Ð•œW‘Ÿ˜YA‰Í’Á@‘A“n粍W—CA‚ŒŽ^ŒáA“¡ŒŽ‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽAÂ–Ø—³’jA•Ÿ“c_“ñA‚‹Ž@A™‘ºGˆê˜YA‰ºìG–ŸFŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ɑ΂·‚é‹@ŠB“I•â•zŠÂŽ¡—Â̎¡—Ð헪‚ÌŒŸ“¢.
‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2015”N4ŒŽ24“ú`26“úA‘åãj

    ƒSpecial Session„

  1. (SS05:The Prediction for the Future in the Large-scale Registry of Cardiovascular Disease) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Miyata S, Takahashi J, Shimokawa H. Perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J 79(Suppl. I):I-47,2015.
  2. (SS09:Rapid Development of Antithrombotic Therapy: Current Status and Future Directions) Fukuda K , Ogawa H, Hirotsug A, Inoue H, Uchiyama S, Kitazono T, Ikeda T, Kaikita K, Kamouchi M, Matsui K, Shimokawa H. Effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation@\First report from the EXPAND study\ Circ J79(Suppl. I):I-74,2015.
  3. (SS10:Therapeutic Strategies of Coronary Artery Disease from the Point of View of Vasomotion and Microvascular Function) Kensuke Nishimiya1 ,Yasuharu Matsumoto1 , Uzuka H1 , Oyama K1 , Tomohiko Shindo1 , Ryuji Tsuburaya1 , Takashi Shiroto1 , Takahashi J , Kenta Ito1 , Hatsue Ishibashi-Ueda2 , Satoshi Yasuda3 , Hiroaki Shimokawa. Involvement of Rho-Kinase pathway in the pathogenesis of coronary hyperconstricting responses after drug-eluting stents implantation. Circ J 79(Suppl. I):I-78,2015.
  4. ƒPlenary Session„

  5. (PL01: New Multi-Modality Cardiovascular Imaging and the Dedicated Management of Diseases) Ota H, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. 4D flow MRI for pulmonary hypertension: an imaging tool to monitor mean pulmonary arterial pressure. Circ J 79(Suppl. I):I-99,2015.
  6. (PL02:Explore the Japanese Style Clinical Investigation beyond the Global Trends) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Miyata S, Takahashi J, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2 (CHART-2) Study: A model case of Japanese observational study. Circ J 79(Suppl. I):I-101,2015.
  7. ƒSymposium„

  8. (SY03:Novel and Advanced Therapy against Acute Coronary Syndrome\From Bench to Bedside\) Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Kagaya Y, Shindo T, Ogata T, Kurosawa R, Shimokawa H. Low-energy cardiac shock wave therapy suppresses left ventricular remodeling after acute myocardial infarction\From bench to bedside\ Circ J 79(Suppl. I):I-176,2015.
  9. (SY10:The Importance of the Right Ventricle in Adult Congenital Heart Disease\Physiological Properties, Diagnosis, and Management of Right Heart Failure in ACHD\) Fujiwara J, Onuma H, Funamizu Y, Tatebe S, Sugimura K, Sakata Y, Saijoh Y, Shimokawa H. Echocardiographic evaluation of right ventricular dysfunction in adult patients with Tetralogy of Fallot. Circ J 79(Suppl. I):I-218,2015.
  10. (SY13:Recent Progress in Pulmonary Hypertension) Aoki T, Tatebe S, Sugimura K, Nochioka K, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Importance of acute hemodynamic responses to inhaled nitric oxide in patients with pulmonary hypertension due to left heart disease. Circ J 79(Suppl. I):I-243,2015.
  11. (SY15:Prevention and Control of Cardiovascular Disease: the WHO Global Strategy) Tadaki S, Sakata Y, Miura M, Miura Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impacts of physical activity in patients with chronic heart failure. A multicenter prospective cohort study. Circ J 79(Suppl. I):I-255,2015.
  12. (SY20:Diagnosis and Treatment of Functional Angina Pectoris\Insight into Vasospasm and Microvascular Disease) Takahashi J, Nihei T, Odaka Y, Tsuburaya R, Hao K, Nishimiya K, Matsumoto Y, Ito K, Shimokawa H. Prognostic impact of Rho-kinase activity in circulating leukocytes of patients with vasospastic angina. Circ J 79(Suppl. I):I-288,2015.
  13. ƒESC-JCS Joint Symposium„

  14. (ESC:Coronary Vasomotion Abnormalities) Takahashi J, Tsuburaya R, Nishimiya K, Matsumoto Y, Shimokawa H. Coronary vasomotion abnormalities induced by drug-eluting stents. Circ J 79(Suppl. I):I-327,2015.
  15. ƒRound Table Discussion„

  16. (RT05:The Current Status and Future Perspective of Acute Cardiovascular Care: the Evolving Real World Evidence from Nation-wide Registry Studies) Takahashi J, Hao K, Ito K, Sakata Y, Shimokawa H. Trends in the emergency care of AMI in Japan\A report from the Miyagi AMI registry study\Circ J 79(Suppl. I):I-381,2015.
  17. ƒTopic„

  18. (TP05:Diagnosis and Treatment of Chronic Thromboembolic Pulmonary Hypertension after an Advent and Development of Balloon Pulmonary Angioplasty) Sugimura K, Aoki T, Tatebe S, Miura M, Yaoita N, Sato H, Kato T, Satoh K, Shimokawa H. Usefulness of optical coherence tomography imaging in management of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-431,2015.
  19. ƒLate Breaking Clinical Trials„

  20. (LBCT4) Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: A report from the SUPPORT Trial. Circ J 79(Suppl. I):I-592,2015.
  21. ƒLate Breaking Cohort Studies„

  22. (LBCS1) Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Adverse prognostic impacts of post-traumatic stress disorder in patients with cardiovascular disease after the Great East Japan Earthquake. Circ J 79(Suppl. I):I-597,2015.
  23. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  24. (YIA-C-3) Satake H, Fukuda K, Sakata Y, Miyata S, Nakano M, Kondo M, Hasebe Y, Segawa M, Shimokawa H. Current status of primary prevention of sudden cardiac death with implantable cardioverter-defibrillator in patients with chronic heart failure\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-625,2015.
  25. ƒYoung Investigator's Award for International Students Finalists Lectures„

  26. (I-YIA-2) Elias-Al-Mamun M, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension through synergistic inhibition of Rho-kinase. Circ J 79(Suppl. I):I-632,2015.
  27. ƒFeatured Research Session„

  28. (FRS-009) Satoh K , Sugimura K , Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Sunamura S, Nogi M, Shimokawa H. Plasma Cyclophilin A as a useful biomarker for effective percutaneous transluminal pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-650,2015.
  29. (FRS-126) Nihei T, Takahashi J, Miyata S, Odaka Y, Nishimiya K, Hao K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Combined Japanese Coronary Spasm Association risk score and Rho-kinase activity provide useful risk stratification in patients with vasospastic angina. Circ J 79(Suppl. I):I-791,2015.
  30. ƒOral Presentation (English)„

  31. (OE-033:Heart Failure (Basic) and Translational Science) Suzuki K, Satoh K, Sunamura S, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice. Circ J 79(Suppl. I):I-824,2015.
  32. (OE-254:Intravascular Imagings OCT/OFDI) Nishimiya K, Matsumoto Y, Takahashi J, Kato T, Oyama K, Uzuka H, Odaka Y, Nihei T, Hao K, Tsuburaya R, Ito K, Shimokawa H. Enhanced adventitial vasa vasorum formation in patients with vasospastic angina\Assessment with optical frequency domain imaging\Circ J 79(Suppl. I):I-1044,2015.
  33. (OE-307: Cardiomyopathy/Hypertrophy (Basic)) Kudo S, Satoh K, Suzuki K, Sunamura S, Nogi M, Kikuchi N, Ohmura J, Ikeda S, Shimokawa H. Crucial role of SmgGDS in the inhibitory effects of statins on cardiac hypertrophy and fibrosis in mice. Circ J 79(Suppl. I):I-1097,2015.
  34. (OE-347:Pulmonary Circulation) Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Suzuki K, Shimokawa H. Endothelial cell-specific AMPK deletion accelerates hypoxia-induced pulmonary hypertension in mice in vivo. Circ J 79(Suppl. I):I-1137,2015.
  35. (OE-350:Pulmonary Circulation) Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Sunamura S, Kurosawa R, Nogi M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Aoki T, Sugimura K, Shimokawa H. Plasma levels of Cyclophilin A correlate with circulating inflammatory cytokines in patients with pulmonary hypertension. Circ J 79(Suppl. I):I-1140,2015.
  36. (OE-352:Pulmonary Circulation) Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Suzuki K, Kudo S, Shimokawa H. Thrombin activatable fibrinolysis inhibitor plays a crucial role in the pathogenesis of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1142,2015.
  37. (OE-358:Prevention/Epidemiology) Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Tsuji K, Takahashi J, Shimokawa H. Recent trends in clinical characteristics, management and prognosis in patients with symptomatic heart failure\The CHART Studies\ Circ J 79(Suppl. I):I-1148,2015.
  38. ƒOral Presentation (Japanese) „

  39. (OJ-009:Heart Failure (Diagnosis)) Miura M, Sakata Y, Miyata S, Nochioka K, Ushigome R, Tadaki S, Yamauchi T , Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H. Prognostic impact of diabetes mellitus in patients with chronic heart failure\With special references to ischemic heart disease and nephropathy\Circ J 79(Suppl. I):I-1210,2015.
  40. (OJ-012:Heart Failure (Diagnosis)) Yamauchi T, Sakata Y, Miyata S, Nochioka K, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Takahashi J, Shimokawa H. Prognostic impacts of anemia in patients with CHF with a special reference to background\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1213,2015.
  41. (OJ-137: Heart Failure (Basic) and Translational Science) Kanazawa M, Matsumoto Y, Takahshi K, Suzuki H, Nishimiya K, Shimokawa H. Post-infarction heart failure reduces bone mineral density and strength in apolipoprotein E-deficient mice. Circ J 79(Suppl. I):I-1336,2015.
  42. (OJ-158:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Odaka Y, Takahashi J, Tsuburaya R, Nihei T, Nishimiya K, Hao K, Matsumoto Y, Ito K, Hirowatari Y, Shimokawa H. Plasma level of serotonin is a novel biomarker for coronary microvascular dysfunction in patient with vasospastic angina. Circ J 79(Suppl. I):I-1357,2015.
  43. (OJ-180: Vascular Disease (Therapy)) Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Kagaya Y, Hanawa K, Aizawa K, Hasegawa H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound improves left ventricular dysfunction in a porcine model of chronic myocardial ischemia\Potential involvement of mechanotransduction\Circ J 79(Suppl. I):I-1379,2015.
  44. (OJ-254: Pulmonary Circulation) Yaoita N, Taiju Sato , Satoh K, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Horiuchi H, Fukumoto Y, Shimokawa H. Involvement of thrombin-activated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1453,2015.
  45. (OJ-269:Prevention/Epidemiology) Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Nochioka K, Miyata S, Shimokawa H. The risk score for the three-year mortality in Japanese patients with aortic stenosis@\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1468,2015.
  46. ƒPoster Session (English)„

  47. (PE-212:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Uzuka H, Matsumoto Y, Nishimiya K, Oyama K, Hirano M, Ogata T, Shindo T, Hanawa K, Hasebe Y , Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Possible involvement of adventitial vasavasorum and sympathetic nerves in coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J 79(Suppl. I):I-1704,2015.
  48. (PE-226:Cardiomyopathy/Hypertrophy (Clinical)) Segawa M, Fukuda K, Nakano M, Kondo M, Satake H, Hirano M, Shimokawa H. Time-course and influencing factors of ventricular tachy-arrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ J 79(Suppl. I):I-1718,2015.
  49. (PE-522:Vascular Biology) Godo S, Ikeda S, Saito H, Suzuki K, Tanaka S, Ito A, Shimokawa H. Disruption of physiological balance between nitric oxide and endothelium-derived hyperpolarizing factor causes impairment of cardiovascular homeostasis in mice in vivo. Circ J 79(Suppl. I):I-2014,2015.
  50. (PE-695:Prevention/Epidemiology) Hao K, Takahashi J, Ito K, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Sakata Y, Shimokawa H. Recent trends in the incidence and mortality of acute myocardial infarction\ A report from the MIYAGI-AMI Registry Study\Circ J 79(Suppl. I):I-2187,2015.
  51. (PE-711:Pulmonary Circulation) Aoki T, Sugimura K, Nochioka K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effects of PTPA on respiratory functions in patients with chronic thromboembolic pulmonary hypertension\Possible importance of intra-pulmonary shunt\Circ J 79(Suppl. I):I-2203,2015.
  52. (PE-713:Pulmonary Circulation) Sato H1, Miura M, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Ota H, Satoh K, Shimokawa H. Usefulness of cardiac MRI for evaluating the effectiveness of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-2205,2015.
  53. ƒPoster Session (Japanese)„

  54. (PJ-103:Autonomic Nervous System and Stress-Psychosomatic Medicine) Suzuki H, Satoh K, Tatebe S, Matsumoto Y, Kondo M, Nakano M, Fukuda K, Watanuki S, Hiraoka K, Tashiro M, Shimokawa H. Evidence for activation of cerebral autonomic center in response to cardiac electrical stimulation in humans\New finding of cardio-cerebral connection\Circ J 79(Suppl. I):I-2326,2015.
  55. (PJ-103: Cardiac Arrest/Resuscitation/Cardiopulmonary/Critical Care/ACLS) Komatsu M, Takahashi J, Nakano M, Kondo M, Tsuburaya R, Hao K, Nishimiya K, Nihei T, Matsumoto Y, Ito K, Fukuda K, Shimokawa H. Usefulness of dual-induction tests for coronary artery spasm and lethal ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J 79(Suppl. I):I-2410,2015.
  56. (PJ-508:Pulmonary Circulation) Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effectiveness of vasodilator therapy for patients with inoperable chronic thromboembolic pulmonary hypertension in prior to percutaneous transluminal pulmonary angioplasty. Circ J 79(Suppl. I):I-2731,2015.
  57. (PJ-525:Arrhythmia, Others (Clinical/Diagnosis/Treatment)) Nakano M, Fukuda K, Kondo M, Satake H, Segawa M, Hirano M, Chiba T, Shimokawa H. Usefulness of late potentials for risk stratification in patients with type 2 brugada electrocardiogram. Circ J 79(Suppl. I):I-2748,2015.
  58. (PJ-655:Pulmonary Circulation) Sato H, Tatebe S, Sugimura K, Aoki T, Miura M, Yaoita N, Nochioka K , Yamamoto S, Satoh K, Shimokawa H. Current status of the treatment for adult congenital heart disease associated with pulmonary arterial hypertension. Circ J, 79(Suppl. I):I-2878,2015.
  59. (PJ-734: Cost-health Care System/DPC/Laws) Nakayama M, Takehana K, Takeda K, Kohro T, Shimokawa H. Report data format of medical examination in cardiology should be standardized for standardized structured medical information exchange extended storage. Circ J 79(Suppl. I):I-2957,2015.
“ú–{“à‰ÈŠw‰ï–k—€Žx•”‘æ64‰ñ¶ŠU‹³ˆçu‰‰‰ïi2015”N3ŒŽ8“úA‹à‘òŽsj
  1. ‰ºìG–ŸFŠ¥¹k«‹·SÇ‚̍ŋ߂̒mŒ©.
‘æ204‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N2ŒŽ21“úAå‘äŽsj
  1. Š™“c—TŠîA—é–؏G–ŸA‰ºìG–ŸA–쑺—º‰îA“ü–ìŽ÷”üA‹vŽu–{–ÎŽ÷F‹}«–ò•š’†“Å‚É‚æ‚é––œ_ŒoáŠQ‚©‚ç’·Šú“I‚ȐlHŒÄ‹zŠíˆË‘¶‚ɊׂÁ‚œ‚P—á.
  2. ²“¡@ꡁAÂ–Ø—³’jA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç—á‚ÉŒo”ç“I”x“®–¬Šg’£p‚ðŽ{s‚µ”x“®–¬úE‚𗈂µ‚œ2 Ç—á.
  3. “c’†Ë˜NAŒ‹{Œ’‰îA¬Œ^‹±A‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFƒXƒeƒƒCƒh•â[ŠJŽnŒã‚ÉŠ¥¹k«‹·SÇ”­ì‚ð”F‚ß‚œACTH’P“ÆŒ‡‘¹Ç‚Ì1—á.
‘æ44‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2015”N2ŒŽ6`7“úA‚Œj

    ƒŠî’²u‰‰„

  1. ‰ºìG–ŸFzŠÂŠí•a‚̃gƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
  2. ƒYIA„

  3. –î”ö”M—TA²“¡‘åŽ÷A²“¡Œö—YA™‘ºGˆê˜YA‘呺~ˆêA•Ÿ–{‹`OA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’TAFI‚Ì”­Œ©‚Æ‚»‚Ì‹@”\“IˆÓ‹`.
  4. ƒYIAÅIŒó•â„

  5. H“¡@rA²“¡Œö—YA—é–؍N‘ŸA»‘ºTˆê˜YA–ì–ؐ³“¹A“c’†^ˆêA“ì@’B˜YA‹e’n‡—TA‘呺~ˆêA’r“c®•œA‰ºìG–ŸFƒXƒ^ƒ`ƒ“‚É‚æ‚é‘œ–Ê“IŒø‰Ê‚ÌŒŽˆö’`”’SmgGDS‚Ì“¯’è‚Æ‚»‚̐S”ì‘åEüˆÛ‰»‚Ì—}§‹@\.
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A•àV@—ºA–î”ö”M—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“AŽó—e‘ÌBasigin‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\.
‘æ8‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2015”N1ŒŽ31“ú`2ŒŽ1“úA“¿“‡j

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŠef—ÉȂɂš‚¯‚鐫·ˆãŠw‚̐i•à„

  1. ‰ºì G–ŸFzŠÂŠí“à‰È—̈æ‚É‚š‚¯‚鐫·ˆãŠw‚̐i•à
  2. ƒÅ—DG‰‰‘聄

  3. ‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA›Á Œ³‹gA‹{“c •qAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç”­Ç—Š‚Ɖ@“àŽ€–S—Š‚ÌŒo”N•Ï‰»‚É‚š‚¯‚鐫·‚ÌŒŸ“¢ -MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ-
  4. ƒ—DG‰‰‘èŒó•â„

  5. ’Ò ŒOØŽqAâ“c ‘וFAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–쐣 „¶Aˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸF¶ŽºŽûk”\‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚É‚š‚¯‚鐫·|CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©|
  6. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  7. Â–Ø —³’jAÂ–Ø—³’jA™‘ºGˆê˜YA£ì«lA–î”ö”M—TAŒš•”r‰îAŽO‰Y³’šA²“¡@—yA²“¡Œö—YA•Ÿ“c_“ñA‰ºìG–ŸFSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̗Տ°“I“Á’¥‚̐«·‚ÉŠÖ‚·‚錟“¢
  8. ’A–Ø šáˆê˜YAâ“c ‘וFA•Ÿ–{ ‹`OAŽO‰Y r˜YA–åã r–ŸA‘ã“c _”VA–k•— ­ŽjA‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ăƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·
  9. ¬–쐣 „¶Aâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA‚‹Ž AŒã‰ª L‘Ÿ˜YA‰ºì G–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ɛ«·|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2014”N
‘æ55‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2014”N10ŒŽ30“ú`11ŒŽ1“úA‘q•~j
  1. ˆÉ“¡Œ’‘ŸA‚‹Ž@AŒ–{‘׎¡A‰~’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA“ñ•r‘Ÿ˜YA‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÁFSŒŒŠÇŽŸŠ³‚ɑ΂·‚éV‚µ‚¢”ñNP«ŒŒŠÇV¶—Ö@.
  2. »‘ºTˆê˜YAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ƉEŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
‘æ18‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2014”N10ŒŽ10`12“úA‘åãj

    ƒƒVƒ“ƒ|ƒWƒEƒ€6FS•s‘S‚É‚š‚¯‚éŠÏŽ@Œ€‹†„

  1. Sakata Y, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. The Chronic Heart Failure Analysis and Registry in the Tohoku District) Study.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€22FzŠÂŠí—̈æ‚É‚š‚¯‚éƒrƒbƒOƒf[ƒ^‚̍ì‚è•û„

  3. Shimokawa H. Large-scale registry study with chronic heart failure -Lessons from the CHART-2 Study-
  4. ƒYIARžu‰‰FŠî‘bŒnF—DGÜŽóÜ„

  5. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of Rho-kinase in pressure overload-induced right ventricular hypertrophy and dusfunction in mice.
  6. ƒYIARžu‰‰F—Տ°ŒnF—DGÜŽóÜ„

  7. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Tsuji K, Shimokawa H. Recent trends in clinical outcomes and prognostic factors in patients with dilated cardiomyopathy -The CHART Studies-
  8. ƒˆê”ʉ‰‘聄

  9. “¡ŒŽ~ŽqA‘åÀG˜aA‘D…N—zAˆÉ“¡‹I•FAŽO–؁@rAŒš•”r‰îA™‘ºGˆê˜YAâ“c‘וFAŒžŠ–F•¶A‰ºìG–ŸFSƒGƒR[‚ð—p‚¢‚œƒtƒ@ƒ[Žl’¥Ç‚š‚æ‚Ñ”x‚ŒŒˆ³Ç—á‚É‚š‚¯‚é‰EŽº‹@”\’ቺ‹@˜‚Ì”äŠr.
  10. Yamauchi T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Shimokawa H. Differences in clinical characteristics of anemic patients with chronic heart failure between ischemic and dilated cardiomyopathy -The CHART-2 Study-
  11. Sato K, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Three-year mortality and prognostic predictors in patients with aortic stenosis -A report from the CHART-2 Study-
  12. Onose T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Shimokawa H. Post-traumatic stress disorder after the Great East Japan Earthquake in patients with heart failure -A report from the CHART-2 Study-
  13. Aoki T, Sugimura K, Yaoita N, Yamamoto S, Tatebe S, Miura M, Nochioka K, Sato H, Satoh K, Shimokawa H. Effects of conventional medical therapy prior to percutaneous transluminal pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.
  14. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impacts of aldosterone antagonists in patients with heart failure with preserved ejection fraction -A report from the CHART-2 Study-
  15. Tadaki S, Sakata Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impact of physical activity level in patients with chronic heart failure -A multicenter prospective cohort study-
  16. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  17. Sato H, Aoki T, Miura M, Yaoita N, Yamamoto S, Tatebe S, Nochioka K, Satoh K, Sugimura K, Shimokawa H. Two cases of pulmonary hypertension associated with portosystemic shunt.
  18. Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Akiyama M, Saiki Y, Shimokawa H. Impact of implantable ventricular assist devices on long-term prognosis of patients with advanced heart failure.
  19. Sato H, Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Yaoita N, Satoh K, Shimokawa H. A case of successful immunosuppressive therapy for chronic myocarditis.
‘æ2‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïE‘æ3‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2014”N10ŒŽ3`4“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1F“ú–{‚©‚琢ŠE‚ÉŒü‚¯‚Ä”x‚ŒŒˆ³Ç‚ÌŠî‘bŒ€‹†‚ð‚Ç‚€”­M‚µ‚Ä‚¢‚­‚©H„

  1. •Ÿ–{‹`OA‰ºìG–ŸF”x‚ŒŒˆ³Ž¡—Âɂš‚¯‚éRhoƒLƒi[ƒ[‘jŠQ–ò‚Ö‚ÌŠú‘ҁFŠî‘b`—Տ°.
  2. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€1FCTEPH„

  3. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éPTPA‚̉EŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
  4. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF”x“®–¬ƒoƒ‹[ƒ“Œ`¬p‚ªCTEPHŠ³ŽÒ‚Ì‘ãŽÓEt‹@”\‚Ö‹y‚Ú‚·‰e‹¿.
  5. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€3FŠî‘b„

  6. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’n‡—SA–î”ö”M—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸFBasigin‚ÍŒŒŠÇ•œŠŠ‹Ø×–E‘B‚𑣐i‚µ”x‚ŒŒˆ³Ç‚ðˆ«‰»‚³‚¹‚é.
  7. ƒˆê”ʉ‰‘聄

  8. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒã–э׊ǐ«”x‚ŒŒˆ³Ç‚ɑ΂·‚éˆêŽ_‰»’‚‘f”xŒŒŠÇ”œ‰žŽŽŒ±‚̈Ӌ`.
  9. –î”ö”M—TA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒŽ”­«’_`«ŠÌd•Ï‚̐¶‘̊̈ڐAŒã‚É”­Ç‚µ‚œ”x‚ŒŒˆ³Ç‚̈ê—á.
  10. ‘Ձ@“NᩁA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸFOCT‚ŃŠƒo[ƒXƒŠƒ‚ƒfƒŠƒ“ƒO‚ð”F‚ß‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚̈ê—á.
  11. ŽO•r@‘zAé“c—SŽqA“n•”@—ŽAŠ›ì—R‹NŽqA“¡“c—mŽqA“¡ˆä”ŽŽiAÖ“¡^ˆê˜YAÎˆä’q“¿A‰ºìG–ŸA’£‘֏G˜YF–Ɖu—}§—Ö@‚ª‘tŒ÷‚µ‚œ‹­”çÇE‹«ŠEŒ^”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  12. ²“¡@ꡁAŽO‰Y³’šA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–ŸF–å–¬\‘åzŠÂƒVƒƒƒ“ƒg‚É”º‚€”x‚ŒŒˆ³Ç‚Ì2Ç—á.
‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2014”N9ŒŽ26`28“úAå‘äjiŽåÃj

    ƒ‰ï’·u‰‰„

  1. ‰ºìG–ŸF–Ú‚ÉŒ©‚Š‚È‚¢‚à‚Ì‚Ì‘åØ‚³
  2. ƒA Year in Cardiology --The EHJ Perspective/The 62nd Annual Japanese College Scientific Session of Cardiology„

  3. Shimokawa H : Conclusion.
  4. ƒ“Á•ÊŠé‰æ6F”x‚ŒŒˆ³f—Â̐i•à„

  5. •Ÿ–{‹`OA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐V–ò‚Ö‚ÌŠú‘Ò.
  6. ƒ“Á•ÊŠé‰æ8F“ú–{‚̗Տ°Œ€‹†‚ÌŒ»ó‚Æ“W–]„

  7. â“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸF“Œ–k–«S•s‘S“o˜^iCHART-2jŒ€‹†‚ÌŒ»ó‚Æ“W–].
  8. ƒ“Á•ÊŠé‰æ9FInternational Symposium on Coronary Vasomotion Abnormalities„

  9. Shimokawa H. Importance of coronary vasomotion abnormalities.
  10. ƒ“Á•ÊŠé‰æ10FzŠÂŠí—̈æ‚É‚š‚¯‚é”ñi’ájNP«Ž¡—Â̐i•à„

  11. ˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹·SÇ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̊J”­.
  12. ŒŒŽ—²•vA‹à’J–@”EA‰ºìG–ŸAˆÉ“¡Œ’‘ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Á@-ÎìŒ§—§’†‰›•a‰@‚É‚š‚¯‚鎡—ÃŒoŒ±-
  13. ƒƒVƒ“ƒ|ƒWƒEƒ€10FdÇS•s‘S‚ÌŽ¡—Â̐i•à„

  14. HŽR³”NAHê”ü‹IA‰Í’Á@‘Aì–{r•ãAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ“c_“ñAÖ–؉ÀŽA‰ºìG–ŸFAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̌»‹µFAž‚ÝŒãÄ“ü‰@‚ð—v‚·‚鎡—Â̌»ó‚Ƒ΍ô.
  15. ƒƒVƒ“ƒ|ƒWƒEƒ€11FAdult Congenital Heart Disease (ACHD)‚̐f—Â̐i•à„

  16. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YAˆÀ’B@—A‰ª“cŽ“TA–Ø‘º³lAHê”ü‹IAÖ–؉ÀŽA‹ß“¡@‹uA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œACHDf—Â̎¡—Ð헪.
  17. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘SŠ³ŽÒ‚ɑ΂·‚é‘œ–Ê“IƒAƒvƒ[ƒ`„

  18. â“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸFÇ—á”wŒi‚ðl—¶‚µ‚œS•s‘S‚ւ̃Aƒvƒ[ƒ`FCHART-2Œ€‹†‚Ì’mŒ©‚©‚ç.
  19. ƒƒVƒ“ƒ|ƒWƒEƒ€13FV‹KŒoŒûR‹ÃŒÅ–ò(NOAC)‚ð‚Ç‚€Žg‚¢‚±‚È‚·‚©„

  20. •Ÿ“c_“ñA¬ì‹v—YAV@”ŽŽŸAˆäã@”ŽA“àŽR^ˆê˜YA–k‰€F¬A’r“cF“¿AŠC–kKˆêAŠ›‘Ő³_AŒˆä–M•FA‰ºìG–ŸF”ñ•Ù–ŒÇ«S–[×“®Š³ŽÒ‚ɑ΂·‚郊ƒo[ƒƒLƒTƒoƒ““o˜^ŠÏŽ@Œ€‹†EXPAND Study“o˜^Ç—á‚Ì”wŒiˆöŽq.
  21. ƒƒVƒ“ƒ|ƒWƒEƒ€17F–«ŽŸŠ³E¶ŠˆKŠµ•a‚ð‡•¹‚µ‚œSŽŸŠ³Š³ŽÒ‚ÌŠÇ—„

  22. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸF‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚š‚¯‚é“œ”A•a‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚錟“¢.
  23. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv4F”x‚ŒŒˆ³‚ðf‚遄

  24. ‘Ÿ“cGŠöA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA‰ºìG–ŸF4D flow MRI (3D phase contrast MRI)‚É‚š‚¯‚é”x“®–¬“àvortex flow‚Æ”x‚ŒŒˆ³Ç‚Æ‚ÌŠÖ˜A.
  25. ™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡@—yA²“¡Œö—YA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐f’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  26. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“1F“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX„

  27. ‰~’J—²Ž¡A’†ŽR‰ë°A‘Ÿ“c—L‰ÀAŒã‰ªL‘Ÿ˜YA’†–ì@œA™‘ºGˆê˜YA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸF“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX`“dŽqƒJƒ‹ƒe“±“üˆÚsŠú‚É‚š‚¯‚é–â‘è“_.
  28. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€„

  29. Œ–{‘׎¡A‹ààV³”́A’|“à‰ëŽjA‰H”öŽ‹MA‰ºìG–ŸF‘å“®–¬•Ùd‰»ÇE‹·óÇ‚ɑ΂·‚é‰^“®—Ö@‚Í—LŒø‚©‹ÖŠõ‚©H
  30. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“EŒû‰‰„

  31. ãâ—T[AŒŒŽ—²•vA‘å–쑏ŒbA•Ð“cŒ\ˆêA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹•ŒŒ«SŽŸŠ³Š³ŽÒ‚̉^“®‘Ï—e”\‚ɑ΂·‚é’áo—͏Ռ‚”gŽ¡—Â̌ø‰Ê.
  32. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[11„

  33. •Ÿ“c_“ñA‰ºìG–ŸF¬nŠú‚ðŒ}‚Š‚œS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ã.
  34. ƒˆê”ʉ‰‘èEŒû‰‰„

  35. “ñ•r‘Ÿ˜YA‚‹Ž@A¬‘é—I“ñAŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ɃXƒeƒ“ƒg—£’f‚ð‚«‚œ‚µŠ¥“®–¬áŽ‚ðŒ`¬‚µ‚œŽá”Nìè•aŒãˆâÇ‚̈ê—á.
  36. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–ŸA‘ã“c_”VA–k•—­ŽjA‰ºìG–ŸF–«S•s‘S‚š‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNÇ—á‚É‚š‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@-‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†-
  37. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c@„A’A–Ø‘sˆê˜YA‹ž—ºˆêA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢ -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
  38. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽR–{¹DAŽO‰Y³’šAÂ–Ø—³’jA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒã–э׊ǐ«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‹z“ü”xŒŒŠÇ”œ‰žŽŽŒ±‚É‚æ‚錟“¢.
  39. Œ‹{Œ’‰îAŒ–{‘׎¡A‰F’Ë—T‹IAi“¡’q•FA’·’J•”—Y”òA“ñ•r‘Ÿ˜YA‰H”öŽ‹MA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFOptical Frequency Domain Imaging (OFDI)‚É‚æ‚銥“®–¬ŠO–ŒVasa Vasorum‚̐¶‘Ì“à‰æ‘œ•]‰¿.
  40. Œ‹{Œ’‰îAŒ–{‘׎¡A‚‹Ž@A‰F’Ë—T‹IA¬‘é—I“ñA“ñ•r‘Ÿ˜YA‰H”öŽ‹MA‰~’J—²Ž¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚Ì•a‘Ô‚É‚š‚¯‚銥“®–¬ŠO–ŒVasa Vasorum‚ÌŠÖ—^-ŒõŠ±Â’f‘w‰æ‘œ(OFDI)‚ð—p‚¢‚œ—Տ°“IŒŸ“¢-
  41. ‰H”öŽ‹MA‚‹Ž@AÂ–Ø—³’jA‹{“c@•qA“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ê‚œS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖŒW‚·‚éˆöŽq‚ÌŒŸ“¢.
  42. ‰~’J—²Ž¡A‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFd“xt‹@”\áŠQ—á‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚̐t‹@”\ˆ«‰»‚ɑ΂·‚é—\–h“IŒŒ‰t“§Í‚ÌŒø‰Ê‚ÉŠÖ‚·‚錟“¢.
  43. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA£ì«lA•œ–쓹ŠîA‰ºìG–ŸF‹·‚¢QRS•‚ð’悵‚Ä‚¢‚œ‚ªCRT‚ª’˜Œø‚µSˆÚA‚ð‰ñ”ð‚Å‚«‚œ‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê—á.
  44. “ñ•r‘Ÿ˜YA‚‹Ž@A¬‘é—I“ñAŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚Ì’·Šú—\Œã—\‘ª‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì—L—p«.
  45. ¬‘é—I“ñA‰~’J—²Ž¡A‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAœA“n—SŽjA‰ºìG–ŸFŠ¥”÷¬ŒŒŠÇ¹k‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  46. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚̉EŽº‹@”\‚É‹y‚Ú‚·Œø‰Ê‚ÉŠÖ‚·‚錟“¢.
  47. ‹ž—ºˆêAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‹{“c@•qAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YAŽR“à@‹BA‰ºìG–ŸF–{–M‚É‚š‚¯‚édÇS•s‘S‚̗Տ°”wŒi‚Æ—\Œã‚ÌŽž‘ã“I•Ï‘JFCHARTŒ€‹†‚©‚ç‚Ì’mŒ©.
  48. ‚ŒK—uŽqAŽMˆä³‹`AŒ³ŽR’åŽqA’Ŗ쌛“ñA‰Í‡GŽ÷AˆÉ“¡@‘nA‰iŒŽNbA‚“c‰À‘ãŽqA‹{é‰èˆßŽqA¬£Š°”VA‰œ‘º‰ë“¿A‘ºŒ@’AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA”öès—YFdÇS‹Ø‹•ŒŒ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂÌCT perfusion‚É‚æ‚錟“¢.
  49. ‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAâ“c‘וFA“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰~’J—²Ž¡AŒ–{‘׎¡AˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚Ì“Á’¥@\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  50. ‚–Ø—S‰îA™@³•¶A–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA–©’J@–LAŒË“c@’ŒAŽR–{‹`lA‰ºìG–ŸFˆÙŽí‚Ì–òÜ—no«ƒXƒeƒ“ƒg‚ð‘g‚ݍ‡‚킹‚œŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚̗Տ°¬Ñ‚ÌŒŸ“¢.
  51. ŒŒŽ—²•vAˆÀ“c•q•FAŽO—ÖŒ’“ñAˆäã@ŸA–ð“c—m•œA–û”ö@‹œAŒˆä’¶A“Œ@Œc”V‰îA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹•ŒŒ«SŽŸŠ³‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̗Տ°Œø‰Ê‚Æ“à”ç×–E‹@”\‚ւ̉e‹¿.
  52. ‰®•~@“µAŒŒŽ—²•vA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸAŽÄ“c—R”üŽqFdÇ‹•ŒŒ«SŽŸŠ³‚ɑ΂·‚é’áo—͏Ռ‚”gŽ¡—ÑOŒã‚É‚š‚¯‚é‚€‚ó‘Ԃ̕ω»‚ɂ‚¢‚Ä.
  53. ƒƒ|ƒXƒ^[”­•\„

  54. –î“c–L—²A‰ºìG–ŸAŒã“¡^ŒÈAŠ’J•¶•FF¶‘Ì“àƒCƒk‹}«Š¥“®–¬•ÂÇŽžA‘€•›ŒŒs˜H‚Ì“à”ç—R—ˆ‰ß•ª‹ÉˆöŽqA‰ßŽ_‰»…‘f‚É‚æ‚錌ŠÇŠg’£‚́A“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  55. –©’J@–LA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’ŒAŽR–{‹`lA™@³•¶A‰ºìG–ŸFDrug Eluting Balloon Šg’£’ŒŒã‚Ì‹»–¡[‚¢OFDI‰æ‘œ.
  56. ]Œû‹v”üŽqAŽR–{‹`lA–ì–ؐ³“¹A›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’ŒA™@³•¶A‰ºìG–ŸF‰EŠ¥“®–¬CTO•a•Ï‚ɑ΂µ‚ÄCART–@‚É‚æ‚é‹Uo‚ւ̃Xƒeƒ“ƒg—¯’uŒãA–«Šú‚ɃXƒeƒ“ƒgŠO^oÄŠJ’Ê‚ð”F‚ß‚œ‚ƍl‚Š‚ç‚ê‚é1—á.
  57. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA•œ–쓹ŠîA‰ºìG–ŸFType 2 BrugadaS“d}Š³ŽÒ‚̃ŠƒXƒN‘w•Ê‰»‚É‚š‚¯‚éLate potentials‚Ì—L—p«.
  58. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA‰ºìG–ŸFS‘ŸˆÚA“o˜^\¿“K‰žŠO‚Æ”»’f‚µ‚œ•s‰Â‹t“IŠÌüˆÛÇ‚ð‡•¹‚µ‚œƒtƒ@ƒ[Žl’¥ÇS“àC•œpŒã‚Ì1—á.
  59. ŽO‰Y—²‰îA—é–؏G–ŸAŒ–{‘׎¡A”öè@‘ׁA‰H”öŽ‹MA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸFƒvƒ‰ƒ“ƒ}[•a‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  60. ŽR–{‹`lA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’ŒA™@³•¶A‰ºìG–ŸFCoronary CTO•a•Ï‚ÌPCI‚É‚š‚¯‚éRendez-vous–@‚̍lŽ@
  61. –©’J@–LA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’ŒA™@³•¶A‰ºìG–ŸFCART–@‚É‚ÄRCA-CTO‚ÌPCI‚ðs‚¢Septal Rupture‚𗈂µ‚œ1—á‚Æ‚»‚Ì’·ŠúŒo‰ß.
  62. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFdÇS•s‘S‚ð’悵‚œ•p”—U”­«S‹ØÇ‚Ì2—á.
  63. Â–Ø—³’jA™‘ºGˆê˜YA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é–ò•š—Ö@‚ÌŒø‰Ê.
  64. •œ–쓹ŠîA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA‰ºìG–ŸFS–[‘e×“®‚Ö‚Ì–[ŽºŒ‹ßECTIƒAƒuƒŒ[ƒVƒ‡ƒ“‚ªS•s‘SƒRƒ“ƒgƒ[ƒ‹‚É‘tŒ÷‚µ‚œCRT-DA‚Šž‚ÝŒã‚ÌŠg’£Œ^S‹ØÇ‚̈ê—á.
  65. •Ÿˆä—æ–µA—é–؏G–ŸA‹{ì”T—ŽqA‰““¡’q”VA‹à“c•ü—mA™‘ºGˆê˜YAŒ–{‘׎¡A‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸFL”͈͔MŠ³ŽÒ‚É”­Ç‚µ‚œŠg’£Œ^S‹ØÇ‚̈ê—á.
  66. ŽO‰Y’ŒWA—é–؏G–ŸA‘OàVãđŸA¬扑’m–ŸA•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸF‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µAƒy[ƒXƒ[ƒJ[—¯’u‚ðs‚í‚È‚©‚Á‚œèò‘¹‚É‚æ‚éS’âŽ~‚̈ê—á.
  67. ²“¡@ꡁAÂ–Ø—³’jA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸF–«S‹Ø‰Š‚ɖƉu—}§—Ö@‚ª’˜Œø‚µ‚œˆê—á.
‘æ203‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N9ŒŽ6“úAH“cj
  1. ’†‘º‹M•jCŒš•”r‰îC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽR–{¹DC–î”ö”M—TC²“¡@—yC²“¡Œö—YC‰ºìG–ŸFOFDI (ŒõŽü”g”—̈æ‰æ‘œ) ‚É‚æ‚èŠÏŽ@‚µ‚Š‚œŒŒŠÇ‰Š‚É”º‚€”x“®–¬‹·ó‚Ì1—á
‘æ29‰ñ“ú–{•s®–¬Šw‰ïE‘æ31‰ñ“ú–{S“dŠw‰ï‡“¯Šwp‘å‰ïi2014”N7ŒŽ22“ú`25“úA“Œ‹žj

    ƒSpecial symposium: Digital recording of ECG data„

  1. Nakayama M, Shimokawa H. Practical issues in the development of cardiovascular disease databases for cardiovascular disease.
  2. ƒRegular papers„

  3. Kondo M, Fukuda K, Nakano M, Hasebe Y, Satake H, Hirano M, Shimokawa H. The significance of the QRS duration for arrhythmic events in postoperative Tetralogy of Fallot.
  4. Nakano M, Fukuda K, Kondo M, Hasebe, Y, Satake H, Hirano M, Shimokawa H. Late potentials could be markers for high-risk patients with type 2 Brugada electrocardiogram.
‘æ20‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2014”N7ŒŽ19“ú`20“úA‹ž“sj

    ƒƒVƒ“ƒ|ƒWƒEƒ€7FƒnƒCƒuƒŠƒbƒhS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FƒfƒoƒCƒX‘S·Žž‘ã‚Å‚Ì‚ ‚è•û„

  1. ˆÉ“¡Œ’‘ŸAŒ–{‘׎¡A‚‹Ž@A‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂƐS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2FV‚œ‚ȗ̈æ‚ւ̐S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FÌ‚̏펯‚͍¡‚Ì”ñíŽ¯„

  3. Œ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‘å“®–¬•Ùd‰»ÇE‹·óÇ‚ɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚Æ‹ÖŠõ.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—vó‘Ô‚Í—\Œã•s—Ç‚ÆŠÖ˜A‚·‚é@--CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  6. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–ŸA‘ã“c_”VA–k•—­ŽjA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚ég‘ÌŠˆ“®—ʂ̈Ӌ`‚ÌŒŸ“¢.
  7. ’|“à‰ëŽjAŒ–{‘׎¡A’‡•y‚¿‚ÁA²“¡–[˜YAX@M–FAˆä“c‰ëËAŒ”ö—@ŽuAˆÉ“¡Z‹PA‘’ÍKOA‰Í’Á@‘AÖ“¡•ŽuAˆÀ’B@—AHŽR³”NAŒF’J‹Iˆê˜YA–{‹g’ŒFAì–{r•ãAˆÉ“¡@CAãŒŽ³”ŽAÖ–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽ‚𒆐S‚Æ‚µ‚œ‘匌ŠÇŽŸŠ³‚̏p‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚èICUÝŽºEpŒãÝ‰@“ú”‚ð’Zk‚·‚é.
  8. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  9. ’|“à‰ëŽjAŒ–{‘׎¡A–x“cˆêŽ÷AŠ`‰Ô—²ºA–îŒût…AX@M–FAˆä“c‰ëËAˆÉ“¡Z‹PA‰Í’Á@‘AHŽR³”NAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘ŸAì–{r•ãAˆÉ“¡@CAãŒŽ³”ŽAÖ–؉ÀŽA‰ºìG–ŸF“ñŠú“I‘匌ŠÇ’uŠ·pŒã‚̑ޏk‚ÉŽŠ‚Á‚œÇ—á@\p‘OŒã‚̌ċzƒŠƒn‚𒆐S‚Æ‚µ‚œ—Šw—Ö@‰î“ü\
‘æ202‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ21“úAå‘äj
  1. ŽO‰Y—²‰îA—é–؏G–ŸAŒ–{‘׎¡A”öè@‘ׁA‰H”öŽ‹MA‚‹Ž@AˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–ŸFƒvƒ‰ƒ“ƒ}[•a‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  2. ŽO‰Y’ŒWA—é–؏G–ŸA‘OàVãđŸA¬‰º’m–ŸA•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–ŸFS’âŽ~E‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µ‚œèò‘¹‚Ì1—á.
  3. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰Á“¡@‹A²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éOCT‚ð—p‚¢‚œŒo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ158‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ7“úA·‰ªj

    ƒÇ—á”­•\•”–åYIAF—DGÜŽóÜ„

  1. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFSŽº’†Šu‹NŒ¹SŽº•p”‚ÌŽ¡—Âɓïa‚µ‚œƒ‰ƒ~ƒ“A/C ˆâ“`ŽqŠÖ˜A‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê–UŒŸ—á.
  2. ƒŒ€‹†”­•\•”–åYIAF—DGÜŽóÜ„

  3. ŽR“à@‹BAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·•nŒŒ‚̉e‹¿‚ƍ¶Žº‹ìo—Š‚ÌŠÖ˜A\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘聄

  5. HŽR³”NA‰Í’Á@‘A‘’ÍKOAì–{r•ãAâV–؉ÀŽAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ“c_“ñA‰ºìG–ŸF“–‰@‚É‚š‚¯‚éAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̐¬Ñ.
  6. •Ð•œW‘Ÿ˜YAHŽR³”NA‰Í’Á@‘AŒF’J‹Iˆê˜YAì–{r•ãAÖ–؉ÀŽA™‘ºGˆê˜YA‰ºìG–ŸF‹}‘¬‚ÈLVAD ‘•’…‚Å‹~–œ‚µ‚œS‹ØÇ‹}«‘ˆ«‚Ì1—á
  7. “ñ•r‘Ÿ˜YA‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA¬‘é—I“ñAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥“®–¬ƒXƒeƒ“ƒg”j‘¹‚ªŠ¥“®–¬áŽŒ`¬‚ÉŠÖ—^‚µ‚œŽá”Nìè•aŒãˆâÇ‚̈ê—á.
  8. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ÌŠÓ•Ê‚ª—L—p‚Å‚ ‚Á‚œŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚É‚æ‚銮‘SŒŒsÄŒšŒã‚Ì1—á.
  9. ŽR“à—I•œAš¢’J—²Ž¡A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF–òÜ•‰‰×S‹ØŒŒ—¬ƒVƒ“ƒ`‚É‚Ä—z«ŠŒ©‚ð’悵‚œŠ¥¹k«‹·SÇ‚̈ê—á.
  10. •œ–쓹ŠîA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA‰ºìG–ŸFS–[‘e×“®‚ɑ΂·‚éCTIƒuƒƒbƒNƒ‰ƒCƒ“ì¬‚š‚æ‚Ñ–[ŽºŒ‹ßƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œCRT-DˆÚAŒã‚ÌDCM‚̈ê—á.
  11. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸF“àèòÃ–¬ƒAƒvƒ[ƒ`‚ª—LŒø‚Å‚ ‚Á‚œŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚̈ê—á.
  12. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFLate potential‚Ítype2ƒuƒ‹ƒKƒ_S“d}Š³ŽÒ‚̃ŠƒXƒN‘w•Ê‰»‚É—L—p‚ȉ”\«‚ª‚ ‚é.
  13. –î”ö”M—TAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”@r‰îAŽR–{¹DA‰ºìG–ŸA“¡ˆä”ŽŽiAÎˆä’q“¿F¬‡«Œ‹‡‘gD•a‚É”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œˆê—á.
  14. Â–Ø—³’jA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–Ÿ:––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ14‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2014”N5ŒŽ16`17“úA²‰êj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FNOƒVƒOƒiƒŠƒ“ƒO‚ÌŽž‹óŠÔÝŒv‚É‚æ‚éSzŠÂƒ_ƒCƒiƒ~ƒYƒ€‚Ì“‡“I—‰ð„

  1. “›ˆä³lA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LFzŠÂŠíE‘ãŽÓ«ŽŸŠ³‚É‚š‚¯‚é“àˆö«‚š‚æ‚ÑŠOˆö«NOŽY¶Œn‚Ì–ðŠ„.
  2. ƒYIAƒZƒbƒVƒ‡ƒ“FÅ—DGÜŽóÜ„

  3. _ŒË–ΗYAÖ“¡‘åŽ÷A’r“c®•œAàV“cˆŒŽqABudbazar EnkhjargalA‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO‚ÆEDHF‚̃oƒ‰ƒ“ƒX‚͐SŒŒŠÇŒn‚̍Pí«ˆÛŽ‚ɏd—v‚Å‚ ‚é.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’n‡—TA™‘ºGˆê˜YA’†‘ºˆê•¶AˆÉ“¡@_A–双Œ’Ž¡A‰ºìG–ŸFBasigin promotes vascular smooth muscle proliferation and pulmonary hypertension.
  6. “à“c‘Ÿ˜YAŒÃ–ì—R”üA’J–{º‰pA‰ºìG–ŸA‘剮—S•ãA–öŒŽ‰„ÍA”ö’ҁ@–LF‘n–ò‚ÉŽ‘‚·‚鎩‘R”­Ç‹}«S‹Ø[Çƒ‚ƒfƒ‹‚ÌŠJ”­F2/3t“Etriple NOSs-/-ƒ}ƒEƒX.
  7. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  8. –î“c–L—²A‰ºìG–ŸA•œŒ@CAŒã“¡^ŒÈA¬Š}ŒŽN•vAŠ’J•¶•FFƒCƒk¶‘Ì“à‹}«Š¥“®–¬•ÂÇŽžA‰ßŽ_‰»…‘f‚É‚æ‚銥”÷¬‘€•›ŒŒs˜HŠg’£‚́A“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  9. Ö“¡‘åŽ÷A_ŒË–ΗYAàV“cˆŒŽqABudbazar EnkhjargalA‰ºìG–ŸF”÷¬ŒŒŠÇ‚É‚š‚¢‚Ä“à”çˆË‘¶«‰ß•ª‹ÉiEDHj”œ‰ž‚ª˜Ži‚µ‚Ä‚¢‚镪Žq‹@˜‚ÌŒŸ“¢.
‘æ51‰ñ“ú–{—Տ°•ªŽqˆãŠw‰ïŠwpW‰ïi2014”N4ŒŽ11“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ä‚ª‘‚É‚š‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‚ÌŒ»ó‚Æ‚±‚ê‚©‚ç‚̉ۑ聄

  1. ‰ºìG–ŸF“Œ–k‘åŠw‚É‚š‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
‘æ78‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2014”N3ŒŽ21“ú`23“úA“Œ‹žj

    ƒPlenary Session„

  1. (PL01:Coronary Revascularization Based on Evidence Based Medicine-ComparingPCI and CABG-Reality and Ideal) Takahashi J, Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Prognostic impacts of revascularization strategy and residual coronary stenosis in patients with ischemic heart failure. Circ J. 78(Suppl. I):I-56,2014.
  2. (PL05:Current Status and Management of Cardiac Failure, Arrhythmias, Pulmonary Hypertension and Sudden Death in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Adult patients with congenital heart disease as an emerging population in cardiovascular medicine. Circ J. 78(Suppl. I):I-75,2014.
  3. ƒSymposium„

  4. (SY01:Coronary Circulation Revisited: Pathogenesis of Myocardial Ischemia and Its Evaluation) Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Shindo T, Hanawa K, Hasebe Y, Nihei T, Hao K, Tsuburaya R, Shiroto T, Ito K, Ishibashi-ueda H, Yasuda S, Shimokawa H. Important role of the adventitia in the pathogenesis of coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J. 78(Suppl. I):I-100,2014.
  5. (SY07:EBM in Hypertension) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Clinical significance of low diastolic blood pressure in development of de-novo heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-137,2014.
  6. (SY09:Frontiers of Coronary Imaging Modalities) Matsumoto Y, Nishimiya K, Tanaka A, Taruya A, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Yasuda S, Shimokawa H. Usefulness of micro-CT and optical coherence tomography for vasa vasorum imaging in porcine coronary arteries with stent implantation. Circ J. 78(Suppl. I):I-148,2014.
  7. (SY11:Clinical Network and Disease Registry for Cardiovascular Disease) Sakata Y, Nochioka K, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. Experience and perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J. 78(Suppl. I):I-161,2014.
  8. (SY15:Treatment Strategy of CKD: Collaboration by Cardiologists and Nephrologists) Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of subclinical albuminuria in chronic heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-184,2014.
  9. (SY17:New Treatment Methods Expected for Pulmonary Hypertension) Sugimura K, Tatebe S, Fukumoto Y, Nochioka K, Yamamoto S, Miura M, Kimio Satoh, Shimokawa H. Reactive post-capillary pulmonary hypertension as a new therapeutic target for left heart disease. Circ J. 78(Suppl. I):I-193,2014.
  10. ƒYoung Investigator's Award for International Students Finalists Lectures„

  11. Nergui S, Fukumoto Y, Do.e Z, Nakajima S, Shimizu T, Ikeda S, Elias-Al-Mamun M, Shimokawa H. Molecular and cellular mechanisms of right ventricular remodeling in pulmonary hypertension. Circ J. 78(Suppl. I):I-516,2014.
  12. ƒFeatured Research Session„

  13. Nihei T, Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Yoshitaka Itoh, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in circulating leukocytes in patients with vasospastic angina. Circ J. 78(Suppl. I):I-597,2014.
  14. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Takada T, Tadaki S, Yamauchi T, Shimokawa H. Improved long-term prognosis of patients with dilated cardiomyopathy\A report from the CHART Studies\ Circ J. 78(Suppl. I): I-549,2014.
  15. ƒOral Presentation (English)„

  16. Nakayama M, Takehana K, Shimokawa H. Data transition platforms in hospital information system should be established to construct database with information communication technology. Circ J. 78(Suppl. I):I-856,2014.
  17. Satoh K, Fukumoto Y, Sugimura K, Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Minami T, Miyata S, Suzuki K, Omura J, Kikuchi N, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Basigin promotes inflammation and pulmonary hypertension through synergistic cooperation with extracellular Cyclophilin A. Circ J. 78(Suppl. I):I-1066,2014.
  18. Suzuki K, Satoh K, Ikeda S, Kadomatsu K, Shimokawa H. Basigin promotes cardiac fibrosis and failure in pressure-overload-induced cardiac hypertrophy in mice. Circ J. 78(Suppl. I):I-1020,2014.
  19. ƒOral Presentation (Japanese)„

  20. Godo S, Saito H, Ikeda S, Sawada A, Shiroto T, Enkhjargal B, Shimokawa H. Importance of the physiological balance between nitric oxide and endotheliumderived hyperpolarizing factor in vascular homeostasis in mice. Circ J. 78(Suppl. I):I-1149,2014.
  21. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. U-Shaped relationship between left atrial diameter and prognosis of patients with heart failure with preserved ejection fraction \The CHART-2 Study\ Circ J. 78(Suppl. I):I-1266,2014.
  22. ƒPoster Session (English)„

  23. Al-mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil exerts synergistic effects through inhibition of Rho-kinase in pulmonary hypertension. Circ J. 78(Suppl. I):I-1831,2014.
  24. Hao K, Takahashi J, Ito K, Miyata S, Sakata Y, Nihei T, Tsuburaya R, Shirato T, Matsumoto Y, Nakayama M, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not undergo primary percutaneous coronary intervention \A Report from MIYAGI-AMI Registry\ Circ J. 78(Suppl. I):I-2038,2014.
  25. Nakano M, Fukuda K. Wakayama Y, Kondoh M, Hasebe Y, Satake H, Shimokawa H. Clinical characteristics of J wave in patients with Brugada syndrome. Circ J. 78(Suppl. I):I-1413,2014.
  26. Tsuburaya R, Takahashi J, Hao K, Shirato T, Matsumoto Y, Ito K, Nakayama M, Shimokawa H. Beneficial effects of a single prophylactic hemodialysis on renal function worsening after percutaneous coronary intervention in patients with severe CKD. Circ J. 78(Suppl. I):I-1796,2014.
  27. ƒPoster Session (Japanese)„

  28. Abe Y, Ito K, Hao K, Hanawa K, Shindo T, Nishimiya K, Hasebe Y, Yamamoto H, Satoh K, Kawakami K, Shimokawa H. Extracorporeal low-energy shock wave therapy improves left ventricular remodeling and reduces inflammatory responses after acute myocardial infarction in rats. Circ J. 78(Suppl. I):I-2399,2014.
  29. Hanawa K, Ito K, Aizawa K, Shindo T, Nishimiya K, Hasebe Y, Tsuburaya R, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. Circ J. 78(Suppl. I):I-2578,2014.
  30. Hasebe Y, Yamamoto H, Fukuda K, Nishimiya K, Hanawa K, Shindo T, Hirano M, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system \A feasiblity study in pigs in vivo\ Circ J. 78(Suppl. I):I-2718,2014.
  31. Ikeda S, Satoh K, Fukumoto Y, Suzuki K, Shimizu T, Shimokawa H. Crucial role of Rho-kinase in pressure-overload myocardial hypertrophy in mice \Comparison between the left and right ventricles\ Circ J. 78(Suppl. I):I-2612,2014.
  32. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Satake H, Shimokawa H. Different characteristics of postoperative atrial tachyarrhythmias between congenital and non-congenital heart disease. Circ J. 78(Suppl. I):I-2871,2014.
  33. Miura M, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Hiramoto T, Inoue K, Tamaki K, Shimokawa H. Prognostic impact of acid-base balance on admission in acute heart failure syndrome\A report from the Tohoku Acute Failure Registry\ Circ J. 78(Suppl. I):I-2463,2014.
  34. Satake H, Fukuda K, Wakayama Y, Nakano M, Kondoh M, Hasebe Y, Hirano M, Shimokawa H. Papillary muscles as an important site of origin of lethal ventricular tachyarrhythmias \Usefulness of the new intra-cardiac echo system\ Circ J. 78(Suppl. I):I-2744,2014.
  35. Shiroto T, Takahashi J, Takagi Y, Tsuburaya R, Matsumoto Y, Nakayama M, Ito K, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Yasuda S, Shimokawa H. Prognostic importance of dual-induction tests for coronary artery spasm and ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J. 78(Suppl. Ij :I-2284,2014.
  36. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Furukawa K, Fukumoto Y, Arai H, Takahashi S, Taki Y, Shimokawa H. Decreased activity of the hippocampus is associated with depression in heart failure patients \Brain Investigation in Heart Failure Trial (B-HeFT)\ Circ J. 7(8 Suppl. I):I-2867,2014.
  37. Tadaki S, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Takada T, Ushigome R, Yamauchi T, Shimokawa H. Accumulation of metabolic disorders is a cardiovascular risk in patients with central obesity \The CHART-2 Study\ Circ J. 78(Suppl. I):I-2346,2014.
  38. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Satoh K, Shimokawa H. Percutaneous transluminal pulmonary angioplasty ameliorates metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2825,2014.
  39. Yaoita N, Fukumoto Y, Horiuchi H, Shimokawa H. Involvement of thrombinactivated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2478,2014.
•œ¬25”N“x•¶•”‰ÈŠwÈ‹Ž“n‚µŒ€‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€i2014”N2ŒŽ28“úA“Œ‹žj
  1. ‰ºìG–ŸFˆãH˜AŒg‚ðŠî”Õ‚Æ‚µ‚œƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‹’“_Œ`¬
‘æ4‰ñ‹Ž“n‚µŒ€‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€‰^‰cˆÏˆõ‰ïi2014”N2ŒŽ27“úA“Œ‹žj
  1. ‰ºìG–ŸF“Œ–k”­‚̈ã—Ë@ŠíŠJ”­‹’“_
‘æ201‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAå‘äj
  1. —L’|G”üC‰Á‰ê’J–LC—é–؏G–Ÿ, ‰~’J—²Ž¡, Œ–{‘׎¡, ‚‹Ž@, ˆÉ“¡Œ’‘Ÿ, ‰ºìG–Ÿ, H“¡‘å‰î, ‹vŽu–{¬Ž÷FlHS”xŠÇ—‚ð—v‚µ‚œ’á‘̉·—Ö@‚É‚æ‚éS‹@”\’ቺ‚Ì1—á
  2. ŽO‰Y’ŒW,ŽO‰Y³’š, ™‘ºGˆê˜Y, Œã‰ªL‘Ÿ˜Y, Œš•”r‰î, ŽR–{¹D, ‰ºìG–ŸF•â•zŠÂ‚ð—v‚µ‚œdÇS•s‘S‚ɃwƒpƒŠƒ“—U”­«ŒŒ¬”ÂŒž­Ç‚ð‡•¹‚µ‚œ2Ç—á‚ÌŒŸ“¢
  3. •Ÿˆä—æ–µC‰Á‰ê’J–LC—é–؏G–Ÿ, ™‘ºGˆê˜Y, ‰ºìG–Ÿ, ‹{ì”T—Žq, ‹vŽu–{¬Ž÷FL”͈͔MŠ³ŽÒ‚É”­Ç‚µ‚œŠg’£Œ^S‹ØÇ‚Ì1—á
‘æ35‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAŒSŽRj
  1. ‚‹Ž@C‰H”öŽ‹MCˆÉ“¡Œ’‘ŸC‹{“c@•qCâ“c‘וFC“ñ•r‘Ÿ˜YC‰~’J—²Ž¡CŒ–{‘׎¡CˆÀ“c@‘C‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚ɉü‘P‚ð”F‚ß‚œ‹}«S‹Ø[ÇŠ³ŽÒ‚ɑ΂·‚é‹~‹}ˆã—Ñ̐§‚ɂ‚¢‚Ä‚ÌŒŸ“¢@\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚ÌŒŸ“¢\
‘æ43‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2014”N2ŒŽ15`16“úA_ŒËj

    ƒƒVƒ“ƒ|ƒWƒEƒ€F“®–¬d‰»‚̍ŐV’mŒ©„

  1. ²“¡Œö—YC‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é“®–¬d‰»‚Ì”­Ç‹@\‚ƐV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«
  2. ƒˆê”ʉ‰‘聄

  3. ’r“c®•œC²“¡Œö—YC•Ÿ–{‹`OCŽ…@‹œC‹{“c@•qC—é–؍N‘ŸC‹e’n‡—TC‘呺~ˆêC‰ºìG–ŸF¶Žº‚ƉEŽº‚̈³•‰‰×‚ɑ΂·‚é—U“±ˆâ“`Žq‚ÌŽž‹óŠÔ“I·ˆÙ‚ƐS”ì‘åES•s‘S‚Ì”­Ç‹@\
  4. —é–؍N‘ŸC²“¡Œö—YC’r“c®•œC–双Œ’Ž¡C‰ºìG–ŸFƒ}ƒEƒXˆ³•‰‰×ƒ‚ƒfƒ‹‚É‚š‚¢‚ÄBasigin‚͐S‘Ÿ‚̐üˆÛ‰»CS•s‘S‚Ì‘ˆ«‚ÉŠñ—^‚·‚é
‘æ14‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€ in Sendaii2014”N2ŒŽ2“úAå‘äj
  1. ‰ºìG–ŸF“Œ“ú–{‘åkÐ‚ƐSŒŒŠÇƒCƒxƒ“ƒg
‘æ7‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2014”N1ŒŽ31“ú`2ŒŽ1“úA“Œ‹žj

    ƒ‹³ˆçu‰‰„

  1. ‰ºìG–ŸFzŠÂŠíŽŸŠ³‚Ɛ«·
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  3. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹Ž@A‰ºìG–ŸF–{–M‚ÌStage C/DS•s‘S‚Ì”wŒiAŽ¡—ÁA’·Šú—\Œã‚É‚š‚¯‚鐫·.
  4. ƒˆê”ʉ‰‘è/ƒ|ƒXƒ^[”­•\„

  5. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚Ɛ«·‚ÌŒŸ“¢.
  6. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸF’ʏíŒ^S–[‘e“®‚̗Տ°“I“Á’¥‚É‚š‚¯‚鐫·‚ÉŠÖ‚·‚錟“¢.
  7. ‰H”öŽ‹MA‚‹Ž@AÂ–Ø—³’jA‹{“c@•qA‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ê‚œS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖ‚·‚鐫·‚ÌŒŸ“¢.
  8. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF¶SŽŸŠ³‚É”º‚€Œã–э׊ǐ«”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌s“®‘Ô“I’j—·‚ÌŒŸ“¢.
‘æ24‰ñ“ú–{‰uŠw‰ïŠwpW‰ïi2014”N1ŒŽ23`25“úAå‘äj
  1. ‹ž—ºˆêCâ“c‘וFCŒã‰ªL‘Ÿ˜YC‹{“c@•qCŽO‰Y³’šC‚“c„ŽjC’A–Ø‘sˆê˜YCŽR“à@‹BC‰ºìG–ŸFŠg’£Œ^S‹ØÇ‚Ì“Á’¥‚Æ‚»‚Ì—\Œã‚ÌŽž‘ã“I•Ï‘JFCHART-1Œ€‹†‚ÆCHART-2Œ€‹†‚Ì”äŠr
  2. ‚“c„ŽjCâ“c‘וFC‹{“c@•qC‚‹Ž@CŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC’A–Ø‘sˆê˜YC‹ž—ºˆêCŽR“à@‹BC‰ºìG–ŸFS•s‘S”­ÇƒnƒCƒŠƒXƒNŠ³ŽÒ‚É‚š‚¯‚éV‹KS•s‘S”­Ç‹K’èˆöŽq@\CHART-2Œ€‹†\

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2013”N
‘æ157‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N12ŒŽ7“úAå‘äj

ƒYIAÇ—á”­•\•”–偄

  1. ‘呺~ˆêA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF–«Šˆ“®«Epstein-BarrƒEƒCƒ‹ƒXŠŽõÇ‚ɍ‡•¹‚µ‚œ”x‚ŒŒˆ³Ç‚Éä`‘ÑŒŒŠ²×–EˆÚA‚ª’˜Œø‚µ‚œˆê—á.iÅ—DGÜŽóÜj
  2. ƒYIAŒ€‹†”­•\•”–偄

  3. Œã‰ªL‘Ÿ˜YAâ“c‘וFAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‹{“c@•qA‰ºìG–ŸFŠg’£Œ^S‹ØÇŽ¡—ЬÑ‚ÌŽž‘ã“I•Ï‘J‚ÌŒŸ“¢FCHARTŒ€‹†‚Ì’mŒ©‚æ‚è.iÅ—DGÜŽóÜj
  4. ƒˆê”ʉ‰‘聄

  5. —L’|G”üA‰Á‰ê’J@–LA—é–؏G–ŸAš¢’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA‘呺@‘ñAH“¡‘å‰îA“ü–ì“c@’A‹vŽu–{¬Ž÷F’á‘̉·—Ö@’†‚ɐS‹@”\’ቺ‚ð‚«‚œ‚µAŒo”ç“IlHS”x‚É‚æ‚éŠÇ—‚ð—v‚µ‚œˆê—á.
  6. ”öŒ`@„A”’ŒË@’Aš¢’J—²Ž¡AŒ–{‘׎¡Aâ“c‘וFAˆÉ“¡Œ’‘ŸA¬‘é@—I“ñA‚‹Ž@A‰ºìG–ŸF”­Ç‹}«Šú‚É‘œŽ}Š¥“®–¬¹k‚ª—U”­‚³‚ê‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚̈ê—á.
  7. •Ð•œW‘Ÿ˜YAHŽR³”NA×ŽRŸŠ°A‰Í’Á@‘AŒF’J‹Iˆê˜YA–{‹g’ŒFAì–{r•ãAâV–؉ÀŽAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸF’°ŠÇ‹•ŒŒ‚𕹔­‚µ‚œŒ€ÇŒ^S‹Ø‰Š2Ç—á.
  8. ¬‘é—I“ñA‚‹Ž@AˆÉ“¡Œ’‘ŸAŒ–{‘׎¡A”’ŒË@’Aš¢’J—²Ž¡A‰H”öŽ‹MA‰ºìG–ŸFŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“’†‚ɐ¶‚¶‚œSlow flow‚ÉRhoƒLƒi[ƒ[‘jŠQ–ò‰–Ž_ƒtƒ@ƒXƒWƒ‹Š¥’‚ª—LŒø‚Å‚ ‚Á‚œˆê—á.
  9. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFS–[•p”‚ð‡•¹‚µ‚“x–[ŽºƒuƒƒbƒN‚ð‚«‚œ‚µ‚œƒtƒ@ƒ[Žl’¥ÇpŒã‚̈ê—á.
  10. âV“¡ˆ»ŽqAš¢’J—²Ž¡A‚‹Ž@AˆÉ“¡ˆ€„A‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚œ¶Š¥“®–¬ŽåŠ²•”‚Ì‹·ó•a•Ï‚É‚æ‚è‹}«S‹Ø[Ç‚𔭏ǂµ‚œŽá”N—«‚Ì1—á.
  11. ²’|—m”VA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA•œ–쓹ŠîA‰ºìG–ŸF‘å“®–¬–³Š¥ë‚©‚çKent ‘©‚Ì—£’f‚ɐ¬Œ÷‚µ‚œ–[Žº‰ñ‹A«•p”‚̈ê—á.
  12. ²“¡‘åŽ÷C“¡“c@‰›CŽRŒû“WŠ°C”öã‹IŽqCÎ’ˁ@‹CŽÂè@‹BF–«S•s‘SŠ³ŽÒ‚̐¶ŠUÄ“ü‰@‰ðÍ.
  13. ’|“à@’qA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFSŽº•p”‚ðŒ_‹@‚ɐf’f‚ÖŽŠ‚Á‚œSƒtƒ@ƒuƒŠ[•a‚̈ê—á.
  14. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹A‰ºìG–ŸF‰EŽº—¬o˜HS“à–Œ‘€‚ُ̈í’x‰„“dˆÊ‚ɑ΂·‚éRFCA‚ªVF”­ì—}§‚É—LŒø‚Å‚ ‚Á‚œBrugadaÇŒóŒQ‚̈ê—á.
  15. ’·’J•”—Y”òA•œ–쓹ŠîA²’|—m”VA‹ß“¡³‹PA’†–ì@œA•Ÿ“c_“ñA‰ºìG–ŸFŒã’†ŠuKent‘©‚ɑ΂µ‚ÄŠ¥óÃ–¬“Ž“à‚Å‚Ì’Ê“d‚É‚æ‚莡—Âɐ¬Œ÷‚µ‚œƒnƒCƒŠƒXƒN‹U«SŽº•p”‚Ì2—á.
  16. –x“cˆêŽ÷A’|“à‰ëŽjAˆÉ“¡‘å—ºAŠ`‰Ô—²ºA²“¡–[˜YA‚‹ŽŽìAX@M–FAˆÉ“¡@CAãŒŽ³”ŽA™‘ºGˆê˜YA‰ºìG–ŸFŠÔŸ[“IƒgƒŒ[ƒjƒ“ƒO‚É‚æ‚è‰^“®‘Ï—e”\‚̉ü‘P‚ª“Ÿ‚ç‚ê‚œ–«S•s‘Sˆê—á.
  17. ŽO‰Y’ŒWAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸAHŽR³”NAâV–؉ÀŽF–„‚ߍž‚ÝŒ^•â•lHS‘Ÿ‚É‚Ä‹~–œ‚µ‚Š‚œ‘ŸŠí•s‘S‚𗈂µ‚œdÇS•s‘S‚̈ê—á.
  18. ŽR“à@‹BAš¢’J—²Ž¡A‚‹Ž@A‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFìè•aŒãˆâÇ‚É‚æ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚œŽá”NŽÒ‚Ì2—á.
  19. ŽR“à—I•œA‰Á‰ê’J@–LA—é–؏G–ŸA™‘ºGˆê˜YA‰ºìG–ŸA‘OàVãđŸA‹{ì”T—ŽqAŒÃì@@A²“¡•—gA‹vŽu–{¬Ž÷A²’|—¥ŽqA‘Šêß–çF‘œŒ`Ÿøo«g”Á‚ð‡•¹‚µ‚œS‹Ø‰Š‚̈ê—á.
  20. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‰ºìG–ŸF¬l‚Ì––œ«”x“®–¬‹·óÇ‚Ì1—á.
‘æ36‰ñ“ú–{•ªŽq¶•šŠw‰ïi2013”N12ŒŽ3`6“úA_ŒËj

ƒƒ[ƒNƒVƒ‡ƒbƒv„

  1. ’†ŽR‰ë°C‹{“c •qC‰ºìG–ŸF—Տ°ˆã‚É‚Æ‚Á‚Ä•K—v‚ȃoƒCƒIƒCƒ“ƒtƒHƒ}ƒeƒBƒVƒƒƒ“E“Œvê–å‰Æ
“ú–{“à‰ÈŠw‰ïŠwpW‰ï‘æ41‰ñ“à‰ÈŠw‚Ì“W–]i2013”N12ŒŽ1“úAå‘äj

ƒ“Œ“ú–{‘åkÐ‚©‚çŠw‚Ô“à‰ÈŽŸŠ³@`“Á’¥A‘ΉžA—\–h`„

  1. ‰ºìG–ŸFzŠÂŠíŽŸŠ³.
‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2013”N11ŒŽ28“ú`30“úA‘å‹{j

ƒESC-HFA/JHFSƒWƒ‡ƒCƒ“ƒgƒZƒbƒVƒ‡ƒ“„

  1. Shimokawa H. Changing heart failure management in Japan --Report from CHART Studies-
  2. ƒ“Á•ÊŠé‰æFÐŠQ‚ƐS•s‘S„

  3. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Longitudinal study of post-traumatic stress disorder after the Great East Japan Earthquake Disaster in cardiovascular disease patients -The CHART Study-
  4. ƒYIAF—Տ°Œ€‹†•”–偄

  5. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Shimokawa H. Prognsotic impact of statin in Japanese patients with heart failure with preserved ejection frcation --A report from the CHART-2 Study-i—DGÜŽóÜj
  6. Suzuki H, Matsumoto Y, Takahashi J, Tsuburaya R, Sugimura K, Ito K, Fukumoto Y, Shimokawa H. Interactions between the heart and the brain in heart failure patients assessed by MRI -Interim results from the B-HeFT Study-iÅ—DGÜŽóÜj
  7. ƒŒû‰‰”­•\„

  8. Hao K, Takahashi J, Miyata S, Sakata Y, Tsuburaya R, Shiroto T, Matsumoto Y, Ito K, Yasuda S, Shimokawa H. Emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -Report from the Miyagi AMI Registry Study-
  9. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shimokawa H. Prognostic impact of urine protein in diabetic patients with ischemic heart failure -A report from the CHART-2 Study-
  10. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of anemia in chronic heart failure with preserved vs. reduced ejection fraction --A report from the CHART-2 Study-
  11. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Percutaneous transluminal balloon angioplasty improves metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension.
  12. ƒƒ|ƒXƒ^[”­•\„

  13. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Satake H, Shimokawa H. MIBI scintigraphy could be useful to identify heart failure patients with narrow QRS who respond to cardiac resynchronization therapy.
  14. Satoh T, Fujita H, Yamaguchi N, Onoue N, Ishizuka T, Shinozaki T. When rehospitalization due to chronic heart failure occurs during life time?
  15. Takada N, Sugimura K, Fukumoto Y, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Triglyceride deposit cardiomyovasculopathy with severe heart failure.
  16. Yamamoto S, Matsumoto Y, Fukumoto Y, Nochioka K, Miura M, tatebe S, Sugimura K, Suzuki T, Shimokawa H. Potential involvement of functional tricuspid regurgitation in the diagnostic errot to assess pulmonary arterial pressure by Doppler echocardiography.
‘æ33‰ñˆã—Ïî•ñŠw˜A‡‘å‰ïE‘æ14‰ñ“ú–{ˆã—Ïî•ñŠw‰ïŠwp‘å‰ïi2013”N11ŒŽ21`23“úA_ŒËj

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  1. ’†ŽR‰ë°FƒAƒŒƒ‹ƒM[î•ñ‚Ì•W€‰»‚ð‚ß‚Ž‚µ‚ā@\ƒAƒŒƒ‹ƒM[î•ñ‚Ì‹€—L‚ɂ͉œ‚ª•K—v‚©\‘S‘ƒAƒ“ƒP[ƒg’²ž‚æ‚è.
‘æ28‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ïi2013”N10ŒŽ17`18“úA–‹’£j
  1. ŠÚ“c@‘C›–쐰•vC¬àV_ŽiC”ª”ŠŒ’ˆê˜YCŽR‰®œŽiCˆÉ“¡Œ’‘ŸC‰ºìG–ŸCˆä”ó‰h“ñFÒ‘‘¹‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Á@\ƒAƒƒfƒBƒjƒA‚Ö‚ÌŒø‰Ê‚ÌŒŸ“¢\.
  2. ”ª”ŠŒ’ˆê˜YC›–쐰•vC¬àV_ŽiCŠÚ“c‘CŽR‰®œŽiCˆÉ“¡Œ’‘ŸC‰ºìG–ŸCˆä”ó‰h“ñF‹}«ŠúÒ‘‘¹‚É‚š‚¯‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂÌVEGF ”­Œ»‘£iE‰^“®‹@”\‰ü‘PŒø‰Ê.
‘æ54‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2013”N10ŒŽ10“ú`12“úA“Œ‹žj

ƒ–¬ŠÇê–åˆã‹³ˆçƒZƒbƒVƒ‡ƒ“„

  1. ‰ºìG–ŸF–¬ŠÇf—Â̓W–].
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F”x‚ŒŒˆ³‚ÌŽ¡—Â̍őOü@–ò•šŽ¡—ÂƐNPŽ¡—Á„

  3. Œã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ–{‹`OAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸFdÇ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚鎡—Ð헪.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. –î”ö”M—TA‘Ձ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFŒõŠ±Â’f‘w–@‚ð—p‚¢‚œŒŸ“¢.
‘æ21‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïŠwpW‰ïi2013”N9ŒŽ26`28“úA–L’†j

ƒ‰ï’·µ‘ҍu‰‰„

  1. ‰ºìG–ŸFŒŒŠÇ•a‚̐¬ˆö‚É‚š‚¯‚éRho-kinase‚̈Ӌ`@-Š¥¹kƒ‚ƒfƒ‹‚©‚ç—Տ°‰ž—p‚Ü‚Å-
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€F‘å“®–¬ŽŸŠ³‚É‚š‚¯‚édanger signal‚ƉŠÇ„

  3. ²“¡Œö—YA‰ºìG–ŸF‘å“®–¬ŽŸŠ³‚É‚š‚¯‚édanger signal.
‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2013”N9ŒŽ20`22“úAŒF–{j

ƒzŠÂŠíƒ^ƒCƒ€ƒgƒ‰ƒxƒ‹ƒtƒH[ƒ‰ƒ€„

  1. ‰ºìG–ŸFŠ¥“®–¬¹k\“®•šƒ‚ƒfƒ‹‚ÌŠJ”­‚©‚番Žq‹@\‚̉𖟂܂Ł\
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€1FˆÀ’芥“®–¬ŽŸŠ³‚ɑ΂·‚鎡—Ð헪„

  3. ‚‹Ž@Aâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjAŽÄ@MsA‰ºìG–ŸF‹•ŒŒ«–«S•s‘S‚É‚š‚¯‚銥“®–¬ŒŒsÄŒšp‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿.
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€2F“œ”A•aŠ³ŽÒ‚̐SŽŸŠ³Ž¡—ÂÌevidence„

  5. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹{“c@•qA‚‹Ž@A‰ºìG–ŸF“œ‘ãŽÓˆÙí‚ð—L‚·‚é‹•ŒŒ«S•s‘SÇ—á‚Ì—\Œã—\‘ª‚É‚š‚¯‚é”A’`”’•]‰¿‚̈Ӌ`.
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€5F‚—îŽÒS•s‘SŽ¡—Â̌»ó‚Æ“W–]„

  7. â“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‚‹Ž@A‰ºìG–ŸF–{–M‚É‚š‚¯‚鍂—îŽÒS•s‘SÇ—á‚̗Տ°“I“Á’¥.
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘S‚É‚š‚¯‚éŽûk•s‘S‚ÆŠg’£•s‘S‚̃gƒsƒbƒNƒX„

  9. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‰ºìG–ŸFŽûk”\‚̒ቺ‚µ‚œS•s‘S‚ÆŽûk”\‚Ì•ÛŽ‚³‚ê‚œS•s‘SŠ³ŽÒ‚É‚š‚¯‚éS””‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚Ì”äŠr.
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€13F––œŒŒŠÇŽŸŠ³Ž¡—Â̍őOü„

  11. ˆÉ“¡Œ’‘ŸA‹Ú‘ò@ŒºA‰Í‘ºŒ\ˆê˜YA²“¡@¬A‰ºìG–ŸF‰ºŽˆ––œ“®–¬ŽŸŠ³‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã.
  12. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv3„

  13. ‘Ձ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA‰ºìG–ŸF”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFOCT‚ð—p‚¢‚œŒŸ“¢.
  14. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“4FƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɂš‚¯‚郁ƒfƒBƒJƒ‹ƒXƒ^ƒbƒt‚̘AŒg„

  15. ¯@^—R”üA•Ÿ“c_“ñA‰ºìG–ŸA‘å—¢‚é‚èFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɍۂµ•K—v‚Æ‚³‚ê‚éŠÅŒìŽÀ‘H‚Ì—v‘f.
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAâ“c‘וFA“ñ•r‘Ÿ˜YAš¢’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÀ“c@‘A‰ºìG–ŸFEmergency care of acute myocardial infarction and the Great East Japan Earthquake Disaster.
  18. ƒˆê”ÊŒû‰‰‰‰‘聄

  19. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@œA’·’J•”—Y”òAŽáŽR—TŽiA™‘ºGˆê˜YAŽÂè@‹BA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鐇–°ŒÄ‹záŠQ‚Æ’vŽ€“I•s®–¬ƒCƒxƒ“ƒg‚Ì”­¶‚ÌŒŸ“¢.
  20. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢.
  21. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽáŽR”ü“ÞŽqAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA‰Á‰ê’J@–LA‰ºìG–ŸF‰EŽºFDGŽæž‚ݘŽi‚Í”x‚ŒŒˆ³Š³ŽÒ‚Ì’·Šú—\Œã‚ð—\‘ª‚·‚é.
  22. “ñ•r‘Ÿ˜YA‚‹Ž@A‹e’r@—ƒA‰H”öŽ‹MAŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì“ú“à•Ï“®F––œŒŒ”’ŒŒ‹…RhoƒL ƒi[ƒ[Šˆ«‚ÉŠî‚­ŒŸ“¢.
  23. ƒÇ—áŒû‰‰”­•\„

  24. ™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF–«Šˆ“®«Epstein-BarŠŽõÇ‚ɍ‡•¹‚µ‚œ”x‚ŒŒˆ³Ç‚̈ê—á.
  25. ™‘ºGˆê˜YA•Ÿ–{‹`OAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA‰ºìG–ŸFŒõŠ±Â’f‘w–@ŽOŽŸŒ³\’z‘œ‚É‚æ‚è”x“®–¬•a•Ï‚ð•]‰¿‚µ“Ÿ‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á.
  26. ƒÇ—áƒ|ƒXƒ^[”­•\„

  27. Œ–{‘׎¡AâV“¡ˆ»ŽqAˆÉ“¡ˆ€„A‰~’J—²Ž¡AˆÉ“¡Œ’‘ŸA™‘ºGˆê˜YA‚‹Ž@A‰ºìG–ŸFIgGŠÖ˜AŽŸŠ³‚ɍ‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  28. ƒ‰ŠúŒ€Cˆã§—ãÜ@ƒ|ƒXƒ^[„

  29. ‘å’Î’mGAŒš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA‰ºìG–ŸFƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚É”x“®–¬«”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì1—á.
‘æ5‰ñ“Œ–k—Տ°•s®–¬Œ€‹†‰ïŠwpW‰ïi2013”N9ŒŽ14“úAŽRŒ`j
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC’·’J•”—Y”òC²’|—m”VC‰ºìG–ŸFŽOë•Ù—ÖˆâŽc‚Ɖº‘åÃ–¬ŠÔ‚Ì‹¬•”‚ª‰ñ˜H‚̈ꕔ‚ÉŠÖ—^‚µ‚œFontanpŒãS–[•p”‚̈ê—á.
‘æ200‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N8ŒŽ31“úAÂXj
  1. —L’|G”üCš¢’J—²Ž¡CŽR“à@‹BC‰H”öŽ‹MC”’ŒË@’CŒ–{‘׎¡C‚‹Ž@C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸFìè•aŒãˆâÇ‚É‚æ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚œ2—á.
  2. ›ŒŽÍlC™‘ºGˆê˜YC‹e’n‡—TC•Ÿ–{‹`OCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šCŽR–{¹DC–î”ö”M—TC‰ºìG–ŸFf’f‚Ü‚Å‚ÉŽžŠÔ‚ð—v‚µ‚œŽá”N”­Ç“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
‘æ19‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2013”N7ŒŽ13“ú`14“úAå‘äj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FdÇS•s‘S‚ɑ΂·‚é•ïŠ‡“IƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̐i•à„

  1. ˆÉ“¡Œ’‘ŸA‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3F‘å‹K–͍ЊQ‚©‚ç‚Ì‹³ŒP‚Ɖۑ聄

  3. •Ÿ–{‹`OAÂ–Ø—³’jA‰ºìG–ŸF‘åkÐ‚É‚š‚¯‚éS•s‘S‚Ì‘‰Á‚Æ‚»‚̑΍ô.
  4. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ã—ÐE‘²‘OE‘²Œã‹³ˆç‚ÌŒ»ó‚Ɖۑ聄

  5. ˆÉ“¡@CA•Ÿ–{‹`OA‰ºìG–ŸAãŒŽ³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê‚Æ“Œ–k‘åŠw‚ÌŒ»ó.
  6. ƒ‹³ˆçƒZƒbƒVƒ‡ƒ“6„

  7. ˆÉ“¡Œ’‘ŸFPCI‚̐i•à
  8. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm1„

  9. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VAƒ‚ƒnƒƒhƒAƒuƒfƒ‹ƒVƒƒƒtƒB[A‰ºìG–ŸFS•s‘Sf’fEŽ¡—Âɂš‚¯‚éBNP‚Ì–ðŠ„.
  10. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm3„

  11. •Ÿ“c_“ñFQRS”gŒ`‚Ì–¡•û
  12. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm4„

  13. ™‘ºGˆê˜YA•Ÿ–{‹`OA‰ºìG–ŸFzŠÂŠíf—Âɂš‚¯‚鋹•”ƒŒƒ“ƒgƒQƒ“ŽÊ^‚Ì“Ç‚Ý•û.
  14. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm6„

  15. Œ–{‘׎¡FS‘ŸƒJƒe[ƒeƒ‹ŒŸž
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¢‚ĉîŒì‚ª•K—v‚Æ‚È‚é—vˆö‚ɂ‚¢‚Ä‚ÌŒŸ“¢@|CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  18. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  19. ‚‹Ž@“wA‘å–î“à@–LA–k‘ºKŽqA”‘qŽu•ÛA¯Žq‹v”üŽqA‹g“c˜aŽqA•Ÿ–{‹`OAŒ–{‘׎¡AãŒŽ³”ŽA‰ºìG–ŸF‹}«S•s‘S‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€“±“ü‘OŒã‚Ì”äŠrŒŸ“¢.
  20. ’|“à‰ëŽjAŒ–{‘׎¡A’‡•yçA“쓇‘å•ãAV‘‰xOA’Ø“c@‹BA˜a’n‘וFA–”é“ŽqA‚‹Ž•‘ŽqA²“¡–[˜YAX@M–FAŽRŒû‘fŽjAŽRçŒõOAˆä“c‰ëËA•Ÿ–{‹`OAŒF’J‹Iˆê˜YAì–{r•ãAãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽ‚𒆐S‚Æ‚µ‚œ‘匌ŠÇŽŸŠ³‚̏p‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚é@|ŒŒˆ³‘ª’艺‚Ì‹C“¹ƒNƒŠƒAƒ‰ƒ“ƒX—ûK\
  21. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚‹Ž@AŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸF‚—îS•s‘SŠ³ŽÒ‚É‚š‚¯‚é”]‘²’†Šù‰‚Ì—\Œã‚ւ̉e‹¿‚ÉŠÖ‚·‚錟“¢@|CHART-2‚©‚ç‚Ì•ñ\
  22. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YAŽÄ@MsA‰ºìG–ŸFSŒŒŠÇ•a‚Ì—\Œã‚É‚š‚¯‚é‰îŒì—\–h‚̏d—v«@|CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
‘æ22‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi2013”N7ŒŽ11-13“úA_ŒËj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FDES —¯’uŒãƒXƒpƒXƒ€FŒ»ó‚Ƒ΍ô„

  1. Nishimiya K, Matsumoto Y, Takahashi J, Tsuburaya R, Ito Y, Shiroto T, Ito K, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stents suppress coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo.
  2. Yasuda S, Aizawa K, Takahashi J, Shimokawa H. Rho-kinase involvement in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease.
‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ïi2013”N7ŒŽ4-6“úA“Œ‹žj
  1. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Kanawa A, Satake H, Shimokawa H. The importance of low voltage area in right atrium as the mechanisms of atrial tachycardia in postoperative Tetralogy of Fallot.
  2. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Kanawa A, Satake H, Shafee MB, Shimokawa H. Catheter ablation to premature ventricular contraction originated from tricuspid valvular annulus suppresses ventricular fibrillation in Brugada syndrome.
‘æ13‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2013”N6ŒŽ28“ú`29“úA“ß”ej

ƒƒVƒ“ƒ|ƒWƒEƒ€2F“à”ç‹@”\Œ€‹†‚̍ŋ߂̐i•à„

  1. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‚–Ø—S‰îA‰~’J—²Ž¡AˆÉ“¡ˆ€„A’†ŽR‰ë°A•“cŽç•FA‚‹Ž@AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éSŒŒŠÇ•a‘£i‹@\‚ƃoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€4FNO“™‚̃Cƒ[ƒWƒ“ƒO„

  3. “›ˆä³lA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LFzŠÂŠíEt‘Ÿ•a‚É‚š‚¯‚éNOSsŒn‚Ì•aˆö“I–ðŠ„.
  4. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[1„

  5. ‰ºìG–ŸFŒŒŠÇ“à”ç‹@”\‚ÌŒ€‹†FÅ‹ß‚Ì’mŒ©.
  6. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[3„

  7. ˆÉ“¡Œ’‘ŸF’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@.
  8. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[4„

  9. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇ‚ÉŠÖ‚·‚éÅ‹ß‚Ì’mŒ©.
  10. ƒYIAƒZƒbƒVƒ‡ƒ“„

  11. –ì“cˆêŽ÷A•Ÿ–{‹`OAâV“¡‘åŽ÷A_ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A“›ˆä³lA‰ºìG–ŸFŽ‰Ž¿‘ãŽÓ‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‚ÆRho-kinase‚Ì–ðŠ„@\NO‡¬y‘fŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
  12. ŒÃ–ì—R”üA“à“c‘Ÿ˜YA‰ºìG–ŸA‘剮—S•ãA–öŒŽ‰„ÍA”ö’ҁ@–LA“c‘º‰ëmA“›ˆä³lF‘n–ò‚É—L—p‚ÈŽ©‘R”­Ç‹}«S‹Ø[Çƒ‚ƒfƒ‹‚ÌŠJ”­.
  13. ƒŒû‰‰”­•\„

  14. ŒŽ”ŽŽuA¬‘܉Á“ÞŠGA‰„‰iŠóAX‰ªOŽuA‹vPº“NA‰ºìG–ŸA“›ˆä³lFNOˆË‘¶“I‚Ȑ_Œoƒyƒvƒ`ƒhÜ‚è‚œ‚œ‚Ý•s‘S˜Ži‚É‚æ‚鎋°‰º•”ƒIƒŒƒLƒVƒ“ƒjƒ…[ƒƒ“‚Ì‘I‘ð“I•Ï«.
  15. ƒƒ|ƒXƒ^[”­•\„

  16. ã–ì@WA“›ˆä³lA–L•œ—R”üŽqA“瓇r—²A‰ºìG–ŸA–öŒŽ‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é_Œos“®‚ɂ‚¢‚Ä‚ÌŒŸ“¢i1jF•sˆÀŠÖ˜As“®‚Ì”­Œ»‚ÆNOSŒn‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚Ä.
  17. ã–ì@WA“›ˆä³lA–L•œ—R”üŽqA“瓇r—²A‰ºìG–ŸA–öŒŽ‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é_Œos“®‚ɂ‚¢‚Ä‚ÌŒŸ“¢i2jFR‚€‚–ò‚ɑ΂·‚锜‰ž«‚©‚猟“¢‚µ‚œNOSŒn‚Ì–ðŠ„‚É‚Â‚¢‚Ä.
  18. _ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹AâV“¡‘åŽ÷AàV“cˆŒŽqA–ì“cˆêŽ÷A‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO/EDHF‚̃oƒ‰ƒ“ƒX‚̏d—v«.
  19. ŒÃ–ì—R”üA–L•œ—R”üŽqAã–ì@WAâ—œ‚Ü‚äŽqAŒèr”ŽA–ìŒûŽ•FA–öŒŽ‰„ÍA‰ºìG–ŸA”ö’ҁ@–LA“c‘º‰ëmA“›ˆä³lFœ‘—R—ˆŒŒŠÇ‘O‹ì×–E‚É”­Œ»‚·‚éNO‡¬y‘fŒn‚̃}ƒEƒXŒŒŠÇ•a•ÏŒ`¬‚ɑ΂·‚é—}§ì—p.
  20. Ô“cŒ›‘Ÿ˜NA–˜a”ŽA‰€@Ž—bA–ìŒû^ŒáAì”g•q‘¥AÎ–{—TŽmA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽ‰„ÍA“›ˆä³lAŒ}@Š°F‹CŠÇŽxšb‘§‚É‚š‚¯‚éNO‚š‚æ‚ÑŠeNOSƒAƒCƒ\ƒtƒH[ƒ€‚Ì–ðŠ„.
  21. –ìŒû^ŒáA–˜a”ŽA‰€@Ž—bAÔìŒ›‘Ÿ˜NAŽRè@Œ[Aì”g•q‘¥AÎ–{—TŽmA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽLÍA“›ˆä³lAŒ}@Š°FNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚œƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛ‰»ƒ‚ƒfƒ‹‚É‚š‚¯‚éNO‚Ì–ðŠ„‚ÌŒŸ“¢.
  22. ƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A_ŒË–ΗYAâV“¡‘åŽ÷Aà_“cˆŒŽqA–ì“cˆêŽ÷A‰ºìG–ŸFImportant role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mouse coronary artery.
  23. X’å’ŒÆA”Ñ“‡ˆêœA‰ºìG–ŸA“›ˆä³lFˆê‘€”AŠÇŒ‹ãFŒã‚̐t•a•ÏŒ`¬‚É‚š‚¯‚éNO‡¬y‘fƒVƒXƒeƒ€‚̐t•ÛŒìì—p.
  24. –î“c–L—²A‰ºìG–ŸA•œŒ@CAŒã“¡^ŒÈA¬Š}ŒŽN•vAŠ’J•¶•FF“œ”A•a«‹}«S‹Ø[ÇŽžŠ¥”÷¬‘€•›ŒŒŠÇ‚É‚š‚¯‚é“à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Æ‚µ‚Ẳߎ_‰»…‘f‚ƃAƒ“ƒWƒIƒeƒ“ƒVƒ“ƒ^ƒCƒvIŽó—e‘̝hR–ò‚ÌŒŒŠÇŠg’£Œø‰Ê‚ɂ‚¢‚Ä.
‘æ2‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2013”N6ŒŽ22“ú`23“úA“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€2@–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇ“àŽ¡—Â̌»ó‚Æ“W–]„

  1. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽR–{¹DCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̐f’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  2. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€2@”x‚ŒŒˆ³”­Ç‚Ì•ªŽq¶•šŠw“IƒAƒvƒ[ƒ`„

  3. Ž… ‹œC•Ÿ–{‹`OC“c’†áÁˆêC²“¡Œö—YC’r“c®•œC‰ºìG–ŸFƒ}ƒEƒX”x‚ŒŒˆ³Çƒ‚ƒfƒ‹‚ð—p‚¢‚œŒŒŠÇ•œŠŠ‹Ø‚É‚š‚¯‚éROCK2‚Ì–ðŠ„‚Ì‰ð–Ÿ.
  4. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€3@¶SŽŸŠ³‚ÉŠÖ˜A‚µ‚œ”x‚ŒŒˆ³Ç„

  5. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽR–{¹DC‰ºìG–ŸF¶SŒnSŽŸŠ³‚É”º‚€”x‚ŒŒˆ³Ç‚ª—\Œã‚É—^‚Š‚é‰e‹¿.
  6. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€4@”x“®–¬«”x‚ŒŒˆ³ÇŽ¡—Â̍őOü„

  7. •Ÿ–{‹`OF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì•a‘Ô‚É‚š‚¯‚éRhoƒLƒi[ƒ[Œo˜H‚ÉŠÖ‚·‚éÅV‚Ì’mŒ©.
  8. ƒÇ—á“O’ê“¢˜_„

  9. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF’·ŠúƒGƒ|ƒvƒƒXƒeƒm[ƒ‹Ž¡—ÃŒã‚É–å–¬ˆ³˜ŽiÇ‚ð’悵‚œ“«”x‚ŒŒˆ³Ç‚Ì1—á.
  10. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  11. Â–Ø—³’jC™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF”xŒŒðÇðÇ‚Ì”­Ç‚É‚š‚¯‚é“Œ“ú–{‘åkÐ‚̉e‹¿.
  12. ’r“c®•œC•Ÿ–{‹`OCŽ… ‹œC‰ºìG–ŸFˆ³•‰‰×‚É‚æ‚éS•s‘S‚Ì•a‘Ô‚É‚š‚¯‚éRho-kinase‚Ì–ðŠ„.
  13. ‘å’Î’mLCŒš•”r‰îC•Ÿ–{‹`OC™‘º Gˆê˜YCŽO‰Y—TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC‰ºìG–ŸF‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ɑ΂·‚éƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚ɍ‡•¹‚µ‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  14. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽ… ‹œC–î”ö”M—TC’†‘ºˆê•¶CˆÉ“¡ _C‰ºìG–ŸF”x‚ŒŒˆ³‚̏dÇ“x‚Æ—\Œã—\‘ª‚Ì‚œ‚߂̐V‹KƒoƒCƒIƒ}[ƒJ[¥ƒTƒCƒNƒƒtƒBƒŠƒ“A.
  15. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  16. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽáŽR”ü“ÞŽqC‰Á‰ê’J –LC‰ºìG–ŸF”x‚ŒŒˆ³Š³ŽÒ‚Ì—\Œã—\‘ª‚ɑ΂·‚éFDG-PET‚Ì—L—p«.
  17. ‘O“c ŒbC”ªŠªd—YCˆÀ“¡‘ŸŽOC•Ÿ–{‹`OC”óŒû‹`˜YC‹àŽq Š®C‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”x¶ŒŸf’f53—á‚€‚¿Ž€–S3Ç—á‚Ì•a—‘gDŠw“IŒŸ“¢.
  18. –î”ö”M—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–ŸF”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌¬”“àSmall GTPase‚Ì•]‰¿.
  19. –î”ö”M—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌ðü—n’ïR«|Thrombin activated fibrinolysis inhibitor|‚ÌŠÖ—^.
  20. Md. Elias Al-MamunC²“¡Œö—YC“c’†áÁˆêCŽ… ‹œCSuvd NerguiC•Ÿ–{‹`OC‰ºì –ŸFCombination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats.
  21. Suvd NerguiC•Ÿ–{‹`OCŽì—–‘Ž‘ŽŠiCMd. Elias Al-MamunC‰ºìG–ŸFImpact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension.
  22. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  23. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é”x“®–¬ƒoƒ‹[ƒ“Œ`¬pŽž‚ÌOCT‚Ì—L—p«|IVUS‚Æ‚Ì”äŠr|
  24. ƒƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“„

  25. ŒŽ‹|ŠGC“¡“ˆŒbŽqC‰ºìG–ŸFŽ‘±Ã’—Ö@‚ÌŽ©ŒÈŠÇ—Žw“±’†‚ÌŠ³ŽÒ‚ªŽw“±‚ð’†’f‚µÄŠJ‚ÉŽŠ‚Á‚œ—vˆö
‘æ199‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ15“úAå‘äj
  1. âV“¡ˆ»ŽqA‚‹Ž@AˆÉ“¡ˆ€„A‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸAÄ“¡^ˆê˜YF‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚œ¶Š¥“®–¬ŽåŠ²•”‚Ì‹·ó•a•Ï‚É‚æ‚è‹}«S‹Ø[Ç‚𔭏ǂµ‚œ1—á.
  2. £ì«lAŒË“c@’ŒA›Á@Œ³‹gA‚–Ø—S‰îA–©’J@–LAŽR–{‹`lA™@³•¶A‰ºìG–ŸFIsoproterenol“Š—^‚ªelectrical storm‚̃Rƒ“ƒgƒ[ƒ‹‚É—LŒø‚Å‚ ‚Á‚œJ wave syndrome‚Ì1—á.
  3. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‰ºìG–ŸF‰@ŠOS’âŽ~‚©‚ç‘h¶‚³‚ê‚œŠ®‘S–[ŽºƒuƒƒbƒN‡•¹–¢C•œ‹@”\“I’PSŽºiDORVj‚Ì1—á.
  4. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
‘æ66‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2013”N6ŒŽ13`14“úA–ŒŒÃ‰®j
  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCÂ–Ø—³’jCŒš•”r‰îCŽR–{¹DCŽ…@‹œC–î”ö”M—TC’†‘ºˆê•¶CˆÉ“¡@_C‰ºìG–ŸFŽ_‰»ƒXƒgƒŒƒX•ª”å’`”’FƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é”x‚ŒŒˆ³‚Ì—\Œã—\‘ª.
‘æ156‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ1“úA·‰ªj
  1. HŽR³”NAì–{r•ãAÖ–؉ÀŽA•Ÿ“c_“ñA•Ÿ–{‹`OA‰ºìG–ŸFdÇS•s‘S‚ɑ΂·‚é•â•lHS‘ŸAS‘ŸˆÚAŽ¡—Ã.
  2. •Ð•œW‘Ÿ˜YAHŽR³”NA–{‹g’ŒFAì–{r•ãAÖ–؉ÀŽAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YAŽO‰Y@—TA™‘ºGˆê˜YA•Ÿ–{‹`OA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸFŠg’£Œ^S‹ØÇ‹}«‘ˆ«‚ɑ΂µBridge to decision‚ðs‚Á‚œ2Ç—á‚ÌŒoŒ±.
  3. _“cŒj•ãA–{‹g’ŒFAì–{r•ãAÖ–؉ÀŽA•Ÿ–{‹`OA‰ºìG–ŸFŽ©ŒÈ•Ù‰·‘¶Šî•”’uŠ·p‚ÌŽ¡—ЬÑ.
  4. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–ŸFCARTO SOUND‚ª—L—p‚Å‚ ‚Á‚œ—Œ‘匌ŠÇ‰EŽº‹NŽnÇªŽ¡pŒãSŽº•p”‚̈ê—á.
  5. Ö“¡ˆ»ŽqAŒ–{‘׎¡AˆÉ“¡ˆ€„Aš¢’J—²Ž¡A”’ŒË@’A‰H”öŽ‹MA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA™‘ºGˆê˜YA‚‹Ž@A‰ºìG–ŸA’†àV‚¿‚ЂëAÎˆä’q“¿A_“cŒj•ãAì–{r•ãA‘å“c‰pŠöA‚£@Œ\FIgG4ŠÖ˜AŽŸŠ³‚ɍ‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  6. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@œA’·’J•”—Y”òAAbdel-Schafee MohamedAŽáŽR—TŽiA™‘ºGˆê˜YA‰ºìG–ŸAŽÂè@‹BF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鐇–°ŽžŒÄ‹záŠQ‚Æ’vŽ€«•s®–¬ƒCƒxƒ“ƒg‚ÌŒŸ“¢.
  7. ”’ŒË@’A‚‹Ž@AŒ–{‘׎¡AˆÉ“¡ˆ€„Aš¢’J—²Ž¡A“ñ•r‘Ÿ˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆŒŒŠÇ“à’Ž‰¹”gŽg—p‚ªƒƒCƒ„[’ʉ߂ɗLŒø‚Å‚ ‚Á‚œ–«Š®‘S•ÂÇ‚Ì1—á.
  8. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³MA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì––œ”x“®–¬‚É‚š‚¯‚éŒõŠ±Â’f‘w–@‚ð—p‚¢‚œ•]‰¿.
  9. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–ŸF”­ìŽž‚ÉJ wave‚ð”F‚ß‚œŽá”N«SŽº×“®‚̈ê—á.
  10. Œã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºL‘Ÿ˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸAHŽR³”NAì–{r•ãAÖ–؉ÀŽAHê”ü‹IF—ŒS•â•lHS‘Ÿ‚𓱓ü‚µ‚œ‚ª‹~–œ•s‰Â”\‚Å‚ ‚Á‚œŒ€ÇŒ^S‹Ø‰Š‚Ì1—á.
  11. ’·’J•”—Y”òA’†–ì@œAŽáŽR—TŽiA‹ß“¡³‹PA²’|—m”VAAbdel-Schafee MohamedA•Ÿ“c_“ñA‰ºìG–ŸFŽž_‚ÌŒŽˆö‚Æ‚È‚Á‚œSŽº«ŠúŠOŽûk‹Nˆö«ˆê‰ß«SŽº×“®‚ɑ΂µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ª—LŒø‚Å‚ ‚Á‚œˆê—á.
  12. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA‹{“c@•qA‚‹Ž@A‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—v“x‚Æ—\‘ªˆöŽq‚ÌŒŸ“¢@CHART-2‚©‚ç‚Ì•ñ.
  13. ‰¡ì—T‘åAì–{r•ãAHŽR³”NA‰Í’Á@‘A–{‹g’ŒFAÖ–؉ÀŽA•Ÿ–{‹`OA‰ºìG–ŸFŽûk«S–Œ‰Š‚ÌŠO‰ÈŽ¡—ЬÑ‚ÌŒŸØ.
‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïi2013”N5ŒŽ30“úAŽRŒ`j
  1. * ‰ºìG–ŸF“Œ“ú–{‘åkÐ‚ƏzŠÂŠíŽŸŠ³.
‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2013”N3ŒŽ15`17“úA‰¡•lj

ƒPlenary Sessions„

  1. (PL03: To Improve Outcomes of Acute Heart Failure Patients: Lessons from Asian and Western Registries) Miura M, Sakata Y, Takada T, Nochioka K, Miyata S, Takahashi J, Hiramoto T, Inoue K, Tamaki K, Shiba N, Shimokawa H. Prognostic impact of blood urea nitrogen increase during hospitalization in patients with acute decompensated heart failure. Circ J. 77(Suppl. I):I-63,2013.
  2. ƒSymposiums„

  3. (SY01: Progress in Coronary Revascularization: CABG and PCI for Severe Coronary Artery Disease) Takahashi J, Sakata Y, Nochioka K, Miura M, Takada T, Miyata S, Shimokawa H. Prognostic impact of coronary revascularization therapy in patients with ischemic heart failure. Circ J. 77(Suppl. I):I-90,2013.
  4. (SY07: Advances in the Cardiovascular Regenerative Medicine -Lesson from the Clinical Studies-) Ito K, Fukumoto Y, Takahashi J, Hanawa K, Shindo T, Serizawa F, Sato A, Shimokawa H. Development of non-invasive regenerative therapies for cardiovascular disorders -Low-energy shock wave therapy and low-intensity pulsed ultrasound therapy- Circ J. 77(Suppl. I):I-120,2013.
  5. (SY10: New Biomarkers for Cardiovascular Disease Prevention) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A is a novel biomarker for oxidative stress and coronary artery disease. Circ J. 77(Suppl. I):I-139,2013.
  6. (SY14: Establishment of Caring Facilities in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamaoto S, Satoh K, Shimokawa H. Current status of chronic heart failure with adult congenital heart disease in Japan. Circ J. 77(Suppl. I):I-162,2013.
  7. (SY17: Recent Progress in Pulmonary Hypertension) Fukumoto Y, Sugimura K, Shimizu T, Qiqige Z, Yamamoto S, Tatebe S, Aoki T, Nochioka K, Miura Y, Satoh K, Shimokawa H. Recent research progress on the role of Rho-kinase pathway in the pathogenesis of pulmonary arterial hypertension -From Bench to Bedside- Circ J. 77(Suppl. I):I-180,2013.
  8. (SY23: Disasters and Cardiovascular Diseases) Aoki T, Fukumoto Y, Yasuda S, Ito K, Takahashi J, Miyata S, Shinozaki T, Inoue K, Yagi T, Komaru T, Katahira Y, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on cardiovascular diseases. Circ J. 77(Suppl. I):I-215,2013.
  9. ƒLate Breaking Cohort Studies„

  10. (LBCS2-4) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of elevated baseline heart rate on outcomes in patients with HFrEF vs. HFpEF: The CHART-2 Study. Circ J. 77(Suppl. I):I-552,2013.
  11. ƒYoung Investigatorfs Award for International Students„

  12. Ellawindy A, Satoh K, Tanaka S, Ikeda S, Shimizu T, Noda K, Fukumoto Y, Kobayashi K, Nakayama K, Shimokawa H. Spontaneous development of arrhythmogenic right ventricular cardiomyopathy in mice overexpressing dominant-negative Rho-kinase in cardiovascular system. Circ J. 77(Suppl. I): I-568,2013.
  13. ƒESC-JCS Joint Symposium„

  14. (Recent Progress in the Understanding, Management and Prevention of Sudden Cardiac Death) Yasuda S, Ogawa H, Shimokawa H. Coronary artery spasm and out-of- hospital cardiac arrest. Circ J. 77(Suppl. I):I-230,2013.
  15. ƒRound Table Discussion„

  16. (RT12: How to Manage Intractable Coronary Artery Spasm) Takagi Y, Takahashi J, Yasuda S, Ogata Y, Sumiyoshi T, Goto T, Ogawa H, Shimokawa H. Nitrates as a concomitant therapy in patients with vasospastic angina -A report from the Japanese Coronary Spasm Association- Circ J. 77(Suppl. I):I-303,2013.
  17. ƒMorning Lecture„

  18. Sugimura K, Fukumoto Y, Shimokawa H. Management of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-525,2013.
  19. ƒFeatured Research Sessions„

  20. (FRS10: Angina pectoris) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A level is a novel biomarker of vasospastic angina. Circ J. 77(Suppl. I):I-636,2013.
  21. Nihei T, Jun Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in patients with vasospastic angina. Circ J. 77(Suppl. I):I-637,2013.
  22. (FRS17: Vascular Diseaese) Takagi Y, Takahashi J, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Ogawa H, Shimokawa H. Chronic nitrate therapy in patients with vasospastic angina -Multicenter registry study of the Japanese Coronary Spasm Association- Circ J. 2013;77(Suppl. I):I-679,2013.
  23. (FRS18: Pulmonary Circulation) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Nakamura K, Ito H, Shimokawa H. Plasma cyclophilin A as a novel biomarker for pulmonary hypertension in humans. Circ J. 77(Suppl. I):I-686,2013.
  24. (FRS20: Heart Failure) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Shimokawa H. Factors influencing development of de novo heart failure from Stage-B asymptomatic status -A report from the CHART-2 Study- Circ J. 77(Suppl. I):I-698,2013.
  25. ƒOral presentations„

  26. Abdel-Shafee M, Fukuda K, Wakayama Y, Nakayama M, Nakano M, Kondoh M, Hasebe Y, Kawana A, Shimokawa H. Improved long-term prognosis of patients with cardiac sarcoidosis in the modern era. Circ J. 77(Suppl. I):I-873,2013.
  27. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Kenta Ito, Yasuda S, Shimokawa H.@Improved emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -The Miyagi AMI Registry Study-@Circ J. 77(Suppl. I):I-835,2013.
  28. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Stratification of mortality risk according to heart rate and systolic blood pressure in heart failure patients. Circ J. 77(Suppl. I):I-1086,2013.
  29. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shimokawa H. Psychological impact of the Fukushima Daiichi Nuclear Accident in patients with cardiovascular diseases -An interim analysis from the CHART-2 Study- Circ J. 277(Suppl. I):I-1054,2013.
  30. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Takahashi J, Fukumoto Y, Shimokawa H. Psychological impact of the Great East Japan Earthquake Disaster in patients with cardiovascular diseases; A report from the CHART-2 Study. Circ J. 77(Suppl. I):I-1055,2013.
  31. Shiroto T, Romero N, Sugiyama T, Sartoretto JL, Kalwa H, Yan Z, Shimokawa H, Michel T, Caveolin-1 plays a key role in the regulation of vascular oxidative stress. Circ J. 77(Suppl. I):I-1024,2013.
  32. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Wakayama M, Kagaya Y, Shimokawa H. Prognostic impact of enhanced [18F]fluorodeoxyglucose accumulation in the right ventricle in patients with pulmonary hypertension. Circ J. 77(Suppl. I):I-1079,2013.
  33. Uchida T, Furuno Y, Tanimoto A, Toyohira Y, Sakanashi M, Matsuzaki T, Noguchi K, Nakasone J, Ohya Y, Yanagihara N, Shimokawa H, Tamura M, Otsuji Y, Tsutsui M. Development of an experimentally useful model of spontaneous myocardial infarction. Circ J. 77(Suppl. I):I-810,2013.
  34. Yada T, Shimokawa H, Hiramatsu O, Goto M, Ogasawara Y, Kajiya F. Beneficial effects of angiotensin type 1 receptor blocker on H2O2-induced vasodilatation of native coronary collateral microvessels in dogs in vivo. Circ J. 77(Suppl. I):I-883,2013.
  35. ƒPoster presentations„

  36. Abe Y, Ito K, Hao K, Shimokawa H. Beneficial effects of low-energy shock wave therapy on inflammatory responses after acute myocardial infarction in rats. Circ J. 77(Suppl. I):I-2013,2013.
  37. Al-Mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats. Circ J. 77(Suppl. I):I-1766,2013.
  38. Dai Z, Fukumoto Y, Tatebe S, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Pulmonary arterial remodeling occurs in the very early stage of pulmonary hypertension -An optical coherence tomography study- Circ J. 77(Suppl. I):I-1762,2013.
  39. Enkhjargal B, Saito H, Godo S, Sawada A, Noda K, Shimokawa H. Important role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mice. Circ J. 77(Suppl. I):I-1640,2013.
  40. Hanawa K, Ito K, Kentaro Aizawa K, Tomohiko Shindo1, Kensuke Nishimiya1, Yuhi Hasebe1, Junyi Gao1, Hideyuki Hasegawa2, Satoshi Yasuda3, Hiroshi Kanai2, Hiroaki Shimokawa1 Low-Intensity Pulsed Ultrasound Induces Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Porcine Model of Chronic Myocardial IschemiaCirculation Journal 2013, 77(Suppl. I):I-2524,2013.
  41. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not receive primary PCI -A report from the Miyagi AMI Study- Circ J. 77(Suppl. I):I-2827,2013.
  42. Hasebe Y, Fukuda K, Yamamoto H, Nishimiya K, Hanawa K, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system -A feasiblity study for atrioventricular node ablation in pigs in vivo- Circ J. 77(Suppl. I):I-1354,2013.
  43. Ikeda S, Fukumoto Y, Shimizu T, Shimokawa H. Cardiac-specific overexpression of dominant-negative Rho-kinase suppresses pressure overload-induced right and left heart failure in mice. Circ J. 77(Suppl. I) : I-2905 ,2013.
  44. Kawana A, Takahashi J, Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Age-dependent differences in clinical characteristics and outcomes of female patients with vasospastic angina. Circ J. 77(Suppl. I):I-2370,2013.
  45. Kondoh M, Fukuda K, Wakayama Y, Nakano M, Kawana A, Hasebe Y, Abdel-Shafee M, Satake H, Shimokawa H. New Occurrence of ventricular arrhythmias after cardiac resynchronization therapy in patients with severe heart failure. Circ J. 77(Suppl. I):I-2346,2013.
  46. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Emerging healthcare issues in the management of chronic heart failure in Japan -An interim analysis of the CHART-2 Study- Circ J. 77(Suppl. I):I-2981,2013.
  47. Miura Y, Fukumoto Y, Sugimura K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Satoh K, Shimokawa H. Impact of positive myocardial biopsy on ventricular function and prognosis in patients with cardiac sarcoidosis. Circ J. 77(Suppl. I):I-2547,2013.
  48. Nergui S, Fukumoto Y, Qiqige Z, Al Mamun E, Shimokawa H. Impact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension. Circ J. 77(Suppl. I):I-1764,2013.
  49. Nishimiya K, Matsumoto Y, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Ishibashi-Ueda H, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stent suppresses coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo. Circ J. 77(Suppl. I):I-1851,2013.
  50. Qiqige Z, Fukumoto Y, Sugimura K, Miura Y, Tatebe S, Yamamoto S, Aoki T, Nochioka K, Satoh K, Nergui S, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Nihei T, Takahashi J, Shimokawa H. Enhanced Rho-kinase activity in circulating leukocytes in patients with heart failure. Circ J. 77(Suppl. I) : I-1424 ,2013.
  51. Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Circ J. 77(Suppl. I):I-2276,2013.
  52. Sugimura K, Fukumoto Y, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Usefulness of optical coherence tomography for diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-2575,2013.
  53. Suzuki H, Sumiyoshi A, Taki Y, Matsumoto Y, Fukumoto Y, Kawashima R, Shimokawa H. Usefulness of voxel-based morphometry for in vivo evaluation of hippocampal damage in a rat model of cardiopulmonary resuscitation. Circ J. 77(Suppl. I):I-2073,2013.
  54. Tsuburaya R, Takahashi J, Itoh Y, Shirato T, Yasuharu Matsumoto, Kenta Ito, Masaharu Nakayama, Hiroaki Shimokawa Beneficial Effects of a Single Prophylactic Hemodialysis on Renal Function Worsening after Percutaneous Coronary Intervention in Patients with Severe CKD.Circulation Journal 2013, 77(Suppl. I):I-2395,2013.
  55. Wakayama Y, Fukuda K, Nakano M, Kondoh M, Abdel-Shafee M, Hasebe Y, Kawana A, Satake H, Shimokawa H. Usefulness of quantitative gated SPECT to predict responders of cardiac resynchronization therapy among patients with a relatively narrow QRS. Circ J. 77(Suppl. I):I-1586,2013.
  56. Yaoita N, Fukumoto Y, Horiuchi M, Shimokawa H. Evidence for resistance to fibrinolysis in patients with chronic thromboembolic pulmonary hypertension -Possible involvement of thrombin activated fibrinolysis inhibitor- Circ J. 77(Suppl. I):I-2745,2013.
‘æ15‰ñ“ú–{¬læ“V«SŽŸŠ³Šw‰ï‘‰ïEŠwpW‰ïi2013”N2ŒŽ19`20“úA“Œ‹žj
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œCì–Œ‹ÅŽqC’·’J•”—Y”òC²’|—m”VCMohamed A. ShafeeC‰ºìG–ŸFæ“V«SŽŸŠ³pŒãS–[•p”‚É‚š‚¯‚é—Տ°“I“Á’¥‚ÌŒŸ“¢.
‘æ198‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ16“úAå‘äj

ƒ‰Šú—Տ°Œ€CˆãƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“E—DGÜŽóÜ„

  1. ‚“cØ¶ŽqA™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŒš•”r‰îA‰ºìG–ŸA‰Á“¡¹ºF’†«Ž‰–b’~ÏS‹ØŒŒŠÇÇ‚Ì1—á.
  2. ƒˆê”ʉ‰‘聄

  3. ²’|—m”VA‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFŠg‘å”xÃ–¬Šu—£pŒã‚ÉŒ°Ý‰»‚µ‚œŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚Ì1—á.
  4. ‚“c“NŽjAŒã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YAÎˆä’q“¿FCoganÇŒóŒQ‚É‘å“®–¬•Âœ•s‘SÇ‚ð‡•¹‚µS•s‘S‚𗈂µ‚œ1—á.
‘æ33‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ9“úAå‘äj
  1. ‚‹Ž@C”’ŒË@’CŒ–{‘׎¡CˆÉ“¡ˆ€„C‰~’J—²Ž¡C“ñ•r‘Ÿ˜YC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸF•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆIVUS ‚ð—˜—p‚·‚邱‚Æ‚Å‘O‰ºsŽ}–{Š²––œ‚ɃƒCƒ„[’ʉ߂ª‰Â”\‚Æ‚È‚Á‚œ1—á.
‘æ42‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2013”N2ŒŽ8“ú`9“úA“ޗǁj

ƒŽáŽèŒ€‹†ŽÒÜŽóÜ„

  1. Ž…@‹œA•Ÿ–{‹`OA“c’†^ˆêA²“¡Œö—YA‰ºìG–ŸF”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚É‚š‚¯‚éROCK2‚Ì–ðŠ„@\”x‚ŒŒˆ³ÇƒƒJƒjƒYƒ€‚̉𖟁\
  2. ƒŽáŽèŒ€‹†ŽÒÜÅIŒó•â„

  3. –ì“cˆêŽ÷A•Ÿ–{‹`OA’†“ˆ‘s‘ŸA‰ºìG–ŸFƒ}ƒEƒX‚É‚š‚¢‚ÄRho-kinase‚ÍAMPKŒo˜H‚ð—}§‚·‚邱‚Æ‚É‚æ‚胁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ðŽä‚«‹N‚·
  4. ƒˆê”ʉ‰‘聄

  5. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽ…@‹œA–î”ö”M—TA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸF”x‚ŒŒˆ³‚̏dÇ“x‚Æ—\Œã—\‘ª‚Ì‚œ‚߂̐V‹KƒoƒCƒIƒ}[ƒJ[EƒTƒCƒNƒƒtƒBƒŠƒ“A.
“ú–{“®–¬d‰»Šw‰ï@‘æ13‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€i2013”N2ŒŽ3“úA‹ž“sj
  1. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇf—Â̍ŋ߂̐i•à.
‘æ6‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2013”N2ŒŽ1`2“úAå‘äj

ƒÅ—DG‰‰‘èÜ„

  1. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA‹{“c@•qA‚‹Ž@AŽÄ@MsA‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—v“x‚ƉîŒì—\–h‚ª•K—v‚Æ‚È‚é—\‘ªˆöŽq‚ÌŒŸ“¢\CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©\
  2. ƒÅ—DG‰‰‘èŒû‰‰„

  3. ‚“c„ŽjAâ“c‘וFA‹{“c@•qAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸF¶ŽºŽûk”\‚Ì•Û‚œ‚ê‚œ–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éS””‚Ì—\Œã‚É—^‚Š‚é‰e‹¿‚Æ‚»‚ê‚ÉŠÖ˜A‚·‚éˆöŽq‚ÌŒŸ“¢\«·‚ÌŠÏ“_‚àŠÜ‚߂ā[
  4. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YA‰~’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚̐«·‚ÉŠÖ‚·‚錟“¢\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  5. ƒƒ|ƒXƒ^[”­•\„

  6. ˆÉ“¡ˆ€„A‚‹Ž@A‰H”öŽ‹MA‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A“ñ•r‘Ÿ˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[Ç‚̉@“àŽ€–S—Š‚̐«·‚ÉŠÖ‚·‚éˆöŽq‚ÌŒŸ“¢\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  7. ì–Œ‹ÅŽqA‚‹Ž@A‚–Ø—S‰îAˆÀ“c@‘AŠp“c—²•ãA•ûN”ŽAŠÖ